

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

=> d his

(FILE 'HOME' ENTERED AT 09:43:05 ON 24 APR 2002)

FILE 'MEDLINE, CAPLUS, EMBASE, BIOSIS, CANCERLIT, USPATFILL' ENTERED AT 09:43:46 ON 24 APR 2002

L1 11314058 S METHOD? OR PROTOCOL?  
L2 12433 S TUMOR INVASION  
L3 3861 S L1 AND L2  
L4 2158 S L3 NOT PY=1999  
L5 1193 DUP REM L4 (965 DUPLICATES REMOVED)  
L6 6017 S RAGE OR RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS  
L7 0 S L5 AND L6

=> s 15 and amphotericin  
L8 0 L5 AND AMPHOTERIN

=> s 15 and agent?  
L9 239 L5 AND AGENT?

=> d 19 1-239

L9 ANSWER 1 OF 239 MEDLINE  
AN 199022638 PubMed ID: 9805796  
DN 99022638 PubMed ID: 9805796  
TI (Is laparoscopic evaluation of digestive cancers legitimate? A prospective study of 109 cases).  
L'evaluation laparoscopique des cancers digestifs est-elle legitime? Etude prospective de 109 cas.

AU Barlat C; Champault G; Catheline J M  
CS Service de Chirurgie Generale et Digestive, Hopital Jean-Verdier, Bondy.  
SO ANNALES DE CHIRURGIE, (1998) 52 (7) 602-6.  
Journal code: 50E; 0140722. ISSN: 0003-3944.

CY France  
DT Journal: Article; (JOURNAL ARTICLE)

LA French  
FS Priority Journals

EM 199812  
ED Entered STN: 19990115  
Last Updated on STN: 20000303  
Entered Medline: 19981202

L9 ANSWER 2 OF 239 MEDLINE  
AN 1998445708 MEDLINE  
DN 98445708 PubMed ID: 9772531  
TI Effects of TIMP-2 gene transfection on biological behaviors of a metastatic human lung carcinoma cell line.

AU Li H; Fang W; Shi Z  
CS Department of Pathology, Beijing Medical University.  
SO CHUNG-HUA I HSUEH TSA CHIH [CHINESE MEDICAL JOURNAL], (1997 Sep) 77 (9) 652-6.

Journal code: CDG; 751141. ISSN: 0376-2491.

CY China  
DT Journal: Article; (JOURNAL ARTICLE)

LA Chinese  
FS Priority Journals

EM 199811  
ED Entered STN: 19990106  
Last Updated on STN: 20000303  
Entered Medline: 19981109

L9 ANSWER 3 OF 239 MEDLINE  
AN 1998443373 MEDLINE

DN 98443373 PubMed ID: 9769365  
TI Conservation treatment intensified with tamoxifen and CAF chemotherapy for subareolar breast cancers.

AU Ogawa Y; Nishioka A; Inomata T; Tsuboi N; Hayase N; Fukumoto M; Yoshida S; Tohchika N; Tanaka Y; Kimon M  
CS Department of Radiology, Kochi Medical School, Oki-cho, Nankoku-shi, Kochi-Prefecture 783-8505, Japan.  
SO ONCOLOGY REPORTS, (1998 Nov-Dec) 5 (6) 1337-41.  
Journal code: C1F; 9422756. ISSN: 1021-335X.

CY Greece  
DT Journal: Article; (JOURNAL ARTICLE)

LA English  
FS Priority Journals

EM 199811  
ED Entered STN: 19990106  
Last Updated on STN: 19990106  
Entered Medline: 19981125

L9 ANSWER 4 OF 239 MEDLINE

AN 1998187878 MEDLINE  
DN 98187878 PubMed ID: 9529029  
TI Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer.  
AU Kanayama H; Yokota K; Kurokawa Y; Murakami Y; Nishitani M; Kagawa S  
CS Department of Urology, School of Medicine, The University of Tokushima, Kuramoto, Japan.  
SO CANCER, (1998 Apr 1) 82 (7) 1359-66.  
Journal code: C1Z; 0374236. ISSN: 0008-543X.

CY United States  
DT Journal: Article; (JOURNAL ARTICLE)

LA English  
FS Ardigid Index Medicus Journals; Priority Journals

EM 199804  
ED Entered STN: 19980430  
Last Updated on STN: 20000303  
Entered Medline: 19980423

L9 ANSWER 5 OF 239 MEDLINE

AN 1998128074 MEDLINE  
DN 98128074 PubMed ID: 9467021

TI [Dura thickening adjacent to intracranial, para-dural space-occupying lesions in MRI. Histologic correlation].  
Duraverdickung am Rand intrakranieller, duranaher Raumforderungen in der MRT. Histologische Korrelation.  
AU Hutzelmann A; Palmie S; Freund M; Buhl R; Heller M  
CS Klinik für Radiologische Diagnostik der Christian-Albrechts-Universität zu Kiel

SO AKTUELLE RADIOLOGIE, (1997 Nov) 7 (6) 305-8.  
Journal code: A08; 9102962. ISSN: 0939-267X.

CY GERMANY: Germany, Federal Republic of

DT Journal: Article; (JOURNAL ARTICLE)

LA German

EM 199803  
ED Entered STN: 19980410  
Last Updated on STN: 19980410  
Entered Medline: 19980331

L9 ANSWER 6 OF 239 MEDLINE

AN 97070117 MEDLINE  
DN 97070117 PubMed ID: 8913076

TI A case of embryonal carcinoma successfully treated by neoadjuvant chemotherapy: report of a case.  
Shibata S; Okumichi T; Kimura A; Nishimura Y; Okamoto H; Kuraoka T; Youki

I; Kajiwara H  
 Department of Surgery, Yoshijima Hospital, Hiroshima, Japan.  
 CS KYOBU GERA. JAPANESE JOURNAL OF THORACIC SURGERY, (1996 Oct) 49 (11)  
 SO 963-5.  
 Journal code: KQJ; 0413533. ISSN: 0021-5252.  
 Japan  
 CY Journal; Article; (JOURNAL ARTICLE)  
 DT Japanese  
 LA Japanese  
 FS Priority Journals  
 EM 199612  
 Entered STN: 19970128  
 Last Updated on STN: 19970128  
 Entered Medline: 19961210

L9 ANSWER 7 OF 239 MEDLINE  
 AN 97045590 MEDLINE  
 DN 97045590 PubMed ID: 8890594  
 TI Progress and clinical usefulness of color Doppler method in  
 diagnosing abdominal diseases.  
 Tomiyama T; Ueno N; Tano S; Nagamine N; Wada S; Miyata T; Aizawa T; Miyata  
 T; Kumakura Y; Kimura K  
 Department of Gastroenterology, Jichi Medical School.  
 CS NIPPON RINSHO. JAPANESE JOURNAL OF CLINICAL MEDICINE, (1996 Sep) 54 (9)  
 SO 2561-73. Ref: 29  
 Journal code: KIM; 0420546. ISSN: 0047-1852.  
 Japan  
 CY Journal; Article; (JOURNAL ARTICLE)  
 DT General Review; (REVIEW)  
 LA Japanese  
 FS Priority Journals  
 EM 199612  
 Entered STN: 19970128  
 Last Updated on STN: 19970128  
 Entered Medline: 19961206

L9 ANSWER 8 OF 239 MEDLINE  
 AN 96228311 MEDLINE  
 DN 96228311 PubMed ID: 8647672  
 TI Local interferon therapy for melanoma patients.  
 Ilic D; Spaventi S; Padovan I; Kusic Z; Cackovic V; Ivankovic D; Dakovic  
 N; Nola P  
 Department of Medicine, Croatian Academy of Sciences and Arts, Zagreb,  
 CS Croatia.  
 SO INTERNATIONAL JOURNAL OF DERMATOLOGY, (1995 Dec) 34 (12) 872-4.  
 Journal code: GRJ; 0243704. ISSN: 0011-9059.  
 United States  
 CY Journal; Article; (JOURNAL ARTICLE)  
 DT English  
 LA English  
 FS Priority Journals  
 EM 199607  
 Entered STN: 19960805  
 Last Updated on STN: 20000303  
 Entered Medline: 19960719

L9 ANSWER 9 OF 239 MEDLINE  
 AN 96208584 MEDLINE  
 DN 96208584 PubMed ID: 8646686  
 TI In vitro modulation of tumor progression-associated properties of hormone  
 refractory prostate carcinoma cell lines by cytokines.  
 Sokoloff M H; Tso C L; Kaboo R; Taneja S; Pang S; deGron J B;  
 Belldgrun A S  
 Immunotherapy Laboratory, Prostate Cancer Program, Division of Urology,  
 CS Department of Surgery, UCLA School of Medicine, Los Angeles, California

90024, USA.  
 NC CA-16024 (NCI)  
 SO CANCER, (1996 May 1) 77 (9) 1862-72.  
 Journal code: CLZ; 0374236. ISSN: 0008-543X.  
 United States  
 CY Journal; Article; (JOURNAL ARTICLE)  
 DT English  
 LA English  
 FS Abridged Index Medicus Journals, Priority Journals  
 EM 199607  
 Entered STN: 19960805  
 Last Updated on STN: 20000303  
 Entered Medline: 19960722

L9 ANSWER 10 OF 239 MEDLINE  
 AN 95395737 MEDLINE  
 DN 95395737 PubMed ID: 7545228  
 TI Complete resection before development of drug resistance is essential for  
 survival from advanced hepatoblastoma--a report from the German  
 Cooperative Pediatric Liver Tumor Study HB-89.  
 von Schweinitz D; Hecker H; Harms D; Bode U; Weinel P; Burger D; Ertmann  
 R; Mildnerberger H  
 Department of Pediatric Surgery, Medical School Hannover, Germany.  
 CS JOURNAL OF PEDIATRIC SURGERY, (1995 Jun) 30 (6) 845-52.  
 SO Journal code: JMJ; 0052631. ISSN: 0022-3468.  
 United States  
 CY Journal; Article; (JOURNAL ARTICLE)  
 DT English  
 LA English  
 FS Priority Journals  
 EM 199510  
 Entered STN: 19951020  
 Last Updated on STN: 19960129  
 Entered Medline: 19951012

L9 ANSWER 11 OF 239 MEDLINE  
 AN 95122813 MEDLINE  
 DN 95122813 PubMed ID: 7822556  
 TI Staging of colon carcinoma using water enema CT.  
 Gazelle G S; Gaa J; Saini S; Shellito P  
 Department of Radiology, Massachusetts General Hospital, Harvard Medical  
 CS School, Boston 02114.  
 SO JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, (1995 Jan-Feb) 19 (1) 87-91.  
 Journal code: HVT; 7703942. ISSN: 0363-8715.  
 United States  
 CY Journal; Article; (JOURNAL ARTICLE)  
 DT English  
 LA English  
 FS Priority Journals  
 EM 199502  
 Entered STN: 19950223  
 Last Updated on STN: 19950223  
 Entered Medline: 19950210

L9 ANSWER 12 OF 239 MEDLINE  
 AN 94237090 MEDLINE  
 DN 94237090 PubMed ID: 8181412  
 TI Colon carcinoma tumors. A population-based study.  
 AU Spread C; Berkel H; Jewell L; Jenkins H; Yakimets W  
 Department of Surgery, University Hospital, University of Alberta,  
 CS Edmonton, Canada.  
 SO DISASES OF THE COLON AND RECTUM, (1994 May) 37 (5) 482-91.  
 Journal code: EAB; 0372764. ISSN: 0012-3706.  
 United States  
 CY Journal; Article; (JOURNAL ARTICLE)  
 DT English  
 LA English  
 FS Priority Journals

EM 199406 Entered STN: 19940621  
 ED Last Updated on STN: 19940621  
 Entered Medline: 19940614

L9 ANSWER 13 OF 239 MEDLINE  
 AN 94164078 MEDLINE  
 DN 94164078 Pubmed ID: 8119210  
 TI Assessment of response of esophageal carcinoma to induction chemotherapy.  
 AU Hordijk M L; Kon T C; Wilson J H; Mulder A H  
 CS Department of Internal Medicine II, University Hospital Rotterdam  
 SO Dijkzigt, The Netherlands.  
 CY Journal code: EHP: 0215166. ISSN: 0013-726X.  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 199404  
 ED Entered STN: 19940412  
 Last Updated on STN: 19940412  
 Entered Medline: 19940401

L9 ANSWER 14 OF 239 MEDLINE  
 AN 94127116 MEDLINE  
 DN 94127116 Pubmed ID: 8296501  
 TI [The contrast enhancement of brain and spinal cord tumors using Gd-DTPA in  
 magnetic resonance tomography with an extra-low magnetic-field intensity].  
 AU Gd-DTPA pri magnitno-rezonansoi tomografi so sverkhnizko  
 SO Korniashenko V N; Pronin I N; Turkun A M; Fadeeva L M  
 AU ZHURNAL VOPROSY NEIROKHIRURGII IMENI N. N. BURDENKO, (1993 Oct-Dec) (4)  
 SO 13-7.  
 CY Journal code: Y9Z: 7809757. ISSN: 0042-8817.  
 DT Russian  
 LA Russian  
 FS Priority Journals  
 EM 199403  
 ED Entered STN: 19940314  
 Last Updated on STN: 19990129  
 Entered Medline: 19940303

L9 ANSWER 15 OF 239 MEDLINE  
 AN 93295116 MEDLINE  
 DN 93295116 Pubmed ID: 1305671  
 TI Development of chemopreventive agents for bladder cancer.  
 AU Kelloff G J; Boone C W; Malone W F; Steele V E; Doody L A  
 CS Chemoprevention Branch, National Cancer Institute, Bethesda, Maryland  
 SO 20892.  
 CY JOURNAL OF CELLULAR BIOCHEMISTRY. SUPPLEMENT, (1992) 161 1-12. Ref: 48  
 DT Journal code: K8K: 8207539. ISSN: 0733-1959.  
 LA English  
 FS Priority Journals  
 EM 199307  
 ED Entered STN: 19930806  
 Last Updated on STN: 19930806  
 Entered Medline: 19930722

L9 ANSWER 16 OF 239 MEDLINE  
 AN 93220208 MEDLINE  
 DN 93220208 Pubmed ID: 8465480  
 TI Intra- and perivesical tumor growth in preoperative staging of bladder  
 cancer: the role of transrectal ultrasonography and high resolution  
 magnetic resonance imaging.  
 AU Ruefner U; Guni L; Schmidt A; Stolz S; Bader H; Nimmensiek C; Rassweiler  
 J; Eisenberger F; Jipp P  
 CS Clinic of Internal Medicine, Department of General Internal Medicine,  
 Institute of Pathology, Katharinenhospital, Stuttgart, FRG.  
 SO UROLOGIA INTERNATIONALIS, (1993) 50 (3) 141-7.  
 CY Journal code: WRI: 0417373. ISSN: 0042-1138.  
 DT Switzerland  
 LA English  
 FS Priority Journals  
 EM 199305  
 ED Entered STN: 19930521  
 Last Updated on STN: 19930521  
 Entered Medline: 19930504

L9 ANSWER 17 OF 239 MEDLINE  
 AN 93215324 MEDLINE  
 DN 93215324 Pubmed ID: 7681744  
 TI Management of malignant pleural effusions.  
 AU Lynch T J Jr  
 CS Division of Clinical Oncology, Dana-Farber Cancer Institute, Harvard  
 Medical School, Boston.  
 SO CHEST, (1993 Apr) 103 (4 Suppl) 385S-389S. Ref: 43  
 CY Journal code: DIC: 0231335. ISSN: 0012-3692.  
 DT United States  
 LA English  
 FS General Review; (REVIEW)  
 EM (REVIEW, TUTORIAL)  
 ED Entered STN: 19930521  
 Last Updated on STN: 19960129  
 Entered Medline: 19930503

L9 ANSWER 18 OF 239 MEDLINE  
 AN 93001740 MEDLINE  
 DN 93001740 Pubmed ID: 1389653  
 TI Nonresectable adenocarcinoma of the rectum assessed by MR imaging before  
 and after chemotherapy and irradiation.  
 AU Frykholm G; Hemmingsson A; Nyman R; Pahlman L; Glimelius B  
 CS Department of Oncology, Uppsala University, Sweden.  
 SO ACTA RADIOLOGICA, (1992 Sep) 33 (5) 447-52.  
 CY Journal code: ATA: 8706123. ISSN: 0284-1851.  
 DT Denmark  
 LA English  
 FS Priority Journals  
 EM 199210  
 ED Entered STN: 19930122  
 Last Updated on STN: 19930122  
 Entered Medline: 19921029

L9 ANSWER 19 OF 239 MEDLINE  
 AN 90208365 MEDLINE  
 DN 90208365 Pubmed ID: 2181681  
 TI Magnetic resonance imaging in the evaluation of lung cancer.  
 AU Gefter W B

CS Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia 19104.  
SEMINARS IN RADIOLOGY. (1990 Jan) 25 (1) 73-84. Ref: 70  
SO Journal code: U03; 0053252. ISSN: 0037-198X.

CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
(REVIEW, TUTORIAL)  
English  
FS Priority Journals  
EM 199005  
ED Entered STN: 19900601  
Last Updated on STN: 19900601  
Entered Medline: 19900508

L9 ANSWER 20 OF 239 MEDLINE  
AN 90150098 PubMed ID: 2302708  
DN 90150098  
TI Effects of cytochalasin B in culture and in vivo on murine Madison 109 lung carcinoma and on B16 melanoma.  
AU Bousquet P F; Paulsen L A; Fondy C; Lipski K M; Loucy K J; Fondy T P  
CS Department of Biology, Syracuse University, New York 13244.  
SO CANCER RESEARCH. (1990 Mar 1) 50 (5) 1431-9.  
ED Journal code: CNF; 2984705R. ISSN: 0008-5472.

CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
English  
FS Priority Journals  
EM 199003  
ED Entered STN: 19900601  
Last Updated on STN: 19970203  
Entered Medline: 19900321

L9 ANSWER 21 OF 239 MEDLINE  
AN 87324971 PubMed ID: 2820315  
DN 87324971  
TI A case of hepatocellular carcinoma with extrahepatic portal vein obstruction due to tumor invasion, responsive to oral administration of UFT.  
AU Nakanishi T; Nishikawa M; Nagase T; Nakagawa C; Maeda S; Kuroda K; Tokunaga K  
SO GAN TO KAGAKU RYOHO [JAPANESE JOURNAL OF CANCER AND CHEMOTHERAPY], (1987 Sep) 14 (9) 2783-6.  
ED Journal code: 6R8; 7810034. ISSN: 0385-0684.

CY Japan  
DT Journal; Article; (JOURNAL ARTICLE)  
Japanese  
FS Priority Journals  
EM 198710  
ED Entered STN: 19900305  
Last Updated on STN: 19900305  
Entered Medline: 19871008

L9 ANSWER 22 OF 239 MEDLINE  
AN 85123287 PubMed ID: 6395923  
DN 85123287  
TI [Hemostasis and tumor invasion. Therapeutic implications].  
AU Hemostase et invasion tumorale. Deductions therapeutiques.  
SO BULLETIN DU CANCER. (1984) 71 (5) 481-93. Ref: 83  
CY Journal code: BDZ; 0072416. ISSN: 0007-4551.  
DT (CLINICAL TRIAL)

LA Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
French  
FS Priority Journals  
EM 198504  
ED Entered STN: 19900320  
Last Updated on STN: 19980206  
Entered Medline: 19850404

L9 ANSWER 23 OF 239 MEDLINE  
AN 84106383 PubMed ID: 6198070  
DN 84106383  
TI Retroperitoneal lymphadenectomy and aggressive chemotherapy in nonbulky clinical Stage II nonseminomatous germinal testis tumors.  
AU Pizzocaro G; Zanoni F; Milani A; Piva L; Salvioni R; Pasi M; Pilotti S; Monfardini S  
SO CANCER. (1984 Mar 15) 53 (6) 1363-8.  
ED Journal code: CLZ; 0374236. ISSN: 0008-543X.

CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
English  
FS Abridged Index Medicus Journals; Priority Journals  
EM 198403  
ED Entered STN: 19900319  
Last Updated on STN: 19900319  
Entered Medline: 19840323

L9 ANSWER 24 OF 239 MEDLINE  
AN 82102255 PubMed ID: 7033659  
DN 82102255  
TI Histochemical localization of cathepsin B at the invasion front of the rabbit V2 carcinoma.  
AU Graf M; Baici A; Strauli P  
SO LABORATORY INVESTIGATION. (1981 Dec) 45 (6) 587-96.  
CY Journal code: K24; 0376617. ISSN: 0023-6837.  
DT United States  
LA English  
FS Priority Journals  
EM 198203  
ED Entered STN: 19900317  
Last Updated on STN: 19900317  
Entered Medline: 19820322

L9 ANSWER 25 OF 239 CAPLUS COPYRIGHT 2002 ACS  
AN 1998-438670 CAPLUS  
DN 129:92270  
TI Clinical study on xenon-enhanced CT and its methodological consideration  
AU Hyotani, Genhachi  
CS Dep. Neurol. Surg., Wakayama Med. Coll., Wakayama, 640-0000, Japan  
SO Wakayama Igaku (1998), 49(12), 223-233  
CODEN: WKMIQO. ISSN: 0043-0013  
PB Wakayama Igakkai  
DT Journal  
LA Japanese

L9 ANSWER 26 OF 239 CAPLUS COPYRIGHT 2002 ACS  
AN 1997-645807 CAPLUS  
DN 127:314418  
TI Anti-invasive activity of alkaloids and polyphenolics in vitro  
AU Patmar, Virinder S.; Bracke, Marc E.; Philippe, Jan; Wengel, Jesper; Jain, Subhash C.; Olsen, Carl E.; Bishr, Kirpal S.; Sharma, Nawal K.; Courtens, Andy; Sharma, Sunil K.; Venekens, Kristi L.; Van Marck, Veerle; Singh,

- Sanjay K.; Kumar, Naresh; Kumar, Ajay; Malhotra, Sanjay; Kumar, Rajesh; Rajwanshi, Vivek K.; Jain, Rajni; Mareel, Marc M. University of Chemistry, University of Delhi, Delhi, 110 007, India
- CS Biorog. Med. Chem. (1997), 5(8), 1609-1619
- SO CODEN: BMECEP; ISSN: 0968-0896
- PB Elsevier
- DT Journal
- LA English
- L9 ANSWER 27 OF 239 CAPLUS COPYRIGHT 2002 ACS
- AN 1997:135978 CAPLUS
- DN 126:223948
- TI Implications for immunosurveillance of altered HLA class I phenotypes in human tumors
- AU Garrido, Federico; Ruiz-Cabello, Francisco; Cabrera, Teresa; Perez-Villadr, Juan J.; Lopez-Botet, Miguel; Duggan-Keen, Maggie; Stern, Peter L. Dpto de Analisis Clinicos e Inmunologia, Univ. Granada, Granada, 18014, Spain
- CS Immunol. Today (1997), 18(2), 89-95
- SO CODEN: IMTOB8; ISSN: 0167-4919
- PB Elsevier
- DT Journal
- LA English
- L9 ANSWER 28 OF 239 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
- AN 1998138973 EMBASE
- TI Adult T-cell leukemia with predominant skin involvement.
- AU Nagatani T.; Miyazawa M.; Matsuzaki T.; Horichi Y.; Iemoto G.; Sugita Y.; Baba N.; Sugiyama A.; Nakajima H.; Kitamura H.
- CS T. Nagatani, Department of Dermatology, Yokohama City Univ. Sch. of Medicine, 30-9 Fukuura, Kanazawa-Ku, Yokohama 236, Japan
- SO International Journal of Dermatology, (1998) 37/4 (275-277).
- Refs: 4
- ISSN: 0011-9059 CODEN: IJDEBB
- CY United Kingdom
- DT Journal; Article
- DN 005
- TI General Pathology and Pathological Anatomy
- FS 013
- TI Dermatology and Venereology
- 016
- TI Cancer
- 037
- TI Drug Literature Index
- LA English
- SL
- L9 ANSWER 29 OF 239 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
- AN 1998129984 EMBASE
- TI Cytostatic agents in the management of malignant gliomas.
- AU Mikkelson T.
- CS Dr. T. Mikkelson, Dept. of Neurology and Neurosurgery, Henry Ford Medical Center, 2799 West Grand Blvd, Detroit, MI 48202-2689, United States
- SO Cancer Control, (1998) 5/2 (150-162).
- Refs: 114
- ISSN: 1073-2748 CODEN: CACOFD
- CY United States
- DT Journal; Article
- DN 008
- TI Neurology and Neurosurgery
- 037
- TI Drug Literature Index
- LA English
- SL
- L9 ANSWER 30 OF 239 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
- AN 95022228 EMBASE
- DN 1995022228
- TI Magnetic resonance imaging in obstetrics and gynecology: Progress and limitations.
- LA English
- SL
- AU Worthington B.S. Sub-Department of Academic Radiology, Magnetic Resonance Centre, University of Nottingham, Nottingham NG7 2RD, United Kingdom
- CS Magnetic Resonance Materials in Physics, Biology, and Medicine, (1994) 2/3 (247-251).
- SO ISSN: 1352-8661 CODEN: MRBMEQ
- CY United States
- DT Journal; Conference Article
- DN 010
- TI Obstetrics and Gynecology
- 014
- TI Radiology
- 016
- TI Cancer
- 027
- TI Biophysics, Bioengineering and Medical Instrumentation
- LA English
- SL
- L9 ANSWER 31 OF 239 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
- AN 93109020 EMBASE
- DN 1993109020
- TI Development of chemopreventive agents for bladder cancer.
- AU Kelloff G.J.; Boone C.W.; Malone W.F.; Steele V.E.; Dody L.A. Chemoprevention Branch, National Cancer Institute, 6130 Executive Boulevard, Bethesda, MD 20892, United States
- CS Journal of Cellular Biochemistry, (1992) 50/SUPPL. 16 I (1-12).
- SO ISSN: 0730-2312 CODEN: JCEBDS
- CY United States
- DT Journal; Conference Article
- DN 016
- TI Cancer
- 028
- TI Urology and Nephrology
- 030
- TI Pharmacology
- 037
- TI Drug Literature Index
- LA English
- SL
- L9 ANSWER 32 OF 239 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
- AN 90090236 EMBASE
- DN 1990090236
- TI The use of gadolinium enhancement in magnetic resonance imaging of bladder lesions.
- AU Hahn D.; Schmidt H. Radiologische Klinik und Poliklinik der Universitaet Muenchen, Zentrale Roentgenabteilung Pettenkoferstr. 8a, 8000 Muenchen 2, Germany
- CS Problems in Urology, (1989) 3/4 (782-792).
- SO ISSN: 0889-471X CODEN: PRUREX
- CY United States
- DT Journal; (Short Survey)
- DN 014
- TI Radiology
- 016
- TI Cancer
- 028
- TI Urology and Nephrology
- 037
- TI Drug Literature Index
- LA English
- SL
- L9 ANSWER 33 OF 239 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
- AN 88092551 EMBASE
- DN 1988092551
- TI An organ culture system designed to study interaction of fetal rat calvaria with human head and neck squamous cell carcinoma.
- AU Wenig B.L.; Steinberg B.M.; Sciubba J.J.; Gomes B.C.; Abramson A.L. Department of Otolaryngology and Communicative Disorders, The Long Island Jewish Medical Center, New Hyde Park, NY 11042, United States
- CS Otolaryngology - Head and Neck Surgery, (1988) 98/3 (235241).
- SO ISSN: 0194-5998 CODEN: OTOLDL
- CY United States
- DT Journal

- FS 005 General Pathology and Pathological Anatomy  
011 Otorhinolaryngology  
LA English  
SL English
- L9 ANSWER 34 OF 239 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B. V.  
AN 78072279 EMBASE  
DN 1978072279  
TI Clinical uses of bone scanning.  
AU Brady L.W.; Croll M.N.  
CS Dept. Radiat. Ther. Nucl. Med., Hahnemann Med. Coll., Philadelphia, Pa.  
SO 19102, United States  
Skeletal Radiology, (1977) 1/3 (161-167).  
CODEN: SKRADI
- CY Germany  
DT Journal  
FS 014 Radiology  
023 Nuclear Medicine  
033 Orthopedic Surgery  
016 Cancer
- LA English
- L9 ANSWER 35 OF 239 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B. V.  
AN 77056736 EMBASE  
DN 1977056736  
TI Carcinoma of the rectum.  
AU Lee Y.T.N.  
CS Dept. Surg., Univ. South. California Sch. Med., Los Angeles, Calif. 90033,  
United States  
Review of Surgery, (1976) 33/2 (75-95).  
CODEN: RESUAR
- SO Journal  
DT Internal Medicine  
FS 006 Gastroenterology  
048 Surgery  
009 Cancer  
016 Gerontology and Geriatrics
- LA English
- L9 ANSWER 36 OF 239 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
AN 1998:230653 BIOSIS  
DN PREV199800230653  
TI Immunohistochemical staining for desmogleins 1 and 2 in keratinocytic neoplasms with squamous phenotype: Actinic keratosis, keratocanthoma and squamous cell carcinoma of the skin.  
AU Krunic, A. L.; Garrod, D. R. (1); Madani, S.; Buchanan, M. D.; Clark, R. E.  
CS (1) Epithelial Morphogenesis Res. Group, Sch. Biol. Sci., Univ. Manchester, 3.239 Stopford Build., Oxford Road, Manchester M13 9PT UK  
SO British Journal of Cancer, (April, 1998) Vol. 77, No. 8, pp. 1275-1279.  
ISSN: 0007-0920.
- DT Article  
LA English
- L9 ANSWER 37 OF 239 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
AN 1998:80460 BIOSIS  
DN PREV19980080460  
TI Novel therapeutic strategies to selectively kill cancer cells.  
AU Panchal, Rekha G. (1)  
CS (1) Human Gene Therapy Res. Inst., Iowa Health Syst., 1415 Woodland Ave., Des Moines, IA 50309-3203 USA  
SO Biochemical Pharmacology, (Feb. 1, 1998) Vol. 55, No. 3, pp. 247-252.  
ISSN: 0006-2952.
- DT Article  
LA English
- L9 ANSWER 38 OF 239 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
AN 1997:403375 BIOSIS  
DN PREV199799703375  
TI Mediastinal epithelioid hemangioendothelioma in a patient with type IV Ehlers-Danlos syndrome: A case report and review of the literature.  
AU Regbie, Stephen D.; Bell, David R. (1); Neveill, David F.  
CS (1) Dep. Clinical Oncol., Royal North Shore Hosp., St. Leonards, NSW 2065 Australia  
SO American Journal of Clinical Oncology, (1997) Vol. 20, No. 4, pp. 412-415.  
ISSN: 0277-3732.  
(CASE REVIEW)
- DT Article  
LA English
- L9 ANSWER 39 OF 239 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
AN 1995:37864 BIOSIS  
DN PREV199598052164  
TI Hypopituitarism and Hyponatremia in a Case with Nasopharyngeal Carcinoma.  
AU Kokatsu, Toshiyuki (1); Tsukuda, Mamoru  
CS (1) Dep. Otorhinolaryngol., School of Med., Yokohama City Univ., 3-9 Fukuura, Kanazawa-ku, Kanazawa-ku, Yokohama, Kanagawa 236 Japan  
SO ORL (Oto-Rhino-Laryngology) (Basel), (1994) Vol. 56, No. 6, pp. 347-351.  
ISSN: 0301-1569.
- DT Article  
LA English
- L9 ANSWER 40 OF 239 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
AN 1994:480113 BIOSIS  
DN PREV199497493113  
TI MRI manifestations of gastrointestinal wall thickening.  
AU Chou, C.-K. (1); Chen, L.-T.; Sheu, R.-S.; Wang, M.-L.; Jaw, T.-S.; Liu, G.-C.  
CS (1) Dep. Radiol., Chi Mei Found. Hosp., No. 901 Chung-Hua Rd., Tainan Taiwan  
SO Abdominal Imaging, (1994) Vol. 19, No. 5, pp. 389-394.  
ISSN: 0942-8925.
- DT Article  
LA English
- L9 ANSWER 41 OF 239 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
AN 1994:348027 BIOSIS  
DN PREV199497361027  
TI Regulation of 92-kD gelatinase release in HL-60 leukemia cells: Tumor necrosis factor-alpha as an autocrine stimulus for basal- and phorbol ester-induced secretion.  
AU Riles, Christian; Kolb, Helmut; Petrides, Petro E.  
CS Mol. Oncol. Lab., Dep. Med. III, Univ. Munich Med. Sch. Grosshadern, Marchionistr. 15, 81377 Munich Germany  
SO Blood, (1994) Vol. 83, No. 12, pp. 3638-3646.  
ISSN: 0006-4971.
- DT Article  
LA English
- L9 ANSWER 42 OF 239 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
AN 1993:346689 BIOSIS  
DN PREV199396043689  
TI Tetrapeptide tachykinin antagonists: Synthesis and modulation of the physicochemical and pharmacological properties of a new series of partially cyclic analogs.  
AU Kucharczyk, Nathalie; Turieau, Christophe; Paladino, Joseph; Morris, Angela D.; Bonnet, Jacqueline; Canet, Emmanuel; Krause, James E.; Regoli, Domenico; Cocure, Rejean; Facuchere, Jean-Luc (1)

CS (1) Inst. Recherches Servier, 11 rue Moulineaux, 92150 Suresnes France  
SO Journal of Medicinal Chemistry, (1993) Vol. 36, No. 11, pp. 1654-1661.  
ISSN: 0022-2623.

DT Article  
LA English

L9 ANSWER 43 OF 239 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
AN 1982:224244 BIOSIS  
DN BAT3:84228  
TI HISTOCHEMICAL LOCALIZATION OF CATHEPSIN B AT THE INVASION FRONT OF THE RABBIT V-2 CARCINOMA.

AU GRAF M; BAICI A; STRAUL P  
CS DIVISION OF CANCER RESEARCH, INSTITUTE OF PATHOLOGY, UNIV. OF ZUERICH, BIRCHSTR. 95, CH-8050 ZUERICH, SWITZERLAND.  
SO LAB INVEST. (1981 (RECD 1982)) 45 (6), 586-596.  
CODEN: LAINMW. ISSN: 0023-6837.

FS BA, OLD  
LA English

L9 ANSWER 44 OF 239 CANCERLIT  
AN 95608359 CANCERLIT  
DN 95608359  
TI A membrane-bound metalloendoprotease expressed by C6 glioblastoma cells plays an important role in tumor invasion and cell migration in the CNS (Meeting abstract).

AU Hensel T; Amberger V; Schwab M E  
CS Brain Res. Inst., Univ. of Zurich, 8029 Zurich, Switzerland.  
SO Proc Annu Meet Am Assoc Cancer Res, (1995). Vol. 36, pp. A580.  
ISSN: 0197-016X

DT (MEETING ABSTRACTS)  
FS ICDB  
LA English  
EM 199506

L9 ANSWER 45 OF 239 CANCERLIT  
AN 94699184 CANCERLIT  
DN 94699184  
TI Transarterial chemoembolization of icteric hepatic tumors (Meeting abstract).

AU Wu D K; Tsai T C; Chou C K; Liu G C  
CS Kachisung Medical Coll., Kachisung, China.  
SO Non-serial, (1993). APCVIR '93: The First Asian-Pacific Congress of Cardiovascular and Interventional Radiology. May 24-27, 1993, Seoul, Korea.

DT Journal, Article; (JOURNAL ARTICLE)  
FS ICDB  
LA English  
EM 199410

L9 ANSWER 46 OF 239 CANCERLIT  
AN 94690810 CANCERLIT  
DN 94690810  
TI A study of the proteinase, cathepsin L, in the context of tumour invasion.

AU Pike R N  
CS Univ. of Natal, South Africa.  
SO Dis Abstr Int [B], (1993). Vol. 53, No. 9, pp. 4645.  
ISSN: 0419-4217.

DT (THESES)  
FS ICDB  
LA English  
EM 199408

L9 ANSWER 47 OF 239 CANCERLIT  
AN 90658011 CANCERLIT

DN 90658011  
TI PROTEASES AS MARKERS FOR INVASIVE AND METASTATIC CANCER.  
AU Wu C W  
CS Inst. of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.  
SO Int Congr Ser, (1989). Vol. 807, pp. 259-73.

DT Journal, Article; (JOURNAL ARTICLE)  
FS ICDB  
LA English  
EM 199111

L9 ANSWER 48 OF 239 CANCERLIT  
AN 90657720 CANCERLIT  
DN 90657720  
TI OVERVIEW OF CURRENT UNDERSTANDING OF TUMOR SPREAD.

AU Goldfarb R H; Brunson K W  
CS Pittsburgh Cancer Inst., 3343 Forbes Ave., Pittsburgh, PA 15213.  
SO Cancer Growth Prog, (1989). Vol. 1, pp. 28-32.

DT Journal, Article; (JOURNAL ARTICLE)  
FS ICDB  
LA English  
EM 199001

L9 ANSWER 49 OF 239 CANCERLIT  
AN 81695438 CANCERLIT  
DN 81695438  
TI CANCER PAIN.

AU Bonica J J  
CS Dept. Anesthesiology, Univ. Washington Sch. Medicine, Seattle, WA, 98195.  
SO Monogr Ser Eur Organ Res Treat Cancer, (1981). Vol. 7, pp. 87-115.  
ISSN: 0146-0447.

DT Journal, Article; (JOURNAL ARTICLE)  
FS ICDB  
LA English  
EM 198103

L9 ANSWER 50 OF 239 CANCERLIT  
AN 81688037 CANCERLIT  
DN 81688037  
TI PLASMINOGEN ACTIVATOR, PLASMIN, AND COLLAGENASE INTERACTIONS.

AU Moscatelli D; Rifkin D B; Isseroff R R; Jaffe E A  
CS Dept. Cell Biology, New York Univ. Medical Sch., New York, NY, 10016.  
SO Non-serial, (1980). Proteinases and Tumor Invasion. Strauli P, Barrett AJ, Baici A, ed. New York, Raven Press, Monograph Series of the European Organization for Research on Treatment of Cancer, Vol. 6, 215, pp., 1980.

DT Book; (MONOGRAPH)  
FS ICDB  
LA English  
EM 198101

L9 ANSWER 51 OF 239 CANCERLIT  
AN 81620284 CANCERLIT  
DN 81620284  
TI HYPERTHERMO-HYDROSTATIC PRESSURE THERAPY COMBINED WITH INTRAVESICAL INSTALLATION OF ANTICANCER DRUGS.

AU Ishizuka G; Morita T; Ishida K  
CS Dept. Urology, Akita Univ. Sch. Medicine, Hondo, Akita 010, Japan.  
SO Risho Hinyokika, (1980). Vol. 34, No. 10, pp. 955-961.

DT Journal, Article; (JOURNAL ARTICLE)





PA Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)  
PI US 5840562 19981124  
AI US 1991-928613 19970912 (8)  
RI Continuation of Ser. No. US-1993-567506, filed on 5 Dec. 1993, now abandoned  
DT Utility  
FS Granted  
LN CNT 1655  
INCL INCLM: 435/212.000  
INCLM: 435/320.100; 435/325.000; 435/254.210; 435/252.330; 536/023.200;  
NCLM: 435/212.000  
NCLM: 435/212.000  
NCLM: 435/252.330; 435/254.210; 435/320.100; 435/325.000; 536/023.100;  
NCLM: 536/023.200; 536/023.500  
IC [6]  
ICM: C12N009-48  
ICS: C07H021-04  
EXF 536/23.2; 536/23.1; 536/23.5; 435/320.1; 435/212; 435/69.1; 435/325;  
435/172.3; 435/252.33; 435/254.21  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 57 OF 239 USPTFULT  
AI 1998.147247 USPTFULT  
TI Nucleic acids, vectors and host cells encoding heregulin  
IN Holmes, Richard L., Hillsborough, CA, United States  
PA Holmes, William E., Pacifica, CA, United States  
PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)  
PI US 5840525 19981124  
AI US 1995-456241 19950531 (8)  
RI Division of Ser. No. US 1993-126145, filed on 23 Sep 1993, now abandoned  
which is a continuation of Ser. No. US 1992-880917, filed on 11 May 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-847743, filed on 6 Mar 1992, now patented, Pat. No. US 5367060, issued on 22 Nov 1994 which is a continuation-in-part of Ser. No. US 1991-908001, filed on 8 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-765212, filed on 25 Sep 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-705256, filed on 24 May 1991, now abandoned  
DT Utility  
FS Granted  
LN CNT 4160  
INCL INCLM: 435/069.100  
INCLM: 435/320.100; 435/325.000; 435/252.300; 536/023.500; 935/077.000;  
NCLM: 935/078.000  
NCLM: 435/069.100  
NCLM: 435/325.300; 435/320.100; 435/325.000; 536/023.500  
IC [6]  
ICM: C12N015-00  
ICS: C12N015-63; C12N015-85; C12N001-21; C07H021-04  
EXF 435/69.1; 435/320.1; 435/242.7; 435/325; 435/252.3; 536/23.5; 530/350;  
530/399  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 58 OF 239 USPTFULT  
AI 1998.147237 USPTFULT  
TI Methods of testing cancer and anticancer drugs  
IN Livant, Donna L., Ann Arbor, MI, United States  
PA The Regents of the University of Michigan, Ann Arbor, MI, United States (U.S. corporation)  
PI US 5840514 19981124  
AI US 1996-754322 19961121 (8)  
DT Utility

FS Granted  
LN CNT 1439  
INCL INCLM: 435/029.000  
INCLM: 435/004.000; 530/300.000; 530/323.000; 530/324.000; 530/325.000;  
INCLM: 530/326.000; 530/327.000; 530/328.000; 530/329.000; 530/330.000;  
530/350.000; 530/382.000; 514/002.000; 514/021.000  
NCLM: 435/029.000  
NCLM: 435/004.000; 514/002.000; 514/021.000; 530/300.000; 530/323.000;  
NCLM: 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/328.000;  
530/329.000; 530/330.000; 530/350.000; 530/382.000  
IC [6]  
ICM: C12O001-02  
ICS: C12O001-00  
EXF 435/29; 435/4; 530/300; 530/323; 530/324; 530/325; 530/326; 530/327;  
530/328; 530/329; 530/330; 530/350; 530/382; 514/2; 514/21  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 59 OF 239 USPTFULT  
AI 1998.144102 USPTFULT  
TI Amino-alcohol substituted cyclic compounds  
IN Kumar, Anil M., Seattle, WA, United States  
IN Michnick, John, Seattle, WA, United States  
IN Underiner, Gail E., Briar, WA, United States  
IN Klein, J. Peter, Vashon Island, WA, United States  
PA Rice, Glenn C., Seattle, WA, United States  
PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)  
PI US 5837703 19981117  
AI US 1993-152650 19931112 (8)  
RI Continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993, now abandoned  
DT Utility  
FS Granted  
LN CNT 2596  
INCL INCLM: 514/183.000  
INCLM: 514/211.000; 514/228.800; 514/241.000; 514/242.000; 514/249.000;  
INCLM: 514/256.000; 514/259.000; 514/263.000; 514/270.000; 514/274.000;  
514/309.000; 514/312.000; 514/315.000; 514/348.000; 514/357.000;  
514/374.000; 514/400.000; 514/425.000; 514/427.000; 540/467.000;  
540/544.000; 544/216.000; 544/257.000; 544/272.000; 544/286.000;  
544/301.000; 544/311.000; 544/335.000; 546/096.000; 546/141.000;  
546/142.000; 546/157.000; 546/246.000; 546/296.000; 546/334.000;  
546/340.100; 548/485.000; 548/546.000; 548/561.000  
NCLM: 514/183.000  
NCLM: 514/228.800; 514/241.000; 514/242.000; 514/249.000;  
NCLM: 514/256.000; 514/266.200; 514/266.300; 514/270.000; 514/274.000;  
514/309.000; 514/312.000; 514/315.000; 514/348.000; 514/357.000;  
514/374.000; 514/400.000; 514/425.000; 514/427.000; 540/467.000;  
540/544.000; 544/216.000; 544/257.000; 544/272.000; 544/286.000;  
544/301.000; 544/311.000; 544/335.000; 546/096.000; 546/141.000;  
546/142.000; 546/157.000; 546/246.000; 546/296.000; 546/334.000;  
548/215.000; 548/340.100; 548/485.000; 548/546.000; 548/561.000  
IC [6]  
ICM: A61K031-55  
ICS: A61K031-515; A61K031-445; A61K031-52  
EXF 544/276; 544/272; 544/216; 544/257; 544/286; 544/301; 544/311;  
544/335; 514/263; 514/183; 514/211; 514/228.8; 514/242;  
514/249; 514/256; 514/259; 514/270; 514/274; 514/309; 514/312; 514/315;  
514/348; 514/357; 514/374; 514/400; 514/425; 514/427; 540/467;  
540/544; 546/96; 546/141; 546/142; 546/157; 546/246; 546/296; 546/334;  
548/215; 548/340.1; 548/485; 548/546; 548/561  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 60 OF 239 USPTFULT  
AI 1998.144079 USPTFULT

**Agents** affecting thrombosis and hemostasis  
**TI** Wolf, David L., Palo Alto, CA, United States  
**IN** Simha, Uma, San Francisco, CA, United States  
**PA** COR Therapeutics, Inc., South San Francisco, CA, United States (U.S. corporation)  
**PI** US 5837699 19981117  
**AI** US 1995-469301 19950606 (8)  
**RLI** Division of Ser. No. US 1994-268003, filed on 29 Jun 1994, now patented, Pat. No. US 5583107 which is a continuation-in-part of Ser. No. US 1994-249777, filed on 26 May 1994, now patented, Pat. No. US 5587799 which is a continuation of Ser. No. US -808329 which is a continuation-in-part of Ser. No. US 1990-578646, filed on 4 Sep 1990, now patented, Pat. No. US 5278144  
**DT** Utility  
**FS** Granted  
**IN.CNT** 2092  
**INCL** INCLM: 514/012.000  
 INCLM: 514/008.000; 514/021.000; 514/834.000; 424/094.640; 435/069.600; 435/212.000; 530/381.000; 530/384.000; 530/395.000; 530/402.000; 530/830.000  
**NCL** NCIM: 514/012.000  
 NCIS: 424/094.640; 435/069.600; 435/212.000; 514/008.000; 514/021.000; 514/834.000; 530/381.000; 530/384.000; 530/395.000; 530/402.000; 530/830.000  
**IC** [6]  
 ICM: A61K038-36  
 ICS: A61K035-14; C07K014-475; C07K001-06  
**EXF** 514/12; 514/21; 514/834; 514/8; 530/380; 530/381; 530/384; 530/350; 530/402; 530/829; 530/830; 530/831; 530/395; 930/100; 435/69.1; 435/69.2; 435/69.6; 435/212; 424/94.64  
**CAS** INDEXING IS AVAILABLE FOR THIS PATENT.  
**L9** ANSWER 61 OF 239 USPTFOLL  
**AN** 1998:144076 USPTFOLL  
**TI** Use of scatter factor to enhance angiogenesis  
**IN** Goldberg, Itzhak D., Englewood, NJ, United States  
**PA** Rosen, Elliot M., Port Washington, NY, United States  
**PI** Long Island Jewish Medical Center, New Hyde Park, NY, United States (U.S. corporation)  
**AI** US 5837676 19981117  
**RLI** US 1996-746636 19961113 (8)  
 Continuation of Ser. No. US 1993-138667, filed on 18 Oct 1993, now abandoned  
**DT** Utility  
**FS** Granted  
**IN.CNT** 475  
**INCL** INCLM: 514/008.000  
 INCLM: 514/021.000; 530/399.000  
**NCL** NCIM: 514/008.000  
 NCIS: 514/021.000; 530/399.000  
**IC** [6]  
 ICM: A61K038-18  
**EXF** 514/8; 514/21; 530/399  
**CAS** INDEXING IS AVAILABLE FOR THIS PATENT.  
**L9** ANSWER 62 OF 239 USPTFOLL  
**AN** 1998:138936 USPTFOLL  
**TI** 3-(2'-halobenzylidenyl)-2-indolinone compounds for the treatment of disease  
**IN** Tang, Peng Cho, Moraga, CA, United States  
**PA** Sun, Li, Foster City, CA, United States  
**PI** McMahon, Gerald, Kenwood, CA, United States  
**RLI** Sugen, Inc., Redwood City, CA, United States (U.S. corporation)  
 US 5834504 19981110

**AI** US 1996-655225 19960605 (8)  
**RLI** Continuation-in-part of Ser. No. US 1995-485323, filed on 7 Jun 1995  
**DT** Utility  
**FS** Granted  
**IN.CNT** 3662  
**INCL** INCLM: 514/418.000  
 INCLM: 548/486.000  
**NCL** NCIM: 514/418.000  
 NCIS: 548/486.000  
**IC** [6]  
 ICM: H61K031-40  
 ICS: C07D209-34  
**EXF** 548/486; 514/418  
**CAS** INDEXING IS AVAILABLE FOR THIS PATENT.  
**L9** ANSWER 63 OF 239 USPTFOLL  
**AN** 1998:138672 USPTFOLL  
**TI** Nucleic acids vectors and host cells encoding and expressing heregulin  
**IN** 2-alpha.  
**PA** Vandlen, Richard L., Hillsborough, CA, United States  
**PI** Holmes, William E., Pacifica, CA, United States  
**RLI** Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)  
 US 5834229 19981110  
 US 1994-330161 19941025 (8)  
 Continuation of Ser. No. US 1993-35430, filed on 22 Mar 1993, now abandoned which is a continuation of Ser. No. US 1991-70556, filed on 24 May 1991, now abandoned  
**DT** Utility  
**FS** Granted  
**IN.CNT** 3467  
**INCL** INCLM: 435/069.100  
 INCLM: 435/091.200; 435/325.000; 435/320.100; 536/023.500; 536/024.310; 536/024.330; 935/077.000; 935/078.000  
**NCL** NCIM: 435/069.100  
 NCIS: 435/091.200; 435/325.000; 435/320.100; 435/325.000; 536/023.500; 536/024.310; 536/024.330  
**IC** [6]  
 ICM: C12N015-00  
 ICS: C12N015-85; C12N007-00; C12N015-63; C07H021-04  
**EXF** 435/91.2; 435/969.1; 435/320.1; 435/240.2; 435/252.3; 435/252.8; 536/23.5; 536/24.33; 536/24.31  
**CAS** INDEXING IS AVAILABLE FOR THIS PATENT.  
**L9** ANSWER 64 OF 239 USPTFOLL  
**AN** 1998:135148 USPTFOLL  
**TI** Inhibitors of metalloproteinases, pharmaceutical compositions comprising same and methods of their use  
**IN** Campbell, David A., San Mateo, CA, United States  
**PA** Patel, Dinesh V., Fremont, CA, United States  
**PI** Xiao, Xiao-Yi, San Diego, CA, United States  
**RLI** Affymax Technologies N.V., Greenford, England (non-U.S. corporation)  
 US 5831004 19981103  
 US 1995-549345 19951027 (8)  
 Continuation-in-part of Ser. No. US 1995-484255, filed on 7 Jun 1995, now abandoned which is a continuation-in-part of Ser. No. US 1994-329420, filed on 27 Oct 1994, now abandoned  
**DT** Utility  
**FS** Granted  
**IN.CNT** 2313  
**INCL** INCLM: 530/331.000  
 INCLM: 514/018.000; 514/019.000; 564/154.000; 546/309.000; 544/159.000  
**NCL** NCIM: 530/331.000  
 NCIS: 544/159.000; 546/309.000; 564/154.000

IC [6]  
 ICM: C07K005-00  
 EXF 530/331; 514/18-19; 564/154; 546/309; 544/159.  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IN ANSWER 65 OF 239 USPTAFULL  
 AN 1998:135060 USPTAFULL  
 TI Phosphoric acid amides as matrix metalloproteinase inhibitors  
 IN Pikul, Stanislaw, Mason, OH, United States  
 McDownham, Kelly Lynn, Loveland, OH, United States  
 De, Biswanath, Cincinnati, OH, United States  
 Taiwo, Yetunde Olabisi, West Chester, OH, United States  
 PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)  
 PI US 5830915 19981103  
 AI US 1997-918950 19970826 (8)  
 PRAT US 1996-24765P 19960828 (60)  
 DT Utility  
 FS Granted  
 LN.CNT 1864  
 INCL INCLM: 514/620.000  
 INCS: 514/357.000; 514/396.000; 514/415.000; 514/438.000; 514/451.000;  
 514/824.000; 514/861.000; 514/863.000; 514/864.000; 514/886.000;  
 514/902.000; 514/903.000; 546/021.000; 546/336.000; 546/337.000;  
 548/112.000; 549/006.000; 549/216.000

NCL NCLM: 514/620.000  
 NCLS: 514/357.000; 514/396.000; 514/415.000; 514/438.000; 514/451.000;  
 514/824.000; 514/861.000; 514/863.000; 514/864.000; 514/886.000;  
 514/902.000; 514/903.000; 546/021.000; 546/336.000; 546/337.000;  
 548/112.000; 549/006.000; 549/216.000

IC [6]  
 ICM: A61K031-16  
 ICS: A61K031-38; A61K031-40; A61K031-44  
 EXF 514/357; 514/396; 514/415; 514/436; 514/451; 514/620; 514/824; 514/861;  
 514/863; 514/864; 514/886; 514/902; 514/903; 546/21; 546/336; 546/337;  
 548/112; 549/6; 549/216; 564/12  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 66 OF 239 USPTAFULL  
 AN 1998:134796 USPTAFULL  
 TI Determining invasiveness of prostatic adenocarcinoma  
 IN Paterno, Steven R., Falls Church, VA, United States  
 Manayak, Michael, Chevy Chase, MD, United States  
 PA George Washington University, Washington, DC, United States (U.S. corporation)  
 PI US 5830640 19981103  
 AI US 1995-486203 19950607 (8)  
 RLI Continuation-in-part of Ser. No. US 1995-400084, filed on 7 Mar 1995  
 DT Utility  
 FS Granted  
 LN.CNT 2164  
 INCL INCLM: 435/004.000  
 INCS: 435/007.100; 435/040.500; 435/040.520; 530/386.000; 530/387.100;  
 530/387.700  
 NCL NCLM: 435/004.000  
 NCLS: 435/007.100; 435/040.500; 435/040.520; 530/386.000; 530/387.100;  
 530/387.900

IC [6]  
 ICM: C120001-00  
 ICS: G01N033-53; C07K016-00  
 EXF 424/94.1; 424/184.1; 424/277.1; 536/23.1; 435/6; 435/7.1; 435/4;  
 435/40.5; 435/40.52; 530/386; 530/387.1; 530/387.7  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 67 OF 239 USPTAFULL  
 AN 1998:134630 USPTAFULL  
 TI Fibrinolytic degradation by fibrinolytic matrix metalloproteinase  
 IN Bini, Alessandra, New York, NY, United States  
 PA The New York Blood Center, Inc., New York, NY, United States (U.S. corporation)  
 PI US 5830468 19981103  
 AI US 1995-446887 19950517 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 1482  
 INCL INCLM: 424/094.670  
 INCS: 424/094.630; 424/094.100; 435/219.000; 530/389.300; 206/210.000;  
 604/173.000  
 NCL NCLM: 424/094.670  
 NCLS: 206/210.000; 424/094.100; 424/094.630; 435/219.000; 530/389.300;  
 604/173.000

IC [6]  
 ICM: A61K038-48  
 ICS: C12N005-50; B65D051-24; A61M005-00  
 EXF 424/94.67; 424/94.64; 424/94.1; 424/93.21; 206/210; 604/173; 530/389.3;  
 435/219  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 68 OF 239 USPTAFULL  
 AN 1998:128378 USPTAFULL  
 TI Human stromelysin-1 promoter  
 IN Borden, Paula Ann, Palo Alto, CA, United States  
 Heller, Renu Anand, Stanford, CA, United States  
 PA Syntex (U.S.A.) Inc., Palo Alto, CA, United States (U.S. corporation)  
 PI US 5824794 19981020  
 AI US 1994-362706 19941223 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 819  
 INCL INCLM: 536/024.100  
 INCS: 435/172.300; 435/320.100; 435/325.000; 435/366.000; 435/252.300;  
 536/023.500

NCL NCLM: 536/024.100  
 NCLS: 435/252.300; 435/320.100; 435/325.000; 435/366.000; 536/023.500

IC [6]  
 ICM: C07H021-04  
 ICS: C12N005-16; C12N015-12; C12N015-85  
 EXF 514/44; 536/23.1; 536/24.1; 536/23.5; 435/320.1; 435/240.2; 435/6;  
 435/252.3; 435/366; 435/172.3; 435/325; 424/93.21  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 69 OF 239 USPTAFULL  
 AN 1998:124586 USPTAFULL  
 TI Hydroxamic acid derivatives as inhibitors of cytokine production  
 IN Criminin, Michael John, Oxford, United Kingdom  
 Beckett, Raymond Paul, Oxford, United Kingdom  
 PA British Biotech Pharmaceuticals Limited, Oxford, England (non-U.S. corporation)  
 PI US 5821262 19981013  
 AI WO 9509841 19950413  
 WO 1994-GB2145 19961028 (8)  
 19941004 19961028  
 19961028 PCT 371 date  
 19961028 PCT 102(e) date

PRAT GB 1993-20660 19931007  
 DT Utility  
 FS Granted  
 LN.CNT 1077

INCL INCLM: 514/445.000  
INCLM: 514/575.000; 549/062.000; 562/621.000; 562/623.000  
NCLM: 514/445.000  
NCLM: 514/445.000  
NCLM: 514/575.000; 549/062.000; 562/621.000; 562/623.000  
IC [6]  
ICM: C07D333-34  
EXF ICS: C07C323-60; C07C317-44; A61K031-16  
514/575; 514/397; 514/419; 514/445; 562/621; 562/623;  
548/315.1; 548/335.1; 548/335.5; 548/494; 548/495; 549/62  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 70 OF 239. USPTAFULL  
AN 1998:122568 USPTAFULL  
TI Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic  
acids  
IN Nanermet, Philippe G., Maplewood, NJ, United States  
Parfer, David T., Livingston, NJ, United States  
Macherson, Lawrence J., Hampton, NJ, United States  
Novartis Corporation, Summit, NJ, United States (U.S. corporation)  
PA US 5817822 19981006  
PI US 1997-787730 19970124 (8)  
RLI Continuation-in-part of Ser. No. US 1995-475166, filed on 7 Jun 1995,  
now patented, Pat. No. US 5646167 which is a continuation-in-part of  
Ser. No. US 1994-333676, filed on 3 Nov 1994, now patented, Pat. No. US  
5552419 which is a continuation-in-part of Ser. No. US 1994-265296,  
filed on 24 Jun 1994, now patented, Pat. No. US 5506242  
Utility  
DT Granted  
FS 1865  
INCL INCLM: 546/194.000  
INCLM: 546/186.000; 546/190.000; 546/192.000; 546/207.000  
NCLM: 546/194.000  
NCLM: 546/186.000; 546/190.000; 546/192.000; 546/207.000  
IC [6]  
ICM: C07D401-02  
EXF ICS: 546/186; 546/190; 546/192; 546/194; 546/207  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 71 OF 239 USPTAFULL  
AN 1998:122413 USPTAFULL  
TI Substituted amino alkyl compounds  
Klein, J. Peter, Vashon Island, WA, United States  
Underiner, Gail E., Brier, WA, United States  
Leigh, Alistair J., Brier, WA, United States  
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)  
PA US 5817662 19981006  
PI US 1995-468656 19950606 (8)  
RLI Division of Ser. No. US 1993-149681, filed on 9 Nov 1993, now abandoned  
which is a continuation-in-part of Ser. No. US 1992-973804, filed on 9  
Nov 1992, now patented, Pat. No. US 5340813  
Utility  
DT Granted  
FS 1358  
INCL INCLM: 514/263.000  
INCLM: 424/824.000; 424/825.000; 424/885.000; 424/921.000  
NCLM: 514/263.000  
NCLM: 424/824.000; 424/825.000  
IC [6]  
ICM: A61K031-52  
EXF ICS: 514/397; 514/263; 424/824; 424/825; 424/885; 424/921  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 72 OF 239 USPTAFULL  
AN 1998:119125 USPTAFULL

TI Compositions containing a disintegrin and methods for its use  
in preventing metastasis and other conditions  
Markland, Jr., Francis S., Manhattan Beach, CA, United States  
Zhou, Qing, Alhambra, CA, United States  
University of Southern California, Los Angeles, CA, United States (U.S.  
corporation)  
PA US 5814609 19980929  
PI US 1996-745603 19961108 (8)  
RLI Continuation-in-part of Ser. No. US 1996-632691, filed on 15 Apr 1996,  
now patented, Pat. No. US 5731288 which is a division of Ser. No. US  
1995-540423, filed on 10 Oct 1995, now abandoned which is a continuation  
of Ser. No. US 1993-141321, filed on 22 Oct 1993, now abandoned  
Utility  
DT Granted  
FS 1085  
INCL INCLM: 514/012.000  
INCLM: 530/324.000  
NCLM: 514/012.000  
NCLM: 530/324.000  
IC [6]  
ICM: A61K038-00  
EXF ICS: A61K038-16; C07K014-00  
514/12; 530/324  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 73 OF 239 USPTAFULL  
AN 1998:111942 USPTAFULL  
TI Therapeutic compounds containing pyrimidinyl moieties  
Klein, J. Peter, Vashon, WA, United States  
Leigh, Alistair J., Brier, WA, United States  
Underiner, Gail E., Brier, WA, United States  
Kumar, Anil M., Seattle, WA, United States  
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)  
PA US 5807862 19980915  
PI US 1995-478112 19950607 (8)  
RLI Continuation-in-part of Ser. No. US 1994-199368, filed on 18 Feb 1994,  
now abandoned  
Utility  
DT Granted  
FS 2190  
INCL INCLM: 514/269.000  
INCLM: 544/309.000; 544/310.000; 544/311.000; 544/312.000  
NCLM: 514/269.000  
NCLM: 544/309.000; 544/310.000; 544/311.000; 544/312.000  
IC [6]  
ICM: A61K031-505  
EXF ICS: C07D239-54  
514/269; 514/274; 544/309; 544/310; 544/311; 544/312  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 74 OF 239 USPTAFULL  
AN 1998:111941 USPTAFULL  
TI Amine substituted xanthinyl compounds  
Klein, J. Peter, Vashon, WA, United States  
Underiner, Gail E., Brier, WA, United States  
Kumar, Anil M., Seattle, WA, United States  
Ridgers, Lance H., Bothell, WA, United States  
Rice, Glenn C., Seattle, WA, United States  
Leung, David W., Mercer Island, WA, United States  
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)  
PA US 5807861 19980915  
PI US 1995-476911 19950607 (8)  
RLI Continuation-in-part of Ser. No. US 1994-217051, filed on 24 Mar 1994,  
now abandoned

DT Utility  
FS Granted  
LN.CNT 1713  
INCL INCLM: 514/263.000  
NCL NCIM: 514/263.350  
NCLM: 514/081.000; 514/151.000; 514/210.210; 514/263.200; 514/263.220;  
514/263.230  
IC [6]  
ICM: A61K031-52  
EXE 514/263  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 75 OF 239 USPATFULT  
AN: 1998:108432 USPATFULT  
TI Methods of cancer treatment using naladase inhibitors  
IN Slusher, Barbara S., Kingsville, MD, United States  
Jackson, Paul F., Bel Air, MD, United States  
Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)  
PI US 5804602 19980908  
AI US 1996-665775 19960617 (8)  
DT Utility  
FS Granted  
LN.CNT 1471  
INCL INCLM: 514/574.000  
INCLM: 562/024.000  
NCL NCIM: 514/574.000  
NCLM: 562/024.000  
IC [6]  
ICM: A61K031-66  
ICS: C07E009-28  
562/24; 514/574  
EXF 562/24; 514/574  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 76 OF 239 USPATFULT  
AN: 1998:108415 USPATFULT  
TI Therapeutic compounds containing a monocyclic five- to six- membered  
ring structure having one to two nitrogen atoms  
IN Underiner, Gail E., Briar, WA, United States  
Portubek, David, Seattle, WA, United States  
Klein, J. Peter, Vashon Island, WA, United States  
Woodson, Paul, Edmonds, WA, United States  
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)  
PI US 5804584 19980908  
AI US 1995-468659 19950606 (8)  
DT Division of Ser. No. US 1993-153256, filed on 16 Nov 1993, now abandoned  
which is a continuation-in-part of Ser. No. US 1992-976533, filed on 16  
Nov 1992, now patented, Pat. No. US 5473070  
FS Utility  
INCL INCLM: 514/269.000  
INCLM: 544/298.000; 544/242.000; 544/301.000; 544/302.000; 514/256.000  
NCL NCIM: 514/269.000  
NCLM: 514/256.000; 544/242.000; 544/298.000; 544/301.000; 544/302.000  
IC [6]  
ICM: C07D239-54  
ICS: A61K031-52  
EXF 514/242; 514/243; 514/269; 544/298; 544/299  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 77 OF 239 USPATFULT  
AN: 1998:108219 USPATFULT  
TI Methods for identifying differentially expressed genes and

IN differences between genomic nucleic acid sequences  
Sylkowski, Arthur J., Arlington, MA, United States  
Yang, Meiheng, Boston, MA, United States  
Beth Israel Deaconess Medical Center, Inc., Boston, MA, United States  
PA (U.S. corporation)  
PI US 5804382 19980908  
AI US 1996-644326 19960510 (8)  
DT Utility  
FS Granted  
LN.CNT 1251  
INCL INCLM: 435/006.000  
INCLM: 435/091.200  
NCL NCIM: 435/006.000  
NCLM: 435/091.200  
IC [6]  
ICM: C12P001-68  
ICS: C12P019-34  
435/6; 435/91.2; 935/77; 935/78  
EXF 435/6; 435/91.2; 935/77; 935/78  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 78 OF 239 USPATFULT  
AN: 1998:104752 USPATFULT  
TI Amine substituted compounds  
IN Klein, J. Peter, Vashon, WA, United States  
Underiner, Gail E., Briar, WA, United States  
Kumar, Anil M., Seattle, WA, United States  
Ridgers, Lance H., Bothell, WA, United States  
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)  
PI US 5801182 19980901  
AI US 1995-485777 19950607 (8)  
DT Continuation-in-part of Ser. No. US 1994-217051, filed on 24 Mar 1994,  
now abandoned  
FS Utility  
INCL INCLM: 514/269.000  
INCLM: 514/274.000; 544/310.000; 544/311.000; 544/312.000  
NCL NCIM: 514/269.000  
NCLM: 514/274.000; 544/310.000; 544/311.000; 544/312.000  
IC [6]  
ICM: A61K031-505  
ICS: C07D239-02  
544/312; 514/269; 514/274; 514/310; 514/311  
EXF 544/312; 514/269; 514/274; 514/310; 514/311  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 79 OF 239 USPATFULT  
AN: 1998:104751 USPATFULT  
TI Amino alcohol substituted cyclic compounds  
IN Michnick, John, Seattle, WA, United States  
Underiner, Gail E., Briar, WA, United States  
Klein, J. Peter, Vashon Island, WA, United States  
Rice, Glenn C., Seattle, WA, United States  
Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)  
PI US 5801181 19980901  
AI US 1995-474820 19950607 (8)  
DT Division of Ser. No. US 1993-152650, filed on 12 Nov 1993, now abandoned  
which is a continuation-in-part of Ser. No. US 1993-40820, filed on 31  
Mar 1993  
FS Utility  
INCL INCLM: 514/263.000  
INCLM: 514/249.000; 514/259.000; 514/274.000; 514/309.000;  
514/183.000; 514/418.000; 514/425.000; 514/617.000; 514/619.000;  
514/315.000; 514/418.000; 514/425.000; 514/617.000; 514/619.000;

514/626.000; 514/668.000; 514/669.000

NCL NCIM: 514/263.350  
NCLIS: 514/183.000; 514/249.000; 514/266.300; 514/274.000; 514/309.000;  
514/315.000; 514/418.000; 514/425.000; 514/617.000; 514/619.000;  
514/626.000; 514/668.000; 514/669.000

IC [6]  
ICM: A01N043-90  
EXF ICS: A01N043-90; A01N043-58; A01N043-42  
514/263; 514/249; 514/266; 514/274; 514/309; 514/315; 514/418;  
514/425; 514/617; 514/619; 514/626; 514/668; 514/669

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 80 OF 239 USPTFULL  
AN 1998:104574 USPTFULL  
TI Method of detecting cancer  
IN Sager, Ruth, Brookline, MA, United States  
Zou, Zhigang, Gaithersburg, MD, United States  
Amisowicz, Anthony, West Newton, MA, United States  
Dana-Farber Cancer Institute, Inc., Boston, MA, United States (U.S. corporation)  
PI US 5801001 19980901  
AI US 1995-477108 19950607 (8)  
RLI Division of Ser. No. US 1993-121714, filed on 1 Sep 1993, now patented, Pat. No. US 5470970 which is a continuation-in-part of Ser. No. US 1992-938823, filed on 1 Sep 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-662216, filed on 28 Feb 1991, now abandoned

DT Utility  
FS Granted  
LN CNT 1502  
INCL INCLM: 435/007.230  
INCLS: 435/007.210; 530/387.700; 530/387.900; 530/388.200; 530/388.800;  
NCL NCIM: 435/007.230  
NCLIS: 435/007.210; 530/387.700; 530/387.900; 530/388.200; 530/388.800;  
530/388.850; 530/389.700

IC [6]  
ICM: G01N033-536  
EXF ICS: G01N033-574; C07K016-30  
435/7.1; 435/7.23; 530/387.7; 530/388.2; 530/387.9; 530/388.8;  
530/388.85; 530/389.7

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 81 OF 239 USPTFULL  
AN 1998:101516 USPTFULL  
TI Nucleic acids encoding protocadherin  
IN Suzuki, Shintaro, Torrance, CA, United States  
PA Doherty Eye Institute, Los Angeles, CA, United States (U.S. corporation)  
PI US 5788224 19980825  
AI US 1994-268161 19940627 (8)  
RLI Continuation-in-part of Ser. No. US 1992-998003, filed on 29 Dec 1992, now patented, Pat. No. US 5643781  
DT Utility  
FS Granted  
LN CNT 3432  
INCL INCLM: 435/069.100  
INCLS: 536/023.500; 435/252.300; 435/254.110; 435/320.100; 435/325.000  
NCL NCIM: 435/069.100  
NCLIS: 435/252.300; 435/254.110; 435/320.100; 435/325.000; 536/023.500

IC [6]  
ICM: C12N015-09  
EXF ICS: 435/69.1; 435/240.1; 435/252.3; 435/254.11; 435/320.1; 435/240.2;  
435/325; 536/23.1; 536/23.5

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 82 OF 239 USPTFULL  
AN 1998:98901 USPTFULL  
TI Inhibitors of NAD(P)ase enzyme activity  
IN Jackson, Paul F., Bel Air, MD, United States  
Slusner, Barbara S., Kingville, MD, United States  
Tays, Kevin L., Elkrige, MD, United States  
McClain, Keith M., Baltimore, MD, United States  
Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)  
PI US 5795877 19980818  
AI US 1996-775586 19961231 (8)  
DT Utility  
FS Granted  
LN CNT 2019  
INCL INCLM: 514/075.000  
INCLS: 562/008.000; 562/024.000  
NCL NCIM: 514/075.000  
NCLIS: 562/008.000; 562/024.000

IC [6]  
ICM: C07F009-30  
EXF ICS: C07F009-38; A61K031-66  
562/8; 562/24; 514/75

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 83 OF 239 USPTFULL  
AN 1998:95356 USPTFULL  
TI 3-heteroaryl-2-indolinone compounds for the treatment of disease  
IN Tang, Peng Cho, Moraga, CA, United States  
Sun, Li, Foster City, CA, United States  
McMahon, Gerald, Kenwood, CA, United States  
PA Sugen, Inc., Redwood City, CA, United States (U.S. corporation)  
PI US 5792783 19980811  
AI US 1996-655223 19960605 (8)  
RLI Continuation-in-part of Ser. No. US 1995-485323, filed on 7 Jun 1995

DT Utility  
FS Granted  
LN CNT 3788  
INCL INCLM: 514/397.000  
INCLS: 514/359.000; 514/361.000; 514/362.000; 514/363.000; 514/364.000;  
514/365.000; 514/372.000; 514/374.000; 514/378.000; 514/381.000;  
514/383.000; 514/406.000; 514/414.000; 548/125.000; 548/127.000;  
548/128.000; 548/131.000; 548/134.000; 548/135.000; 548/143.000;  
548/202.000; 548/214.000; 548/235.000; 548/247.000; 548/250.000;  
548/255.000; 548/266.400; 548/312.100; 548/364.700; 548/468.000  
514/397.000

NCL NCIM: 514/359.000; 514/361.000; 514/362.000; 514/363.000; 514/364.000;  
514/365.000; 514/372.000; 514/374.000; 514/378.000; 514/381.000;  
514/383.000; 514/406.000; 514/414.000; 548/125.000; 548/127.000;  
548/128.000; 548/131.000; 548/134.000; 548/135.000; 548/143.000;  
548/202.000; 548/214.000; 548/235.000; 548/247.000; 548/250.000;  
548/255.000; 548/266.400; 548/312.100; 548/364.700; 548/468.000

IC [6]  
ICM: A61K031-40  
EXF ICS: A61K031-415; C07D403-06  
548/468; 548/125; 548/127; 548/128; 548/131; 548/134; 548/136; 548/143;  
548/202; 548/214; 548/235; 548/247; 548/250; 548/255; 548/266.4;  
548/312.1; 548/364.7; 514/414; 514/359; 514/361; 514/362; 514/363;  
514/364; 514/365; 514/372; 514/374; 514/378; 514/381; 514/383; 514/397;  
514/406

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 84 OF 239 USPTFULL

AN 1998:91603 USPTFLL  
 TI Composition and method for enhancing wound healing  
 IN Henkin, R. I., 6601 Broxburn Dr., Bethesda, MD, United States 20817.  
 PI US 5788667 19980804  
 AI US 1993-480.100 19950607 (8)  
 RLI Division of Ser. No. US 1994-297083, filed on 26 Aug 1994, now abandoned  
 which is a division of Ser. No. US 1993-76058, filed on 14 Jun 1993, now  
 patented, Pat. No. US 5384308  
 DT Utility  
 FS Granted  
 LN.CNT 649  
 INCL INCLM: 424/172.100  
 INCLTS: 424/130.100; 424/137.100; 530/387.100; 530/387.900; 530/389.100  
 NCL NCLM: 424/172.100  
 NCLTS: 424/130.100; 424/137.100; 530/387.100; 530/387.900; 530/389.100  
 IC [6]  
 ICM: A61K039-395  
 ICS: C07K016-00  
 EXF 424/130.1; 424/137.1; 424/172.1; 530/387.9; 530/387.1; 530/389.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 85 OF 239 USPTFLL  
 AN 1998:86037 USPTFLL  
 TI Hyaluronan receptor expressed in human umbilical vein endothelial  
 IN Hawkins, Phillip R., Mountain View, CA, United States  
 PI Wilde, Craig G., Sunnyvale, CA, United States  
 AI Seilheimer, Jeffrey J., Los Altos Hills, CA, United States  
 PA Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S.  
 corporation)  
 PI US 5783669 19980721  
 AI US 1996-700178 19960820 (8)  
 RLI Division of Ser. No. US 1995-402217, filed on 10 Mar 1995, now patented,  
 Pat. No. US 5587301  
 DT Utility  
 FS Granted  
 LN.CNT 1140  
 INCL INCLM: 530/350.000  
 INCLTS: 435/069.100; 536/023.500  
 NCL NCLM: 530/350.000  
 NCLTS: 435/069.100; 536/023.500  
 IC [6]  
 ICM: C07K014-705  
 ICS: 530/350; 435/69.1; 536/23.5  
 EXF 530/350; 435/69.1; 536/23.5  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 86 OF 239 USPTFLL  
 AN 1998:82763 USPTFLL  
 TI Hydroxyl-containing xanthine compounds  
 IN Underiner, Gail E., Briar, WA, United States  
 PI Pombek, David, Seattle, WA, United States  
 AI Klein, J. Peter, Vashon Island, WA, United States  
 PA Woodson, Paul, Edmonds, WA, United States  
 PI Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)  
 AI US 5780476 19980714  
 AI US 1995-468660 19950606 (8)  
 RLI Division of Ser. No. US 1993-153256, filed on 16 Nov 1993, now abandoned  
 which is a continuation-in-part of Ser. No. US 1992-976353, filed on 16  
 Nov 1992, now patented, Pat. No. US 5473070  
 DT Utility  
 FS Granted  
 LN.CNT 1672  
 INCL INCLM: 514/263.000  
 INCLTS: 544/267.000  
 NCL NCLM: 514/263.360

IC [6]  
 ICM: A61K031-52  
 ICS: C07D473-04  
 EXF 514/263; 514/256; 514/257; 514/258; 514/259; 514/261; 514/269; 514/270  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 87 OF 239 USPTFLL  
 AN 1998:79342 USPTFLL  
 TI Acetal and ketal-substituted pyrimidine compounds  
 IN Leigh, Alistair, Briar, WA, United States  
 AI Underiner, Gail, Briar, WA, United States  
 PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)  
 PI US 5777115 19980707  
 AI US 1994-193331 19940207 (8)  
 RLI Continuation-in-part of Ser. No. US 1993-4353, filed on 14 Jan 1993, now  
 abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 1632  
 INCL INCLM: 544/242.000  
 INCLTS: 544/267.000; 514/269.000; 514/270.000; 514/256.000  
 NCL NCLM: 544/242.000  
 NCLTS: 544/267.000  
 IC [6]  
 ICM: C07D239-26  
 ICS: A61K031-505  
 EXF 544/267; 544/242; 546/242; 546/243; 514/256; 514/269; 514/270  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 88 OF 239 USPTFLL  
 AN 1998:78967 USPTFLL  
 TI Reversible protease inhibitors  
 IN Palmer, James T., San Ramon, CA, United States  
 PI Rasnick, David, San Francisco, CA, United States  
 AI Klaus, Jeffrey Lee, Redwood City, CA, United States  
 PA Atrix Pharmaceutical Corporation, So. San Francisco, CA, United States  
 PI US 5776718 19980707  
 AI US 1996-618704 19960320 (8)  
 RLI Continuation of Ser. No. US 1995-409996, filed on 24 Mar 1995 Ser. No. US  
 Ser. No. US 1995-409553, filed on 24 Mar 1995 Ser. No. US  
 1995-409997, filed on 24 Mar 1995 And Ser. No. US 1995-410000, filed on  
 24 Mar 1995  
 DT Utility  
 FS Granted  
 LN.CNT 3717  
 INCL INCLM: 435/023.000  
 INCLTS: 435/024.000; 435/004.000; 514/208.000; 514/001.000; 514/019.000;  
 514/012.000; 514/588.000; 514/600.000; 514/601.000; 424/070.240;  
 530/233.000; 530/336.000; 544/106.000  
 NCL NCLM: 435/023.000  
 NCLTS: 424/070.240; 435/004.000; 435/024.000; 514/001.000; 514/012.000;  
 514/019.000; 514/208.000; 514/588.000; 514/600.000; 514/601.000;  
 530/233.000; 530/336.000; 544/106.000  
 IC [6]  
 ICM: C12Q001-37  
 ICS: C12Q001-00; A01N047-28  
 EXF 435/23; 435/24; 435/4; 514/208; 514/1; 514/19; 514/12; 514/588; 514/600;  
 514/601; 424/70.24; 530/233; 530/336; 544/106  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 89 OF 239 USPTFLL  
 AN 1998:75584 USPTFLL  
 TI Synthetic matrix metalloprotease inhibitors and use thereof



IN Levy, Daniel E., Alameda, CA, United States  
Grobelyny, Damian, Matsonia North, Australia  
Tang, Cho; Moraga, CA, United States  
Holme, Kevin R., Alameda, CA, United States  
Galatzky, Richard E., Guilford, CT, United States  
Schultz, Gregory S., Gainesville, FL, United States  
Nematalla, Asaad, Alameda, CA, United States  
Musser, John H., San Carlos, CA, United States  
Glycomed Incorporated, Alameda, CA, United States (U.S. corporation)  
The University of Florida, Gainesville, FL, United States (U.S. corporation)

PI US 5773438 19980630  
AI US 1994-464927 19940605 (8)  
RLI Division of Ser. No. US 1994-184727, filed on 21 Jan 1994 which is a continuation-in-part of Ser. No. US 1993-44324, filed on 7 Apr 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-817039, filed on 7 Jan 1992, now patented, Pat. No. US 5268384, issued on 7 Dec 1993 which is a continuation-in-part of Ser. No. US 1990-477751, filed on 9 Feb 1990, now abandoned which is a continuation-in-part of Ser. No. US 1991-747752, filed on 20 Aug 1991, now patented, Pat. No. US 5189178 which is a continuation-in-part of Ser. No. US 1990-615798, filed on 21 Nov 1990, now patented, Pat. No. US 5183900, issued on 2 Feb 1993 which is a continuation-in-part of Ser. No. US 1992-881630, filed on 12 May 1992, now patented, Pat. No. US 5270326, issued on 14 Dec 1993 which is a continuation of Ser. No. US 1990-616021, filed on 21 Nov 1990, now patented, Pat. No. US 5114953, issued on 19 May 1992

DT Utility  
FS Granted  
LN.CNT 2719  
INCL INCLM: 514/237.800 514/419.000; 544/168.000; 546/334.000; 548/496.000  
NCLM: 514/227.800  
NCL NCLM: 514/227.800 514/419.000; 544/168.000; 546/334.000; 548/496.000  
IC NCLM: 514/357.000; 514/419.000; 544/168.000; 546/334.000; 548/496.000  
[6]  
ICM: A61K031-535  
EXF ICS: A61K031-40; C07D265-28; C07D207-32  
548/496; 514/419; 514/237.8; 514/357; 546/334; 544/168  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 90 OF 239 USPTFULT  
AN 1998:72649 USPTFULT  
TI Certain alpha-substituted arylsulfonamido acetohydroxamic acids  
IN Parker, David Thomas, Livingston, NJ, United States  
PA Novartis Corp., Summit, NJ, United States (U.S. corporation)  
PI US 5770624 19980623  
AI US 1996-763273 19961210 (8)  
PRAI US 1995-8661P 19951215 (60)  
DT Utility  
FS Granted  
LN.CNT 1246  
INCL INCLM: 514/575.000 514/311.000; 514/428.000; 514/365.000; 514/372.000;  
514/374.000; 514/378.000; 514/383.000; 514/381.000; 514/399.000;  
514/438.000; 562/621.000; 546/337.000; 546/175.000; 548/567.000;  
548/146.000; 548/215.000; 548/255.000; 549/072.000  
NCLM: 514/575.000  
NCL NCLM: 514/311.000; 514/357.000; 514/365.000; 514/372.000; 514/374.000;  
514/378.000; 514/381.000; 514/383.000; 514/399.000; 514/428.000;  
514/438.000; 546/175.000; 546/337.000; 548/146.000; 548/215.000;  
548/255.000; 548/567.000; 549/072.000; 562/621.000  
IC [6]  
ICM: A61K031-19  
EXF ICS: A61K031-44; C07C311-15; C07D211-70  
562/621; 514/575; 514/357; 514/311; 514/428; 514/365; 514/372; 514/374;

514/378; 514/383; 514/381; 514/399; 514/438; 548/337; 548/567; 548/568;  
548/146; 548/206; 548/215; 548/240; 548/255; 548/267.6; 548/253;  
548/406; 548/338.1; 546/175; 549/72  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 91 OF 239 USPTFULT  
AN 1998:72620 USPTFULT  
TI Oxime substituted therapeutic compounds  
IN Klein, J. Peter, Vashon, WA, United States  
PA Leigh, Ailsa, Briar, WA, United States  
PI Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)  
AI US 5770595 19980623  
RLI US 1994-193344 19940207 (8)  
Continuation of Ser. No. US 1993-6083, filed on 19 Jan 1993, now abandoned

DT Utility  
FS Granted  
LN.CNT 2183  
INCL INCLM: 514/263.000 544/273.000  
INCLM: 544/271.000; 544/273.000  
NCLM: 514/263.350  
NCL NCLM: 514/263.350 544/271.000; 544/273.000  
IC NCLM: 514/151.000; 544/271.000; 544/273.000  
[6]  
ICM: M61K031-52  
EXF 514/263; 544/271; 544/273

L9 ANSWER 92 OF 239 USPTFULT  
AN 1998:72589 USPTFULT  
TI Heparin- and sulfate binding peptides from the type I repeats of human  
IN thrombospondin and conjugates thereof  
PA Roberts, David D., Bethesda, MD, United States  
Browning, Philip J., Brentwood, TN, United States  
Bryant, Joseph L., Bethesda, MD, United States  
Imman, John K., Bethesda, MD, United States  
Kruttsch, Henry C., Bethesda, MD, United States  
Guo, Nenghua, Gaithersburg, MD, United States  
The United States of America as represented by the Department of Health  
and Human Services, Washington, DC, United States (U.S. government)  
PI US 5770563 19980623  
AI US 1995-487568 19950607 (8)  
RLI Continuation-in-part of Ser. No. US 1994-215085, filed on 21 Mar 1994,  
now abandoned which is a continuation-in-part of Ser. No. US  
1991-801812, filed on 6 Dec 1991, now patented, Pat. No. US 5357041

DT Utility  
FS Granted  
LN.CNT 3518  
INCL INCLM: 514/008.000 514/012.000; 514/013.000; 514/014.000; 514/015.000; 514/016.000;  
514/017.000; 514/018.000; 530/326.000  
NCLM: 514/008.000  
NCL NCLM: 514/012.000; 514/013.000; 514/014.000; 514/015.000; 514/016.000;  
514/017.000; 514/018.000; 530/326.000  
IC [6]  
ICM: A61K038-00  
EXF ICS: A61K038-04; C07K005-00; C07K007-00  
514/12; 514/13; 514/14; 514/15; 514/16; 514/17; 514/18; 530/326  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 93 OF 239 USPTFULT  
AN 1998:61411 USPTFULT  
TI Cancer related antigen  
IN Kohnajda, Francis P., Lutherville, MD, United States  
Pateneck, Gary R., Baltimore, MD, United States  
The Johns Hopkins University, Baltimore, MD, United States (U.S.

PI corporation) 19980602  
 US 5759791 19940124 (8)  
 AI US 1994-188426  
 RLI Confirmation-in-part of Ser. No. US 1993-96908, filed on 26 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-917716, filed on 21 Jul 1992, now abandoned And Ser. Nos. US 1991-735522, filed on 26 Jul 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-622407, filed on 4 Dec 1990, now abandoned which is a continuation of Ser. No. US 1989-298722, filed on 17 Jan 1989, now abandoned

DT Utility  
 FS Granted  
 LN.CNT 2345  
 INCL INCLM: 435/007.230  
 INCLS: 435/007.900; 435/007.920; 435/975.000; 435/006.000; 436/518.000; 436/064.000; 530/324.000; 530/350.000; 530/388.800; 530/389.700; 536/023.100; 536/024.300

NCL NCLM: 435/007.230  
 NCLS: 435/006.000; 435/007.900; 435/007.920; 435/975.000; 436/064.000; 436/518.000; 530/324.000; 530/350.000; 530/388.800; 530/389.700; 536/023.100; 536/024.300

IC [6]  
 ICM: G01N033-574

EXF 436/504; 436/518; 436/531; 436/548; 436/15; 436/63; 436/64; 436/86; 436/804; 436/813; 436/819; 435/7.1; 435/7.23; 435/7.9; 435/7.92; 435/7.95; 435/28.6; 435/960; 435/112.1; 530/324; 530/350; 530/385; 530/388.1; 530/388.8; 530/389.7; 530/828; 935/81; 536/23.1; 536/24.3

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 94 OF 239 USPATFULL  
 AN 1998:54522 USPATFULL  
 TI Method for enhancing functional properties of submucosal tissue graft constructs  
 IN Badylak, Stephen F., W. Lafayette, IN, United States  
 PA Vovlik, Sherry, Lafayette, IN, United States  
 Purue Research Foundation, West Lafayette, IN, United States (U.S. corporation)  
 PI US 5753267 19980519  
 AI US 1993-530001 19950919 (8)  
 RLI Division of Ser. No. US 1993-38452, filed on 10 Feb 1995, now patented. Pat. No. US 5695998

DT Utility  
 FS Granted  
 LN.CNT 893  
 INCL INCLM: 424/551.000  
 INCLS: 424/093.100; 435/325.000; 435/366.000; 435/371.000; 435/377.000; 435/402.000; 623/015.000

NCL NCLM: 424/551.000  
 NCLS: 424/093.100; 435/325.000; 435/366.000; 435/371.000; 435/377.000; 435/402.000

IC [6]  
 ICM: A61K035-38  
 ICS: C12N005-00; C12N005-08; A61E002-08  
 EXF 435/325; 435/366; 435/371; 435/377; 435/402; 424/93.1; 424/551; 623/15

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 95 OF 239 USPATFULL  
 AN 1998:48432 USPATFULL  
 TI Metalloproteinase inhibitors  
 IN Beckett, Raymond Paul, Cowley, United Kingdom  
 Whitaker, Mark, Cowley, United Kingdom  
 Miller, Andrew, Cowley, United Kingdom  
 Martin, Fiona Mitchell, Cowley, United Kingdom  
 British Biotech Pharmaceuticals Limited, Oxford, England (non-U.S. corporation)

PI corporation) 19980505  
 US 5747514 19960719 (8)  
 AI US 1996-685330  
 PRAI GB 1994-1034 19940120  
 GB 1994-15619 19940802

DT Utility  
 FS Granted  
 LN.CNT 2561  
 INCL INCLM: 514/352.000  
 INCLS: 514/362.000; 514/363.000; 514/370.000; 514/372.000; 514/477.000; 514/626.000; 546/309.000; 548/135.000; 548/139.000; 548/192.000; 548/206.000; 549/069.000; 564/153.000; 564/155.000

NCL NCLM: 514/352.000  
 NCLS: 514/362.000; 514/363.000; 514/370.000; 514/372.000; 514/477.000; 514/626.000; 546/309.000; 548/135.000; 548/139.000; 548/192.000; 548/206.000; 549/069.000; 564/153.000; 564/155.000

IC [6]  
 ICM: C07D213-75  
 ICS: A61K031-44

EXF 546/309; 514/352; 514/362; 514/363; 514/370; 514/372; 514/487; 514/626; 548/192; 548/206; 548/135; 548/139; 549/69; 564/153; 564/155

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 96 OF 239 USPATFULL  
 AN 1998:45226 USPATFULL  
 TI Method for inhibiting angiogenesis  
 IN Kohn, Elise C., Olney, MD, United States  
 Liotta, Lance A., Potomac, MD, United States  
 Alessandro, Riccardo, Bethesda, MD, United States  
 PA United States of America, Washington, DC, United States (U.S. government)  
 PI US 5744492 19980428  
 AI US 1994-209651 19940310 (8)  
 RLI Continuation-in-part of Ser. No. US 1993-123614, filed on 17 Sep 1993, now abandoned

DT Utility  
 FS Granted  
 LN.CNT 775  
 INCL INCLM: 514/359.000  
 INCLS: 514/356.000; 514/648.000; 514/650.000

NCL NCLM: 514/359.000  
 NCLS: 514/356.000; 514/648.000; 514/650.000

IC [6]  
 ICM: A61K031-41

EXF 514/359; 514/356; 514/648; 514/650

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 97 OF 239 USPATFULL  
 AN 1998:36567 USPATFULL  
 TI Cathepsin O protease  
 IN Bromme, Dieter, San Bruno, CA, United States  
 Okamoto, Kathleen, Mountain View, CA, United States  
 PA Arris Pharmaceutical, South San Francisco, CA, United States (U.S. corporation)  
 PI US 5736357 19980407  
 AI US 1994-330121 19941027 (8)

DT Utility  
 FS Granted  
 LN.CNT 1306  
 INCL INCLM: 435/069.100  
 INCLS: 435/320.100; 435/325.000; 435/252.300; 435/254.110; 536/023.500

NCL NCLM: 435/069.100  
 NCLS: 435/252.300; 435/254.110; 435/320.100; 435/325.000; 536/023.500

IC [6]

ICM: C12N001-21  
 ICS: C12N015-15; C12N015-63; C12P021-02  
 EXF 536/23.2: 435/219; 435/320.1; 435/240.2; 435/252.3; 435/325  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 98 OF 239 USPTAFULL  
 AN 1998:28192 USPTAFULL  
 TI Bone and prostate-derived protein factors affecting prostate cancer growth, differentiation, and metastasis  
 IN Chung, Ireland W. K., Houston, TX, United States  
 Chan, James, Sugarland, TX, United States  
 Logothetis, Christopher, Houston, TX, United States  
 Hsieh, Jer-Tsong, Sugarland, TX, United States  
 Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)  
 PA States (U.S. corporation)  
 PI US 5728815  
 RLI US 1994-179569  
 DT Continuation-in-part of Ser. No. US 1992-859228, filed on 30 Mar 1992, now abandoned  
 FS Utility  
 IN.CNT 2175  
 INCL INCLM: 530/399.000  
 NCL INCLM: 530/350.000; 530/412.000; 514/002.000  
 NCLM: 530/399.000  
 NCIS: 530/350.000; 530/412.000  
 [6]  
 ICM: C07K014-475  
 EXF 530/350; 530/399; 530/412; 435/240.1; 514/2  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 99 OF 239 USPTAFULL  
 AN 1998:25076 USPTAFULL  
 TI Method to determine metastatic potential of tumor cells  
 IN Mattisian, Lynn M., Nashville, TN, United States  
 Vanderbilt University, Nashville, TN, United States (U.S. corporation)  
 PA US 5726015  
 PI US 1995-371082  
 RLI Continuation of Ser. No. US 1993-61827, filed on 17 May 1993, now abandoned which is a continuation of Ser. No. US 1991-700505, filed on 15 May 1991, now abandoned  
 DT Utility  
 FS Granted  
 IN.CNT 500  
 INCL INCLM: 435/006.000  
 NCL INCLM: 435/023.500  
 NCLM: 435/006.000  
 NCIS: 536/023.500  
 [6]  
 ICM: C12Q001-68  
 EXF 435/6; 435/7.1; 435/7.2; 536/23.5  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 100 OF 239 USPTAFULL  
 AN 1998:12007 USPTAFULL  
 TI Method of inhibiting tumor cell dissemination with a metalloproteinase inhibitor  
 IN Langley, Keith E., Newbury Park, CA, United States  
 Declercq, Yves A., Los Angeles, CA, United States  
 Boone, Thomas C., Newbury Park, CA, United States  
 Angen Inc., Thousand Oaks, CA, United States (U.S. corporation)  
 PA US 5714465  
 PI US 1994-212660  
 RLI Continuation of Ser. No. US 1993-87021, filed on 6 Jul 1993, now

abandoned which is a continuation of Ser. No. US 1991-710728, filed on 3 Jun 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-501904, filed on 29 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-355027, filed on 19 May 1989  
 DT Utility  
 FS Granted  
 IN.CNT 2845  
 INCL INCLM: 514/012.000  
 NCL INCLM: 514/002.000; 530/350.000  
 NCIS: 514/012.000  
 NCIS: 514/002.000; 530/350.000  
 [6]  
 ICM: A61K038-57  
 EXF 530/350; 530/351; 514/12; 424/85.4; 424/85.5; 424/85.6; 424/85.7  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 101 OF 239 USPTAFULL  
 AN 1998:9533 USPTAFULL  
 TI Methods of inducing the production of hemoglobin and treating pathologies associated with abnormal hemoglobin activity using phenylacetic acids and derivatives thereof  
 IN Samid, Dvorit, Rockville, MD, United States  
 The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)  
 PA US 5712307  
 PI US 1995-465924  
 RLI Division of Ser. No. US 1993-135661, filed on 12 Oct 1993 which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991  
 DT Utility  
 FS Granted  
 IN.CNT 4169  
 INCL INCLM: 514/538.000  
 NCL INCLM: 514/563.000; 514/567.000  
 NCLM: 514/538.000  
 NCIS: 514/563.000; 514/567.000  
 [6]  
 ICM: A01N037-12  
 EXF 514/538; 514/563; 514/567  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 102 OF 239 USPTAFULL  
 AN 1998:7096 USPTAFULL  
 TI Compositions and methods for therapy and prevention of pathologies including cancer, AIDS, and anemia  
 IN Samid, Dvorit, Rockville, VA, United States  
 The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)  
 PA US 5710178  
 PI US 1995-469691  
 RLI Division of Ser. No. US 1993-135661, filed on 12 Oct 1993 which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991  
 DT Utility  
 FS Granted  
 IN.CNT 4261  
 INCL INCLM: 514/557.000  
 NCL INCLM: 514/568.000; 514/570.000  
 NCIS: 514/557.000  
 NCIS: 514/568.000; 514/570.000  
 [6]  
 ICM: A01N037-00  
 EXF 514/557; 514/568; 514/570; 562/405; 562/493; 562/511; 562/473; 562/490  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 103 OF 239 USPATFULL  
 AN 1998:4741 USPATFULL  
 TI Protocadherin materials and methods  
 IN Suzuki, Shin-iro, Torrance, CA, United States  
 PA Doherty Eye Institute, Los Angeles, CA, United States (U.S. corporation)  
 PI US 5708143 19980113  
 AI US 1995-453695 19950530 (8)  
 RLI Division of Ser. No. US 1994-268161, filed on 27 Jun 1994 which is a continuation-in-part of Ser. No. US 1992-098003, filed on 29 Dec 1992

DT Utility  
 FS Granted  
 LN.CNT 1738  
 INCL INCLM: 530/350.000  
 INCL INCLM: 435/069.100; 530/395.000  
 NCL NCIM: 530/350.000  
 NCL NCIS: 435/069.100; 530/395.000  
 IC [6]  
 ICM: C07K014-435  
 ICS: C12N015-12  
 EXF 530/350; 530/395; 435/69.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 104 OF 239 USPATFULL  
 AN 1998:4624 USPATFULL  
 TI Methods for promoting wound healing  
 IN Samid, Dvorit, Rockville, MD, United States  
 PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)  
 PI US 5708025 19980113  
 AI US 1995-465835 19950606 (8)  
 RLI Division of Ser. No. US 1993-135661, filed on 12 Oct 1993 which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991

DT Utility  
 FS Granted  
 LN.CNT 4206  
 INCL INCLM: 514/538.000  
 INCL INCLM: 514/567.000; 514/885.000; 514/886.000; 514/928.000  
 NCL NCIM: 514/538.000  
 NCL NCIS: 514/567.000; 514/885.000; 514/886.000; 514/928.000  
 IC [6]  
 ICM: A01N037-12  
 ICS: A01N037-44; A61K031-24  
 EXF 514/538; 514/567; 514/885; 514/886; 514/928; 560/19  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 105 OF 239 USPATFULL  
 AN 1998:1797 USPATFULL  
 TI Signal transduction inhibitor compounds  
 IN Kohn, Elise C., Olney, MD, United States  
 PA Reid, Christian C., Bethesda, MD, United States  
 PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)  
 PI US 5705514 19980106  
 AI US 1995-455825 19950531 (8)  
 RLI Division of Ser. No. US 1994-270181, filed on 1 Jul 1994, now patented, Pat. No. US 5482954 which is a division of Ser. No. US 1992-985402, filed on 4 Dec 1992, now patented, Pat. No. US 5359078 which is a continuation-in-part of Ser. No. US 1989-355744, filed on 19 May 1989, now patented, Pat. No. US 5132315 which is a continuation-in-part of Ser. No. US 1992-944009, filed on 11 Sep 1992, now abandoned which is a continuation of Ser. No. US 1991-637145, filed on 3 Jan 1991, now abandoned And a continuation-in-part of Ser. No. US 1992-894891, filed

DT Utility  
 FS Granted  
 LN.CNT 1502  
 INCL INCLM: 514/359.000  
 INCL INCLM: 514/383.000; 514/396.000; 514/398.000; 514/399.000; 548/255.000; 548/265.400; 548/265.800; 548/335.500; 548/343.500  
 NCL NCIM: 514/359.000  
 NCL NCIS: 514/383.000; 514/396.000; 514/398.000; 514/399.000; 548/255.000; 548/265.400; 548/265.800; 548/335.500; 548/343.500  
 IC [6]  
 ICM: A61K031-41  
 ICS: A61K031-415  
 EXF 514/359; 514/383; 514/396; 514/398; 514/399; 548/255; 548/265.4; 548/265.8; 548/326.5; 548/335.5; 548/343.5  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 106 OF 239 USPATFULL  
 AN 97:123228 USPATFULL  
 TI Hydroxamic acid compounds as metalloprotease and TNF inhibitors  
 IN Xue, Chu-Biao, Hockessin, DE, United States  
 PA DeGrado, William F., Philadelphia, PA, United States  
 PA Decicco, Carl Peter, Newark, DE, United States  
 PA Jacobson, Irina Cipora, Boothwyn, PA, United States  
 PA The DuPont Merck Pharmaceutical Company, Wilmington, DE, United States (U.S. corporation)  
 PI US 5703092 19971230  
 AI US 1996-632863 19960416 (8)  
 RLI Continuation-in-part of Ser. No. US 1995-423197, filed on 18 Apr 1995, now abandoned

DT Utility  
 FS Granted  
 LN.CNT 2204  
 INCL INCLM: 514/303.000  
 INCL INCLM: 514/394.000; 514/399.000; 546/334.000; 546/118.000; 548/309.700; 548/180.000; 548/204.000; 548/217.000; 548/235.000; 548/247.000; 548/253.000; 548/338.100; 548/375.100; 562/623.000  
 NCL NCIM: 514/303.000  
 NCL NCIS: 514/394.000; 514/399.000; 546/118.000; 546/334.000; 548/180.000; 548/204.000; 548/217.000; 548/235.000; 548/247.000; 548/253.000; 548/309.700; 548/338.100; 548/375.100; 562/623.000  
 IC [6]  
 ICM: A61K031-435  
 ICS: A61K031-415; C07D471-04; C07D235-16  
 EXF 546/118; 546/334; 548/180; 548/204; 548/217; 548/235; 548/247; 548/253; 548/309.7; 548/333.1; 548/375.1; 514/303; 514/394; 514/399  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 107 OF 239 USPATFULL  
 AN 97:123185 USPATFULL  
 TI Protection against liver damage by HGF  
 IN Roos, Filip, Brisbane, CA, United States  
 PA Schwall, Ralph, Pacifica, CA, United States  
 PA Genentech, Inc., So. San Francisco, CA, United States (U.S. corporation)  
 PI US 5703048 19971230  
 AI US 1995-452485 19950526 (8)  
 RLI Continuation of Ser. No. US 1994-310361, filed on 21 Sep 1994, now abandoned which is a continuation of Ser. No. US 1992-968711, filed on 30 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-946663, filed on 16 Sep 1992, now abandoned

DT Utility  
 FS Granted  
 LN.CNT 2062  
 INCL INCLM: 514/012.000

INCL: 514/002.000; 514/893.000; 514/894.000; 514/838.000; 530/350.000;  
 530/399.000; 435/360.000; 935/013.000  
 NCL: 514/012.000  
 NCIS: 435/360.000; 514/002.000; 514/838.000; 514/893.000; 514/894.000;  
 530/350.000; 530/399.000  
 IC [6]  
 ICM: A61K038-18  
 ICS: C07K014-475; C12N015-12; C07H021-04  
 514/12; 514/893; 514/894; 514/838; 514/2; 424/130.1; 530/350; 530/399;  
 435/360; 935/13  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 108 OF 239 USPTAFULL  
 AN 97:120654 USPTAFULL  
 TI Hydroxamic acid derivatives as metalloproteinase inhibitors  
 IN Dickens, Jonathan Philip, Cambridge, United Kingdom  
 Crimmin, Michael John, Cowley, United Kingdom  
 Beckett, Raymond Paul, Cowley, United Kingdom  
 British Biotech Pharmaceuticals Limited, Oxford, United Kingdom  
 PA (non-U.S. corporation)  
 PI US 5700838 19971223  
 WO 9402447 19940203  
 US 1995-374602 19950123 (8)  
 WO 1993-GB1557 19930723  
 PCT 371 date  
 19950123 PCT 102(e) date  
 19920723  
 PRAI GB 1992-15665 19920723  
 DT Utility  
 FS Granted  
 LN.CNT 1624  
 INCL INCL: 514/575.000  
 INCL: 562/623.000  
 NCIS: 514/575.000  
 NCL NCIS: 562/623.000  
 IC [6]  
 ICM: A61K031-19  
 ICS: 562/623; 514/575  
 EXF 562/623; 514/575  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 109 OF 239 USPTAFULL  
 AN 97:120498 USPTAFULL  
 TI Selection of cells having increased cell adhesion properties  
 IN Pierschbacher, Michael D., San Diego, CA, United States  
 Riosabli, Erkki I., San Diego, CA, United States  
 Dedhar, Shoukat, North Vancouver, Canada  
 La Jolla Cancer Research Foundation, La Jolla, CA, United States (U.S. corporation)  
 PI US 5700681 19971223  
 US 1994-359956 19941220 (8)  
 Continuation of Ser. No. US 1991-683482, filed on 9 Apr. 1991, now abandoned which is a continuation of Ser. No. US 1987-102021, filed on 28 Sep. 1987, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 921  
 INCL INCL: 435/240.210  
 INCL: 435/240.200; 435/240.230; 530/350.000; 530/356.000  
 NCL NCIS: 435/377.000  
 NCIS: 435/378.000; 530/350.000; 530/356.000  
 IC [6]  
 ICM: C12N005-06  
 ICS: C07K014-00  
 EXF 435/240.2; 435/240.21; 435/240.23; 435/948; 435/70.3; 435/375; 435/377;  
 530/390; 530/356  
 DT

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 110 OF 239 USPTAFULL  
 AN 97:117898 USPTAFULL  
 TI Method of predicting fetal membrane rupture based on  
 pro-matrix metalloproteinase-9 (pro-mmp-9)  
 IN Strauss, III, Jerome Frank, Wyndmoor, PA, United States  
 Vadillo-Oreaga, Felipe, La Magdalena, Mexico  
 University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)  
 PI US 5698404 19971216  
 US 1996-727883 19961009 (8)  
 Continuation of Ser. No. US 1994-246814, filed on 20 May 1994, now patented, Pat. No. US 5641636  
 RLI  
 DT Utility  
 FS Granted  
 LN.CNT 681  
 INCL INCL: 435/074.000  
 INCL: 435/018.000; 435/023.000; 435/024.000; 436/518.000; 436/530.000;  
 436/531.000  
 NCL NCIS: 435/007.400  
 NCIS: 435/018.000; 435/023.000; 435/024.000; 436/518.000; 436/530.000;  
 436/531.000  
 IC [6]  
 ICM: G01N033-53  
 EXF 435/7.1; 435/7.4; 435/18; 435/23; 435/24; 436/518; 436/528; 436/529;  
 436/530; 436/531  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 111 OF 239 USPTAFULL  
 AN 97:115252 USPTAFULL  
 TI Methods and compositions for inhibiting metastasis of  
 epithelial cell-derived cancers  
 IN Paterno, Steven R., Falls Church, VA, United States  
 Manyak, Michael, Chevy Chase, MD, United States  
 George Washington University, Washington, DC, United States (U.S. corporation)  
 PI US 5696092 19971209  
 US 1995-400084 19950307 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 1239  
 INCL INCL: 514/021.000  
 INCL: 514/012.000  
 NCIS: 514/021.000  
 NCL NCIS: 514/012.000  
 IC [6]  
 ICM: A61K038-17  
 EXF 530/350; 530/352; 530/359; 530/386; 530/395; 530/850; 530/851; 530/853;  
 514/7; 514/8; 514/12; 514/21  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 112 OF 239 USPTAFULL  
 AN 97:115246 USPTAFULL  
 TI Methods and kits using macrophage stimulating protein  
 IN Avraham, Hava Karsenty, Brookline, MA, United States  
 Godowski, Paul J., Burlingame, CA, United States  
 Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)  
 Beth Israel Deaconess Medical Center, Inc., Boston, MA, United States (U.S. corporation)  
 PI US 5696086 19971209  
 US 1994-334177 19941103 (8)  
 DT Utility

FS Granted  
LN.CNT 1417  
INCL INCLM: 514/012.000  
INCL INCLM: 530/351.000; 536/380.000  
NCLM: 514/012.000  
NCLM: 530/351.000; 536/380.000  
IC [6]  
ICM: A61K038-16  
ICS: A61K038-19; C07K014-00; C07K014-52  
530/351; 530/380; 530/412; 514/42  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 113 OF 239 USPATFULL  
AN 97:115162 USPATFULL  
TI Submucosa as a growth substrate for islet cells  
IN Badylak, Stephen F., W. Lafayette, IN, United States  
Boder, George, Martinsville, IN, United States  
Voytk, Sherry, Lafayette, IN, United States  
Demeter, Robert J., Mooresville, IN, United States  
Crisser, John, Carmel, IN, United States  
Liu, Chi, Indianapolis, IN, United States  
Purdue Research Foundation, West Lafayette, IN, United States (U.S. corporation)

PA Methodist Hospital of Indiana, Inc., Indianapolis, IN, United States (U.S. corporation)  
AI US 5695998 19971209  
DT US 1995-386452 19950210 (8)  
FS Utility  
FS Granted

LN.CNT 847  
INCL INCLM: 435/391.000  
NCLM: 435/391.000  
IC [6]  
ICM: C12N005-00  
EXF 435/240.2; 435/240.23; 435/240.243; 435/240.3; 435/391  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 114 OF 239 USPATFULL  
AN 97:109937 USPATFULL  
TI Hydroxamic and carbocyclic acids as metalloprotease inhibitors  
IN Jacobson, Irina Cipora, Boothwyn, PA, United States  
Decicco, Carl Peter, Newark, DE, United States  
Cherney, Robert Joseph, Newark, DE, United States  
The DuPont Merck Pharmaceutical Company, Wilmington, DE, United States (U.S. corporation)  
PI US 5691381 19971125  
AI US 1996-632973 19960416 (8)  
RLI Continuation-in-part of Ser. No. US 1995-423192, filed on 18 Apr 1995, now abandoned  
DT Utility  
FS now abandoned  
FS Granted

LN.CNT 1970  
INCL INCLM: 514/562.000  
INCLM: 514/563.000; 514/575.000; 546/348.000; 548/100.000; 548/338.100; 562/405.000; 562/430.000; 562/440.000; 562/442.000; 562/452.000;  
NCLM: 514/562.000  
NCLM: 514/563.000; 514/575.000; 546/348.000; 548/100.000; 548/338.100; 562/405.000; 562/430.000; 562/440.000; 562/444.000; 562/452.000;  
NCLM: 514/565.000; 562/430.000; 562/440.000; 562/444.000; 562/452.000;  
562/455.000; 562/512.000; 562/801.000  
IC [6]  
ICM: A61K031-195  
ICS: A61K031-19; C07D211-72  
EXF 562/801; 562/405; 562/512; 562/430; 562/440; 562/444; 562/452; 562/455;

514/575; 514/562; 514/563; 548/100; 548/338.1; 546/348  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 115 OF 239 USPATFULL  
AN 97:106931 USPATFULL  
TI Cancer diagnosis using nucleic acid hybridization  
IN Sager, Ruth, Brookline, MA, United States  
Zou, Zhiqiang, Gaithersburg, MD, United States  
Lee, Sam Whan, Newton, MA, United States  
Tomasello, Catherine Laure, Strasbourg, France  
Dana-Farber Cancer Institute, Inc., Boston, MA, United States (U.S. corporation)

PA [6]  
PI US 5688641 19971118  
AI US 1994-322742 19941013 (8)  
RLI Continuation of Ser. No. US 1992-938823, filed on 1 Sep 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-844296, filed on 28 Feb 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-662216, filed on 28 Feb 1991, now abandoned  
DT Utility  
FS Granted

LN.CNT 1283  
INCL INCLM: 435/006.000  
INCLM: 435/040.500; 436/503.000; 436/811.000  
NCLM: 435/006.000  
NCLM: 435/040.500; 436/503.000; 436/811.000  
IC [6]  
ICM: C12Q001-68  
EXF 436/501; 436/503; 436/811; 435/6; 435/40.5; 530/350; 536/23.5  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 116 OF 239 USPATFULL  
AN 97:104449 USPATFULL  
TI Basic, alpha.-aminoalkylphosphonate derivatives  
IN Powers, James C., Atlanta, GA, United States  
Boduszek, Bogdan, Wroclaw, Poland  
Oleksyszyn, Jozef, Arlington, MA, United States  
Georgia Tech Research Corp., Atlanta, GA, United States (U.S. corporation)

PA [6]  
PI US 5686419 19971111  
AI US 1994-184286 19940121 (8)  
DT Utility  
FS Granted

LN.CNT 1660  
INCL INCLM: 514/018.000  
INCLM: 514/019.000; 514/007.000; 562/445.000; 530/331.000; 530/345.000  
NCLM: 514/018.000  
NCLM: 514/007.000; 514/019.000; 530/331.000; 530/345.000; 562/445.000  
IC [6]  
ICM: A61K038-06  
EXF 514/18; 514/19; 562/445; 530/331; 530/345  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 117 OF 239 USPATFULL  
AN 97:104323 USPATFULL  
TI Hepatocyte growth factor receptor antagonist antibodies and uses thereof  
IN Scwail, Ralph H., Pacifica, CA, United States  
Tabor, Kelly Helen, Hillsborough, CA, United States  
Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

PA [6]  
PI US 5686292 19971111  
AI US 1995-460368 19950602 (8)  
DT Utility  
FS Granted

LN.CNT 1406

INCL INCLM: 435/240.270  
INCL: 424/133.100; 424/143.100; 530/387.300; 530/387.700; 530/388.100;  
530/388.200; 530/388.220; 530/388.800; 530/388.850; 530/389.100;  
530/389.700  
NCL NCLM: 424/143.100  
NCL: 424/133.100; 435/334.000; 530/387.300; 530/387.700; 530/388.100;  
530/388.200; 530/388.220; 530/388.800; 530/388.850; 530/389.100;  
530/389.700  
IC [6]  
ICM: C12N005-12  
ICS: A61K039-395; C07K06-28  
EXF 530/387.7; 530/388.1; 530/388.2; 530/388.8; 530/388.85; 530/389.1;  
530/389.7; 530/387.3; 424/133.1; 424/143.1; 435/240.27  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 118 OF 239 USPTAFULL  
AN 97.101902 USPTAFULL  
TI Preparation of carbonylalkyl derivatives as inhibitors of matrix  
metalloproteinases  
IN Pomplom, Miree M., Branchburg, NJ, United States  
Hagmann, William K., Westfield, NJ, United States  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 5684152 19971104  
AI US 1996-716042 19960919 (8)  
PRAI US 1995-5272P 19950928 (60)  
DT Utility  
FS Granted  
LN.CNT 1337  
INCL INCLM: 544/242.000  
INCL: 544/264.000; 544/336.000; 544/358.000; 546/152.000; 546/193.000;  
546/221.000; 548/152.000; 548/206.000; 548/213.000; 548/215.000;  
548/221.000; 548/335.100; 548/343.500; 548/440.000;  
548/469.000; 548/470.000; 548/489.000; 548/491.000; 548/530.000;  
549/006.000; 549/023.000; 549/030.000; 549/049.000;  
549/229.000; 549/266.000; 549/273.000; 549/307.000; 549/313.000;  
568/735.000  
NCL NCLM: 544/264.000  
NCL: 544/242.000; 544/336.000; 544/358.000; 546/152.000; 546/193.000;  
546/221.000; 548/152.000; 548/206.000; 548/213.000; 548/215.000;  
548/221.000; 548/335.100; 548/343.500; 548/440.000;  
548/469.000; 548/470.000; 548/489.000; 548/491.000; 548/530.000;  
549/006.000; 549/023.000; 549/030.000; 549/049.000;  
549/229.000; 549/266.000; 549/273.000; 549/307.000;  
549/313.000  
IC [6]  
ICM: C07C039-225  
ICS: C07D009-02; C07D027-00; C07D263-04; C07D277-04; C07D307-00;  
C07D413-08; C07D279-00  
EXF 544/242; 544/336; 544/358; 544/264; 546/152; 546/193; 546/249; 548/152;  
548/206; 548/213; 548/335.1; 548/343.5; 548/250; 548/215; 548/221;  
548/440; 548/469; 548/470; 548/489; 548/491; 548/530; 549/6; 549/23;  
549/30; 549/33; 549/49; 549/229; 549/313; 549/266; 549/273; 549/307;  
568/735  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 119 OF 239 USPTAFULL  
AN 97.99272 USPTAFULL  
TI Fluorescent 1-peptidylaminoalkane phosphonate derivatives  
IN Powers, James C., Atlanta, GA, United States  
Abuelyaman, Ahmed S., St. Paul, MN, United States  
PA Georgia Tech Research Corp., Atlanta, GA, United States (U.S.  
corporation)  
PI US 5681821 19971028  
AI US 1994-324809 19941018 (8)  
DT Utility  
FS Granted

LN.CNT 927  
INCL INCLM: 514/019.000  
INCL: 514/018.000; 514/007.000; 530/331.000; 435/004.000  
NCL NCLM: 514/019.000  
NCL: 435/004.000; 514/007.000; 514/018.000; 530/331.000  
IC [6]  
ICM: A61K038-05  
EXF 514/18; 514/19; 514/7; 530/331  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 120 OF 239 USPTAFULL  
AN 97.96892 USPTAFULL  
TI Substituted phosphonic acid-containing (peptidyl) derivatives as  
antidysplastic agents  
IN Caldwell, Charles G., Scotch Plains, NJ, United States  
Durette, Philippe L., New Providence, NJ, United States  
Goulet, Jean L., Westfield, NJ, United States  
Hagmann, William K., Westfield, NJ, United States  
PA Sano, Soumya P., Old Bridge, NJ, United States  
PI Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
AI US 5679700 19971021  
RUI US 1995-555535 19951109 (8)  
Continuation of Ser. No. US 1994-256217, filed on 5 Jul 1994, now  
abandoned which is a continuation-in-part of Ser. No. US 1992-821113,  
filed on 15 Jan 1992, now abandoned  
DT Utility  
FS Granted  
LN.CNT 1997  
INCL INCLM: 514/416.000  
INCL: 514/417.000; 514/422.000; 514/429.000; 514/399.000; 514/418.000;  
514/419.000; 548/413.000; 548/414.000; 548/415.000; 548/481.000;  
548/472.000; 548/491.000; 548/412.000; 549/058.000; 549/005.000;  
549/220.000; 549/048.000; 549/221.000; 546/145.000; 546/117.000;  
544/243.000; 544/337.000; 568/015.000; 568/170.000  
NCL NCLM: 514/416.000  
NCL: 514/399.000; 514/417.000; 514/418.000; 514/419.000; 514/422.000;  
514/428.000; 546/117.000; 546/145.000; 548/112.000; 548/413.000;  
548/414.000; 548/415.000; 548/472.000; 548/481.000; 548/491.000;  
549/005.000; 549/058.000; 549/218.000; 549/220.000; 549/221.000  
IC [6]  
ICM: A61K031-40  
ICS: C07F009-50  
EXF 514/399; 514/416; 514/419; 514/417; 514/422; 514/428; 548/481; 548/472;  
548/491; 548/112; 548/414; 548/415; 548/413; 549/58; 549/5; 549/220;  
549/218; 549/221; 546/145; 546/117; 544/243; 544/337; 568/15; 568/170  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 121 OF 239 USPTAFULL  
AN 97.96832 USPTAFULL  
TI Bone and prostate-derived protein factors affecting prostate cancer  
growth, differentiation, and metastasis  
IN Chung, Leland W. K., Houston, TX, United States  
Chan, James C., Sugarland, TX, United States  
PA Logothetis, Christopher J., Houston, TX, United States  
Board of Regents, The University of Texas, Austin, TX, United States  
PI US 5679636 19971021  
AI US 1994-341297 19941115 (8)  
RUI Continuation of Ser. No. US 1992-859228, filed on 30 Mar 1992, now  
abandoned  
DT Utility  
FS Granted  
LN.CNT 1620  
INCL INCLM: 514/002.000

INCL INCL: 530/399.000; 530/350.000; 530/412.000; 530/413.000  
 NCL NCIM: 514/002.000  
 NCL: 530/350.000; 530/399.000; 530/412.000; 530/413.000  
 IC [6] A61K038-18  
 ICM: C07K014-475; A23J001-00  
 EXF 514/2; 530/350; 530/399; 530/412; 530/413  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 122 OF 239 USPTAFULL  
 AN 97:96559 USPTAFULL  
 TI Method of delivery of a medicament to a cancer cell using a pathway of plasmidogen activator material  
 IN Jankun, Jerzy, Sylvania, OH, United States  
 PA Hart, Richard, Greenwich, CT, United States  
 PI The University of Toledo, Toledo, OH, United States (U.S. corporation)  
 RLI US 5679380 19971021  
 US 1996-646561 19960508 (8)  
 Continuation of Ser. No. US 1994-294950, filed on 24 Aug 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-59813, filed on 10 May 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-889783, filed on 28 May 1992, now abandoned

DT Utility  
 FS Granted  
 LN.CNT 1079  
 INCL INCL: 424/193.100  
 INCL: 424/197.110; 424/542.000; 435/326.000; 435/346.000  
 NCL NCIM: 424/193.100  
 NCL: 424/197.110; 424/542.000; 435/326.000; 435/346.000  
 IC [6] ICM: A61K039-385  
 EXF 424/193.11; 424/197.11; 424/196.11; 424/542; 435/240.26; 435/240.27; 435/326; 435/346  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 123 OF 239 USPTAFULL  
 AN 97:96548 USPTAFULL  
 TI Method of using IL-11 for treating spondyloarthropathies  
 IN Keith, James, 28 Vine St., Andover, MA, United States 01810  
 PI Schendel, Paul, 39 Jeffrey Rd., Wayland, MA, United States 01778  
 US 5679339 19971021  
 US 1995-495724 19950627 (8)  
 Utility  
 FS Granted  
 LN.CNT 711  
 INCL INCL: 424/085.200  
 INCL: 530/351.000  
 NCL NCIM: 424/085.200  
 NCL: 530/351.000  
 IC [6] ICM: A61K045-05  
 ICS: C07K017-00  
 EXF 530/350T; 530/351; 424/85.1; 424/85.2  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 124 OF 239 USPTAFULL  
 AN 97:94079 USPTAFULL  
 TI Recombinant DNA encoding CCK 2, a receptor tyrosine kinase  
 IN Ullrich, Axel, Adalbertstr. 108, Munchen, Germany, Federal Republic of  
 PI Alves, Franke Hildegard Elisabeth, Rohmsweg 2, Gollingen, Germany, Federal Republic of  
 US 5677144 19971014  
 US 1994-336343 19941108 (8)  
 Continuation-in-part of Ser. No. US 1993-153397, filed on 16 Nov 1993

DT Utility  
 FS Granted  
 LN.CNT 2400  
 INCL INCL: 435/069.100  
 INCL: 435/069.700  
 NCL NCIM: 435/069.100  
 NCL: 435/069.700; 435/252.300; 435/320.100; 530/350.000; 536/023.400; 536/023.500  
 IC [6] ICM: C07K014-705  
 ICS: C12N015-62; C12N015-12  
 EXF 435/69.1; 435/69.7; 435/252.3; 435/320.1; 530/350; 536/23.4; 536/23.5  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 125 OF 239 USPTAFULL  
 AN 97:88995 USPTAFULL  
 TI Arylsulfonamido-substituted hydroxamic acids  
 IN MacPherson, Lawrence J., Hampton, NJ, United States  
 PA Farber, David Thomas, Livingston, NJ, United States  
 PI Novartis Corporation, Summit, NJ, United States (U.S. corporation)  
 RLI US 5672615 19970930  
 US 1996-613303 19960311 (8)  
 Division of Ser. No. US 1994-333676, filed on 3 Nov 1994, now patented, Pat. No. US 5552419 which is a continuation-in-part of Ser. No. US 1994-265296, filed on 24 Jun 1994, now patented, Pat. No. US 5506242 which is a continuation-in-part of Ser. No. US 1993-1136, filed on 6 Jan 1993, now patented, Pat. No. US 5455258, issued on 3 Nov 1995

DT Utility  
 FS Granted  
 LN.CNT 3487  
 INCL INCL: 514/357.000  
 INCL: 514/327.800; 514/311.000; 514/331.000; 514/332.000; 514/341.000; 514/365.000; 514/396.000; 514/406.000; 514/432.000; 514/445.000; 514/451.000; 514/602.000; 514/604.000; 540/524.000; 540/531.000; 544/168.000; 544/168.000; 544/130.000; 544/131.000; 544/133.000; 546/175.000; 546/194.000; 546/209.000; 546/237.000; 546/265.000; 546/283.400; 546/282.100; 546/333.000; 546/337.000; 546/280.400; 546/284.400; 546/281.700; 546/275.100; 548/205.000; 548/335.100; 548/338.100; 549/013.000; 549/065.000; 549/426.000; 564/084.000; 564/090.000; 564/092.000; 564/094.000  
 NCL NCIM: 514/357.000  
 NCL: 514/237.800; 514/311.000; 514/331.000; 514/332.000; 514/341.000; 514/365.000; 514/396.000; 514/406.000; 514/432.000; 514/445.000; 514/451.000; 514/602.000; 514/604.000; 540/524.000; 540/531.000; 544/168.000; 544/168.000; 544/130.000; 544/131.000; 544/133.000; 546/175.000; 546/194.000; 546/209.000; 546/237.000; 546/265.000; 546/283.400; 546/282.100; 546/280.400; 546/281.700; 546/275.100; 548/205.000; 548/335.100; 548/338.100; 549/013.000; 549/065.000; 549/426.000; 564/084.000; 564/090.000; 564/092.000; 564/094.000  
 IC [6] ICM: C07D213-42  
 ICS: A61K031-44  
 EXF 514/237.81; 514/357; 514/311; 514/331; 514/332; 514/341; 514/365; 514/396; 514/406; 514/432; 514/445; 514/451; 514/602; 514/604; 540/524; 540/531; 544/168; 544/130; 544/131; 546/175; 546/194; 546/209; 546/247; 546/265; 546/283.4; 546/282.1; 546/333; 546/337; 546/280.4; 546/284.4; 546/281.7; 546/275.1; 548/205; 548/335.1; 548/338.1; 549/13; 549/65; 549/426; 564/84; 564/90; 564/92; 564/94  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 126 OF 239 USPTAFULL  
 AN 97:88979 USPTAFULL



TI Lactam-containing hydroxamic acids  
 IN De, Bismarck, Cincinnati, OH, United States  
 Mahl, Christopher Thomas, Hamilton, OH, United States  
 Natchus, Michael George, Cincinnati, OH, United States  
 Geng, Henry, West Chester, OH, United States  
 The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)  
 PA US 5672598 19970930  
 AI US 1996-407839 19950321 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 1837  
 INCL INCLM: 514/212.000  
 INCLM: 540/528.000; 546/243.000; 548/550.000; 514/327.000; 514/424.000  
 NCLM: 514/212.030  
 NCLM: 514/327.000; 514/424.000; 540/528.000; 546/243.000; 548/550.000  
 IC [6]  
 ICM: C07D223-10  
 ICS: A61K031-35  
 EXF 540/528; 546/243; 548/550; 514/212; 514/327; 514/424  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 127 OF 239 USPTFOLL  
 AN 97.88973 USPTFOLL  
 TI Certain phosphonometyl-pentanedioic acid derivatives thereof  
 IN Jackson, Paul F., Bel Air, MD, United States  
 Slusher, Barbara S., Kingsville, MD, United States  
 Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)  
 PA US 5672592 19970930  
 AI US 1996-665776 19960617 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 1347  
 INCL INCLM: 514/075.000  
 INCLM: 562/008.000; 562/012.000; 546/021.000; 546/022.000; 548/412.000; 548/413.000; 549/005.000; 549/006.000; 549/216.000; 549/218.000; 549/219.000; 562/008.000; 562/012.000  
 NCLM: 514/075.000  
 NCLM: 546/021.000; 546/022.000; 548/412.000; 548/413.000; 549/005.000; 549/006.000; 549/216.000; 549/218.000; 549/219.000; 562/008.000; 562/012.000  
 IC [6]  
 ICM: A61K031-66  
 ICS: C07F009-38; C07F009-58; C07F009-572  
 EXF 562/8; 562/12; 514/75  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 128 OF 239 USPTFOLL  
 AN 97.88965 USPTFOLL  
 TI Carboxy-peptidyl derivatives as antidegenerative active agents  
 IN Chapman, Kevin, Scotch Plains, NJ, United States  
 Hagmann, William, Westfield, NJ, United States  
 Barette, Philippe, New Providence, NJ, United States  
 Baser, Craig, Belford, NJ, United States  
 Kopka, Ihor, Millburn, NJ, United States  
 Caldwell, Charles, Scotch Plains, NJ, United States  
 Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
 PA US 5672583 19970930  
 AI US 1995-436347 19950517 (8)  
 WO 1993-US11207 19931118  
 RLI 19950517 PCT 311 date  
 19950517 PCT 102(e) date  
 Continuation-in-part of Ser. No. US 1992-981970, filed on 25 Nov 1992, now abandoned

DT Utility  
 FS Granted  
 LN.CNT 3440  
 INCL INCLM: 514/019.000  
 INCLM: 514/020.000; 514/330.000; 514/375.000; 514/367.000; 514/394.000; 514/416.000; 562/450.000; 562/574.000; 548/152.000; 548/217.000; 548/304.400; 548/486.000; 548/400.000; 548/116.000; 548/206.000; 548/254.000; 548/336.000; 548/357.000; 548/213.000; 548/252.000; 546/152.000; 549/491.000; 549/498.000; 549/029.000; 549/065.000; 549/069.000; 549/462.000; 549/049.000; 544/295.000; 544/296.000; 544/264.000; 544/336.000; 544/357.000  
 NCLM: 514/019.000  
 NCLM: 514/020.000; 514/330.000; 514/367.000; 514/375.000; 514/394.000; 514/416.000; 548/152.000; 548/206.000; 548/213.000; 548/217.000; 548/304.400; 548/486.000; 562/450.000; 562/574.000  
 IC [6]  
 ICM: A61K037-02  
 ICS: C07C259-06; C07C237-52; C07D277-62  
 EXF 514/19; 514/20; 514/416; 514/394; 514/367; 514/375; 514/330; 562/567; 562/574; 562/450; 548/486; 548/304.4; 548/152; 548/217; 548/400; 548/146; 548/206; 548/252; 548/254; 548/336; 548/357; 548/215; 548/240; 546/245  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 129 OF 239 USPTFOLL  
 AN 97.81418 USPTFOLL  
 TI Cancer related antigen  
 IN Kuhajda, Francis P., Lutherville, MD, United States  
 Pasternack, Gary R., Baltimore, MD, United States  
 John Hopkins University, Baltimore, MD, United States (U.S. corporation)  
 PA US 566874 19970909  
 AI US 1995-469005 19950605 (8)  
 RLI Division of Ser. No. US 1994-188426, filed on 24 Jan 1994 which is a continuation-in-part of Ser. No. US 1993-96908, filed on 26 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-917716, filed on 24 Jul 1992, now abandoned and a continuation-in-part of Ser. No. US 1991-735522, filed on 26 Jul 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-622407, filed on 4 Dec 1990, now abandoned which is a continuation of Ser. No. US 1989-297722, filed on 17 Jan 1989, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 2924  
 INCL INCLM: 536/024.300  
 INCLM: 536/022.100; 536/023.100; 536/024.310; 536/024.320; 536/024.330; 435/006.000; 435/912.000; 435/320.100; 435/325.000  
 NCLM: 536/024.300  
 NCLM: 435/006.000; 435/091.200; 435/320.100; 435/325.000; 536/022.100; 536/023.100; 536/024.310; 536/024.320; 536/024.330  
 IC [6]  
 ICM: C07H021-02  
 ICS: C07H021-04; C12P019-34; C12Q001-68  
 EXF 536/22.1; 536/23.1; 536/24.3; 536/24.32; 536/24.33; 435/240.2; 435/91.2; 435/20.1; 435/6  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 130 OF 239 USPTFOLL  
 AN 97.81301 USPTFOLL  
 TI Cytokine inhibiting imidazole substituted hydroxamic acid derivatives  
 IN Frazee, James Simpson, Sewell, NJ, United States  
 Gleason, John Gerald, Downingtown, PA, United States  
 Metcalf, Brian Walter, Radnor, PA, United States  
 SmithKline Beecham Corporation, Philadelphia, PA, United States (U.S. corporation)

PI US 5665753 19970909  
 WO 9523790 19950908  
 AI US 1996-702528 19960903 (8)  
 WO 1995-US2606 19950303  
 19960903 PCT 371 date  
 19960903 PCT 102 (e) date  
 PRAI GB 1994-4046 19940303  
 DT Utility Granted  
 FS Granted  
 LN CNT 1021  
 INCL INCLM: 514/394.000  
 INCLM: 514/396.000; 548/302.700; 548/304.400; 548/335.100; 548/338.100;  
 NCLM: 514/394.000  
 NCLM: 514/396.000; 548/302.700; 548/304.400; 548/335.100; 548/338.100;  
 NCLM: 514/394.000  
 NCLM: 514/396.000; 548/302.700; 548/304.400; 548/335.100; 548/338.100;  
 IC [6]  
 ICM: A01N043-52  
 ICS: A61K031-415; C07D233-64; C07D235-04  
 EXF 514/394; 514/396; 548/302.7; 548/304.4; 548/335.1; 548/338.1; 548/343.5  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 131 OF 239 USPTAFULL  
 AN 97:78669 USPTAFULL  
 TI Sphingosine-1-phosphate essentially free of L-threo isomer  
 IN Igarashi, Yasuyuki, Seattle, WA, United States  
 Ruan, Fugiang, Seattle, WA, United States  
 Sadahira, Yoshito, Seattle, WA, United States  
 Kawa, Shigeyuki, Seattle, WA, United States  
 Hakomori, Sen-itiroh, Seattle, WA, United States  
 Onomomachi, Seattle, WA, United States (U.S. corporation)  
 PA US 5664404 19970902  
 PI US 1995-371866 19950112 (8)  
 Division of Ser. No. US 1993-104504, filed on 9 Aug 1993, now patented,  
 Pat. No. US 5391800 which is a division of Ser. No. US 1992-863179,  
 filed on 3 Apr 1992, now patented, Pat. No. US 5260288  
 DT Utility Granted  
 FS Granted  
 LN CNT 983  
 INCL INCLM: 558/169.000  
 INCLM: 558/169.000  
 NCLM: 558/169.000  
 IC [6]  
 ICM: C07F009-09  
 ICM: 558/169  
 EXF 558/169  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 132 OF 239 USPTAFULL  
 AN 97:78569 USPTAFULL  
 TI Proccadherin-42  
 IN Suzuki, Shintaro, Torrance, CA, United States  
 PA Dohany Eye Institute, Los Angeles, CA, United States (U.S. corporation)  
 PI US 5663300 19970902  
 AI US 1995-453274 19950530 (8)  
 Division of Ser. No. US 1992-998003, filed on 29 Dec 1992  
 DT Utility Granted  
 FS Granted  
 LN CNT 1474  
 INCL INCLM: 530/350.000  
 INCLM: 530/350.000  
 NCLM: 530/350.000  
 NCLM: 530/350.000  
 NCLM: 530/350.000  
 IC [6]  
 ICM: C07K014-705  
 EXF 530/350; 530/395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 133 OF 239 USPTAFULL  
 AN 97:76161 USPTAFULL  
 TI Methods for treating neoplastic conditions using phenylacetic  
 acid and derivatives thereof  
 IN Samd, Dvorit, Rockville, MD, United States  
 PA The United States of America as represented by the Department of Health  
 and Human Services, Washington, DC, United States (U.S. Government)  
 PI US 5661179 19970826  
 AI US 1995-469466 19950606 (8)  
 Continuation of Ser. No. US 1993-135661, filed on 12 Oct 1993 which is a  
 continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991,  
 now abandoned  
 DT Utility Granted  
 FS Granted  
 LN CNT 4056  
 INCL INCLM: 514/538.000  
 INCLM: 514/563.000; 514/567.000; 560/019.000  
 NCLM: 514/538.000  
 NCLM: 514/563.000; 514/567.000; 560/019.000  
 NCLM: 514/563.000; 514/567.000; 560/019.000  
 IC [6]  
 ICM: A01N037-12  
 ICS: A01N037-44  
 EXF 514/538; 514/563; 514/567; 560/19  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 134 OF 239 USPTAFULL  
 AN 97:73765 USPTAFULL  
 TI Tumor procease activated prodrugs of phosphoramidate mustard analogs with  
 toxification and detoxification functionalities  
 IN Glazier, Arnold, Newton, MA, United States  
 PA Drug Innovation & Design, Inc., Newton, MA, United States (U.S.  
 corporation)  
 PI US 5659061 19970819  
 AI US 1995-425477 19950420 (8)  
 DT Utility Granted  
 FS Granted  
 LN CNT 758  
 INCL INCLM: 558/166.000  
 INCLM: 558/169.000; 558/170.000; 558/171.000; 514/114.000; 514/118.000;  
 INCLM: 514/137.000; 514/553.000; 514/603.000; 562/067.000; 564/085.000;  
 NCLM: 558/166.000  
 NCLM: 558/169.000; 558/170.000; 558/171.000; 562/067.000; 564/085.000;  
 NCLM: 558/166.000  
 NCLM: 558/169.000; 558/170.000; 558/171.000; 562/067.000; 564/085.000;  
 IC [6]  
 ICM: C07F009-02  
 ICS: A61K031-66  
 EXF 558/166; 558/169; 558/170; 558/171; 558/172; 514/118; 514/553; 514/603;  
 514/114; 514/137; 562/67; 564/85; 564/94  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 135 OF 239 USPTAFULL  
 AN 97:68570 USPTAFULL  
 TI Protection against liver damage by HGF  
 IN Roos, Filip, Brisbane, CA, United States  
 PA Genentech, Inc., So. San Francisco, CA, United States (U.S. corporation)  
 PI US 5654404 19970805  
 AI US 1995-419654 19950410 (8)  
 Division of Ser. No. US 1994-310361, filed on 21 Sep 1994 which is a  
 continuation of Ser. No. US 1992-968711, filed on 30 Oct 1992, now  
 abandoned which is a continuation-in-part of Ser. No. US 1992-946263,

filed on 16 Sep 1992, now abandoned  
utility  
FS Granted  
LN.CNT 2330  
INCL INCLM: 530/387.300  
INCLM: 530/350.000; 424/134.100; 424/136.100; 424/178.100  
NCLM: 530/387.300  
NCLM: 530/387.300  
NCLM: 424/134.100; 424/136.100; 424/178.100; 530/350.000  
IC [6]  
ICM: C07K014-435  
ICS: C12N021-08; A61K039-00; A61K038-16  
EXF 530/389.1; 530/387.3; 530/399; 530/350; 424/138.1; 424/124.1; 424/145.1;  
514/12; 514/2  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 136 OF 239 USPTAFULL  
97.68500 USPTAFULL  
TI Methods for prevention of cancer using phenylacetic acids and  
derivatives thereof  
IN Samdi, Dvorit, Rockville, MD, United States  
PA The United States of America as represented by the Department of Health  
and Human Services, Washington, DC, United States (U.S. government)  
PI US 5654333 19970805  
AI US 1995-465941 19950606 (8)  
RL Division of Ser. No. US 1993-135661, filed on 12 Oct 1993 which is a  
continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991  
DT Utility  
FS Granted  
LN.CNT 4088  
INCL INCLM: 514/538.000  
INCLM: 514/563.000; 514/567.000  
NCLM: 514/538.000  
NCLM: 514/538.000  
NCLM: 514/563.000; 514/567.000  
IC [6]  
ICM: A01N037-12  
ICS: A01N037-44; A61K031-24  
EXF 514/538; 514/563; 514/567  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 137 OF 239 USPTAFULL  
97.59225 USPTAFULL  
TI Arylsulfonamido-substituted hydroxamix acids  
IN Macpherson, Lawrence J., Hampton, NJ, United States  
PA Parker, David T., Livingston, NJ, United States  
PI Ciba-Geigy Corporation, Tarrytown, NY, United States (U.S. corporation)  
AI US 3646167 19970708  
AI US 1995-475166 19950607 (8)  
RL Continuation-in-part of Ser. No. US 1994-333676, filed on 3 Nov 1994,  
now patented, Pat. No. US 5552419 which is a continuation-in-part of  
Ser. No. US 1994-265296, filed on 24 Jun 1994, now patented, Pat. No. US  
5506242 which is a continuation-in-part of Ser. No. US 1993-1136, filed  
on 6 Jan 1993, now patented, Pat. No. US 5455258  
DT Utility  
FS Granted  
LN.CNT 3483  
INCL INCLM: 514/357.000  
INCLM: 546/336.000; 546/337.000  
NCLM: 514/357.000  
NCLM: 514/357.000  
NCLM: 546/336.000; 546/337.000  
IC [6]  
ICM: A61K031-44  
ICS: C07D213-42  
EXF 546/175; 546/247; 546/265; 546/276.4; 546/336; 546/337; 548/205;  
548/335.1; 548/338.1; 544/168; 549/13; 549/65; 549/426; 564/84; 564/92;

564/94; 564/90; 514/237.8; 514/311; 514/331; 514/332; 514/341; 514/357;  
514/365; 514/396; 514/445; 514/462; 514/604; 514/406; 514/432; 514/451  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 138 OF 239 USPTAFULL  
97.59098 USPTAFULL  
TI Nucleic acids encoding hepatocyte growth factor receptor antagonist  
antibodies  
IN Schwall, Ralph H., Pacifica, CA, United States  
PA Tabor, Kelly Helen, Hillsborough, CA, United States  
denentech, Inc., South San Francisco, CA, United States (U.S.  
corporation)  
PI US 5646036 19970708  
AI US 1995-459388 19950602 (8)  
DT Utility  
FS Granted  
LN.CNT 1402  
INCL INCLM: 435/252.300  
INCLM: 435/240.200; 435/320.100; 536/023.530; 530/387.700; 530/388.220;  
530/388.800; 530/388.850; 530/389.100; 530/389.700  
NCLM: 435/252.300  
NCLM: 435/320.100; 435/334.000; 530/387.700; 530/388.220; 530/388.800;  
530/388.850; 530/389.100; 530/389.700; 536/023.530  
IC [6]  
ICM: C12N015-13  
ICS: C12N015-85; C12N001-21; C07K016-28  
EXF 536/23.53; 530/387.7; 530/388.1; 530/388.22; 530/388.8; 530/388.85;  
530/389.1; 530/389.7; 435/320.1; 435/240.2; 435/252.3  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 139 OF 239 USPTAFULL  
97.56730 USPTAFULL  
TI Natural amino acid derivatives as metalloproteinase inhibitors  
IN Dickens, Jonathan Philip, Cambridge, England  
Crimmin, Michael John, Cowley, England  
Beckett, Raymond Paul, Cowley, England  
PA British Biotech Pharmaceuticals Limited, Cowley, United Kingdom  
(non-U.S. corporation)  
PI US 5643964 19970701  
AI WO 9402446 19940203 #STR1#  
AI US 1995-374601 19950123 (8)  
AI WO 1993-GB1556 19950123 PCT 371 date  
19950123 PCT 102(e) date  
PRAI GB 1992-15665 19920723  
DT Utility  
FS Granted  
LN.CNT 772  
INCL INCLM: 514/575.000  
INCLM: 562/623.000  
NCLM: 514/575.000  
NCLM: 562/623.000  
IC [6]  
ICM: A01N037-28  
EXF 562/623; 514/575  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 140 OF 239 USPTAFULL  
97.56656 USPTAFULL  
TI Synthetic oligonucleotides which mimic telomeric sequences for use in  
treatment of cancer and other diseases  
IN Iversen, Patrick L., Ralston, NE, United States  
Mata, John E., Omaha, NE, United States  
PA The Board of Regents of the University of Nebraska, Lincoln, NE, United

States (U.S. corporation)  
 PI US 5643890 19970701  
 US 1995-381097 19950131 (8)  
 Utility  
 FS Granted  
 LN.CNT 1011  
 INCL INCLM: 514/044.000  
 INCLIS: 424/093.210; 435/375.000; 536/023.100  
 NCL NCIM: 514/044.000  
 NCIS: 424/093.210; 435/375.000; 536/023.100  
 IC [6]  
 ICM: A61K048-00  
 ICS: C12N005-10; C07H021-04  
 EXF 435/240.2; 514/44; 536/24.5; 424/93.21  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 141 OF 239 USPTFUL  
 AN 97:56553 USPTFUL  
 TI Adenocarcinoma cell basement membrane composition  
 IN Baskin, Sanford H., Los Angeles, CA, United States  
 PA The Regents of the University of California, Oakland, CA, United States  
 PI US 5643787 19970701  
 US 1995-381384 19950131 (8)  
 Continuation-in-part of Ser. No. US 1994-184720, filed on 21 Jan 1994,  
 now patented, Pat. No. US 5508188, issued on 16 Apr 1996  
 DT Utility  
 FS Granted  
 LN.CNT 1397  
 INCL INCLM: 435/371.000  
 INCLIS: 435/378.000; 435/373.000; 435/395.000; 435/383.000; 435/391.000;  
 435/366.000  
 NCL NCIM: 435/371.000  
 NCIS: 435/373.000; 435/378.000; 435/383.000; 435/391.000;  
 435/395.000  
 IC [6]  
 ICM: C12N005-00  
 ICS: C12N005-02  
 EXF 435/172.3; 435/240.1; 435/371; 435/240.2; 435/373; 435/240.21;  
 435/240.25; 435/391; 424/93.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 142 OF 239 USPTFUL  
 AN 97:56547 USPTFUL  
 TI DNA encoding protocadherin-42  
 IN Suzuki, Shintaro, Torrance, CA, United States  
 PA Doheny Eye Institute, Los Angeles, CA, United States (U.S. corporation)  
 PI US 5643781 19970701  
 US 1992-998003 19921229 (7)  
 DT Utility  
 FS Granted  
 LN.CNT 1496  
 INCL INCLM: 435/325.000  
 INCLIS: 435/252.330; 435/328.100; 536/023.400  
 NCL NCIM: 435/325.000  
 NCIS: 435/252.330; 435/320.100; 536/023.400  
 IC [6]  
 ICM: C12N001-21  
 ICS: C12N005-10; C12N015-70; C12N015-85  
 EXF 435/69.1; 435/172.3; 435/320.1; 435/252.3; 536/23.4  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 143 OF 239 USPTFUL

AN 97:56527 USPTFUL  
 TI Method for generating a subtracted cDNA library and uses of  
 the generated library  
 IN Fisher, Paul B., Scarsdale, NY, United States  
 PA Jiang, Hongping, New York, NY, United States  
 PI US 5643761 19970701  
 US 1993-143576 19931027 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 5927  
 INCL INCLM: 435/091.100  
 INCLIS: 435/006.000; 435/091.200; 435/069.100; 435/172.300; 435/810.000;  
 436/501.000; 536/023.100; 536/024.100; 536/024.300; 536/024.310;  
 536/024.320; 536/024.330; 935/009.000; 935/077.000; 935/078.000  
 NCL NCIM: 435/091.100  
 NCIS: 435/006.000; 435/069.100; 435/091.200; 435/488.000; 435/489.000;  
 435/810.000; 436/501.000; 536/023.100; 536/024.100; 536/024.300;  
 536/024.310; 536/024.320; 536/024.330  
 IC [6]  
 ICM: C12P019-34  
 EXF 435/6; 435/91.1; 435/91.2; 435/69.1; 435/810; 435/172.3; 436/501;  
 536/22.1; 536/23.5; 536/24.5; 536/24.3-24.33; 935/9; 935/77; 935/78  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 144 OF 239 USPTFUL  
 AN 97:54319 USPTFUL  
 TI Method for purifying heterogulin  
 IN Vandlen, Richard L., Hillsborough, CA, United States  
 PA Holmes, William E., Pacifica, CA, United States  
 PI Genentech, Inc., South San Francisco, CA, United States (U.S.  
 corporation)  
 PI US 5641869 19970624  
 US 1995-456201 19950531 (8)  
 Continuation of Ser. No. US 1993-126145, filed on 23 Sep 1993, now  
 abandoned which is a continuation of Ser. No. US 1992-880917, filed on  
 11 May 1992, now abandoned which is a continuation-in-part of Ser. No.  
 US 1992-847743, filed on 6 Mar 1992, now patented, Pat. No. US 5367060,  
 issued on 22 Nov 1994 which is a continuation-in-part of Ser. No. US  
 1991-790801, filed on 8 Nov 1991, now abandoned which is a  
 continuation-in-part of Ser. No. US 1991-765212, filed on 25 Sep 1991,  
 now abandoned which is a continuation-in-part of Ser. No. US  
 1991-705256, filed on 24 May 1991, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 3894  
 INCL INCLM: 530/413.000  
 INCLIS: 530/412.000; 530/415.000; 530/416.000; 530/417.000; 530/418.000  
 NCL NCIM: 530/413.000  
 NCIS: 530/412.000; 530/415.000; 530/416.000; 530/417.000; 530/418.000  
 IC [6]  
 ICM: C07K001-14  
 ICS: C07K001-18; C07K001-20; C07K001-22  
 EXF 530/415; 530/412; 530/413; 530/416; 530/417; 530/418  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 145 OF 239 USPTFUL  
 AN 97:54088 USPTFUL  
 TI Method of predicting fetal membrane rupture based on matrix  
 metalloproteinase-9 activity  
 IN Strauss, Ili, Jerome Frank, Wyndmoor, PA, United States  
 PA Vadillo-Ortega, Felipe, La Magdalena, Mexico  
 University of Pennsylvania, Philadelphia, PA, United States (U.S.

corporation)  
 PI US 5641636 19970624  
 AI US 1994-246814 19940520 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 692  
 INCL INCLM: 435/007.400  
 INCL: 435/018.000; 435/023.000; 436/065.000  
 NCLM: 435/007.400  
 NCL: 435/018.000; 435/023.000; 436/065.000  
 IC [6]  
 ICM: G01N033-573  
 ICS: C120001-34; C120001-37  
 EXF 435/7.4; 435/18; 435/24; 435/23; 435/4; 436/518; 436/530; 436/65  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 146 OF 239 USPTFULL  
 AN 97:31993 USPTFULL  
 TI Hydroxamic acid-containing inhibitors of matrix metalloproteases  
 IN Yelm, Kenneth Edward, Fairfield, OH, United States  
 PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)  
 PI US 5639746 19970617  
 AI US 1994-366062 19941229 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 1062  
 INCL INCLM: 514/210.000  
 INCL: 514/212.000; 514/277.000; 514/359.000; 514/507.000; 546/341.000; 548/535.000; 560/041.000; 560/049.000; 562/623.000  
 NCLM: 514/018.000  
 NCL: 514/019.000; 514/210.020; 514/210.170; 514/212.030; 514/217.110; 514/277.000; 514/359.000; 514/507.000; 530/331.000; 546/341.000; 548/535.000; 560/041.000; 560/049.000; 562/623.000  
 IC [6]  
 ICM: A61K031-215  
 ICS: C07D007-00; C07C229-00  
 EXF 562/623; 560/41; 560/169; 514/507; 514/210; 514/212; 514/277; 514/359; 548/535; 546/341  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 147 OF 239 USPTFULL  
 AN 97:49530 USPTFULL  
 TI Method of modulating DNA binding activity of recombinant  
 IN alpha-1 antichymotrypsin and other serine protease inhibitors  
 PA Roblin, Harvey, Philadelphia, PA, United States  
 PA Cooperman, Barry, Penn Valley, PA, United States  
 PA The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)  
 PI US 5637479 19970610  
 AI US 1995-435480 19950505 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 2642  
 INCL INCLM: 530/388.200  
 INCL: 530/388.700; 530/389.600; 435/070.210; 435/172.200; 424/139.100; 424/144.100; 424/158.100; 424/172.100  
 NCLM: 530/388.200  
 NCL: 424/139.100; 424/144.100; 424/158.100; 424/172.100  
 IC [6]  
 ICM: C07K014-435  
 ICS: C07K014-81; C12N015-15  
 EXF 435/69.2; 435/172.3; 530/350; 530/395.000; 536/023.500  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 148 OF 239 USPTFULL  
 AN 97:49514 USPTFULL  
 TI Cathespin C homolog  
 IN Coleman, Roger, Mountain View, CA, United States  
 PA Braxton, Scott M., San Mateo, CA, United States  
 PA Seilheimer, Jeffrey J., Los Altos Hills, CA, United States  
 PA Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)  
 PI US 5637462 19970610  
 AI US 1995-426428 19950419 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 1076  
 INCL INCLM: 435/006.000  
 INCL: 536/022.100; 536/023.100; 536/024.300; 536/024.310  
 NCLM: 435/006.000  
 NCL: 435/091.200; 536/022.100; 536/023.100; 536/024.300; 536/024.310  
 IC [6]  
 ICM: C120001-68  
 ICS: C12P019-34; C07H021-02; C07H021-04  
 EXF 536/22.1; 536/23.1; 536/24.3; 536/24.31; 435/6; 435/91.2  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 149 OF 239 USPTFULL  
 AN 97:47505 USPTFULL  
 TI Beta-8 integrin subunit antibodies  
 IN Moyle, Matthew, Walnut Creek, CA, United States  
 PA McLean, John W., San Francisco, CA, United States  
 PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)  
 PI US 5635601 19970603  
 AI US 1995-454455 19950530 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 2642  
 INCL INCLM: 530/388.200  
 INCL: 530/388.700; 530/389.600; 435/070.210; 435/172.200; 424/139.100; 424/144.100; 424/158.100; 424/172.100  
 NCLM: 530/388.200  
 NCL: 424/139.100; 424/144.100; 424/158.100; 424/172.100  
 IC [6]  
 ICM: A61K039-395  
 ICS: C07K016-28; C12P021-08; C12N015-06  
 EXF 424/139.1; 424/143.1; 424/144.1; 424/158.1; 424/172.1; 435/69.6; 435/172.2; 435/172.3; 435/240.27; 530/387.9; 530/388.2; 530/388.22; 530/388.7; 530/389.2; 530/389.6  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

corporation)  
 PI US 5641636 19970624  
 AI US 1994-246814 19940520 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 692  
 INCL INCLM: 435/007.400  
 INCL: 435/018.000; 435/023.000; 436/065.000  
 NCLM: 435/007.400  
 NCL: 435/018.000; 435/023.000; 436/065.000  
 IC [6]  
 ICM: G01N033-573  
 ICS: C120001-34; C120001-37  
 EXF 435/7.4; 435/18; 435/24; 435/23; 435/4; 436/518; 436/530; 436/65  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 146 OF 239 USPTFULL  
 AN 97:31993 USPTFULL  
 TI Hydroxamic acid-containing inhibitors of matrix metalloproteases  
 IN Yelm, Kenneth Edward, Fairfield, OH, United States  
 PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)  
 PI US 5639746 19970617  
 AI US 1994-366062 19941229 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 1062  
 INCL INCLM: 514/210.000  
 INCL: 514/212.000; 514/277.000; 514/359.000; 514/507.000; 546/341.000; 548/535.000; 560/041.000; 560/049.000; 562/623.000  
 NCLM: 514/018.000  
 NCL: 514/019.000; 514/210.020; 514/210.170; 514/212.030; 514/217.110; 514/277.000; 514/359.000; 514/507.000; 530/331.000; 546/341.000; 548/535.000; 560/041.000; 560/049.000; 562/623.000  
 IC [6]  
 ICM: A61K031-215  
 ICS: C07D007-00; C07C229-00  
 EXF 562/623; 560/41; 560/169; 514/507; 514/210; 514/212; 514/277; 514/359; 548/535; 546/341  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 147 OF 239 USPTFULL  
 AN 97:49530 USPTFULL  
 TI Method of modulating DNA binding activity of recombinant  
 IN alpha-1 antichymotrypsin and other serine protease inhibitors  
 PA Roblin, Harvey, Philadelphia, PA, United States  
 PA Cooperman, Barry, Penn Valley, PA, United States  
 PA The Trustees of the University of Pennsylvania, Philadelphia, PA, United States (U.S. corporation)  
 PI US 5637479 19970610  
 AI US 1995-435480 19950505 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 2642  
 INCL INCLM: 530/388.200  
 INCL: 530/388.700; 530/389.600; 435/070.210; 435/172.200; 424/139.100; 424/144.100; 424/158.100; 424/172.100  
 NCLM: 530/388.200  
 NCL: 424/139.100; 424/144.100; 424/158.100; 424/172.100  
 IC [6]  
 ICM: C07K014-435  
 ICS: C07K014-81; C12N015-15  
 EXF 435/69.2; 435/172.3; 530/350; 530/395.000; 536/023.500  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 148 OF 239 USPTFULL  
 AN 97:49514 USPTFULL  
 TI Cathespin C homolog  
 IN Coleman, Roger, Mountain View, CA, United States  
 PA Braxton, Scott M., San Mateo, CA, United States  
 PA Seilheimer, Jeffrey J., Los Altos Hills, CA, United States  
 PA Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)  
 PI US 5637462 19970610  
 AI US 1995-426428 19950419 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 1076  
 INCL INCLM: 435/006.000  
 INCL: 536/022.100; 536/023.100; 536/024.300; 536/024.310  
 NCLM: 435/006.000  
 NCL: 435/091.200; 536/022.100; 536/023.100; 536/024.300; 536/024.310  
 IC [6]  
 ICM: C120001-68  
 ICS: C12P019-34; C07H021-02; C07H021-04  
 EXF 536/22.1; 536/23.1; 536/24.3; 536/24.31; 435/6; 435/91.2  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 149 OF 239 USPTFULL  
 AN 97:47505 USPTFULL  
 TI Beta-8 integrin subunit antibodies  
 IN Moyle, Matthew, Walnut Creek, CA, United States  
 PA McLean, John W., San Francisco, CA, United States  
 PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)  
 PI US 5635601 19970603  
 AI US 1995-454455 19950530 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 2642  
 INCL INCLM: 530/388.200  
 INCL: 530/388.700; 530/389.600; 435/070.210; 435/172.200; 424/139.100; 424/144.100; 424/158.100; 424/172.100  
 NCLM: 530/388.200  
 NCL: 424/139.100; 424/144.100; 424/158.100; 424/172.100  
 IC [6]  
 ICM: A61K039-395  
 ICS: C07K016-28; C12P021-08; C12N015-06  
 EXF 424/139.1; 424/143.1; 424/144.1; 424/158.1; 424/172.1; 435/69.6; 435/172.2; 435/172.3; 435/240.27; 530/387.9; 530/388.2; 530/388.22; 530/388.7; 530/389.2; 530/389.6  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 150 OF 239 USPATFULL  
 AN 97:47438 USPATFULL  
 TI **Methods for inducing differentiation of a cell using**  
 IN phenacetic acid and derivatives  
 PA Schmid, Dvorit, Rockville, MD, United States  
 PI The United States of America as represented by the Department of Health  
 US 5635533  
 US 1995-470229  
 RLI Division of Ser. No. US 1993-135661, filed on 12 Oct 1993 which is a  
 continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991  
 DT Utility  
 FS Granted  
 LN.CNT 4108  
 INCL INCLM: 514/538.000  
 NCL INCLM: 514/563.000; 514/567.000  
 NCLM: 514/538.000  
 NCLS: 514/563.000; 514/567.000  
 IC [6]  
 ICM: A01N037-12  
 ICS: A01N037-44; A61K031-24  
 EXF 514/538; 514/563; 514/567  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 151 OF 239 USPATFULL  
 AN 97:47437 USPATFULL  
 TI **Compositions and methods for therapy and prevention of**  
 IN pathologies including cancer, AIDS and anemia  
 PA Samdi, Dvorit, Rockville, MD, United States  
 PI The United States of America as represented by the Secretary of the  
 (U.S. government)  
 US 5635532  
 US 1993-135661  
 RLI Continuation-in-part of Ser. No. US 1991-779744, filed on 21 Oct 1991  
 DT Utility  
 FS Granted  
 LN.CNT 4105  
 INCL INCLM: 514/538.000  
 NCLM: 514/563.000; 514/567.000; 560/019.000  
 NCLS: 514/563.000; 514/567.000; 560/019.000  
 IC [6]  
 ICM: A01N037-12  
 ICS: A01N037-44; A61K031-19; A61K031-24  
 EXF 514/538; 514/563; 514/567; 560/19  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 152 OF 239 USPATFULL  
 AN 97:40821 USPATFULL  
 TI **N-(mercaptoacyl) peptidyl derivatives as antidegenerative agents**  
 IN Hagmann, William, Westfield, NJ, United States  
 PA Kopka, Inc, Millburn, NJ, United States  
 PI Werck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
 US 5629343  
 WO 9407481 19940414  
 AI US 1995-392730  
 WO 1993-US9137  
 19950223 (8)  
 19930927  
 19950223 PCT 371 date  
 19950223 PCT 102(e) date  
 DT Utility  
 FS Granted  
 LN.CNT 1091  
 INCL INCLM: 514/513.000

NCL INCLM: 514/562.000; 514/616.000; 564/154.000; 558/254.000; 562/426.000  
 NCLM: 514/513.000  
 NCLS: 514/562.000; 514/616.000; 558/254.000; 562/426.000; 564/154.000  
 IC [6]  
 ICM: A61K031-21  
 EXF 564/154; 558/254; 562/426; 514/513; 514/562; 514/616  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 153 OF 239 USPATFULL  
 AN 97:40640 USPATFULL  
 TI **Diagnostic assay for inhibitor of tissue-type and urokinase-type**  
 IN plasminogen activators, and gene coding for the inhibitor  
 PA Loskutov, David U., Solana Beach, CA, United States  
 NY, Tor, Umea, Sweden  
 Sawdey, Michael, La Jolla, CA, United States  
 PI The Scripps Clinic and Research Foundation, La Jolla, CA, United States  
 (U.S. corporation)  
 US 5629160  
 US 1994-248348  
 RLI Division of Ser. No. US 1992-877271, filed on 29 Apr 1992, now patented,  
 Pat. No. US 5314994 which is a continuation of Ser. No. US 1990-573485,  
 filed on 27 Aug 1990, now abandoned which is a division of Ser. No. US  
 1986-897990, filed on 19 Aug 1986, now patented, Pat. No. US 4952512  
 which is a continuation-in-part of Ser. No. US 1984-623357, filed on 22  
 Jun 1984, now patented, Pat. No. US 4791068  
 DT Utility  
 FS Granted  
 LN.CNT 2639  
 INCL INCLM: 435/007.100  
 NCLM: 435/007.920; 435/007.930; 435/013.000; 435/069.200; 436/518.000  
 NCLS: 435/007.920; 435/007.930; 435/013.000; 435/069.200; 436/518.000  
 IC [6]  
 ICM: G01N033-53  
 EXF 435/7.1; 435/7.9; 435/7.92-7.93; 435/13; 435/69.2; 435/240.1; 436/518  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 154 OF 239 USPATFULL  
 AN 97:38606 USPATFULL  
 TI **Integrin-binding peptides**  
 IN Ronslahti, Erkki, Rancho Santa Fe, CA, United States  
 PA Koivunen, Erkki, San Diego, CA, United States  
 PI La Jolla Cancer Research Foundation, La Jolla, CA, United States (U.S.  
 corporation)  
 US 5627263  
 US 1995-425238  
 RLI Continuation of Ser. No. US 1993-158001, filed on 24 Nov 1993, now  
 abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 725  
 INCL INCLM: 530/327.000  
 NCLM: 530/328.000  
 NCLS: 530/327.000  
 NCLS: 530/328.000  
 IC [6]  
 ICM: A61K038-04  
 ICS: C07K007-06; C07K007-08  
 EXF 530/327; 530/328; 530/329; 514/14; 514/16  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 155 OF 239 USPATFULL  
 AN 97:29499 USPATFULL  
 TI **Hydroxamic acid and carboxylic acid derivatives, process for their**

IN preparation and use thereof  
Gomravan, Madhusudan R., West Chester, PA, United States  
Johnson, Jeffrey, Phoenixville, PA, United States  
Cook, Ewell R., Royersford, PA, United States  
Wahl, Robert C., Collegeville, PA, United States  
Mathowitz, Alan M., Schwenksville, PA, United States  
Tomczuk, Bruce E., Collegeville, PA, United States  
Sama, Ashis K., Harleysville, PA, United States  
P. Sanoft S.A., Paris Cedex, France (non-U.S. corporation)  
PI US 5618844 19970408  
US 1995-461079 19950605 (8)  
Division of Ser. No. US 1994-201837, filed on 25 Feb 1994, now patented,  
Pat. No. US 5514716  
RLI  
DT Utility  
FS Granted  
IN CNT 1712  
INCL INCLM: 514/575.000  
NCLM: 562/621.000  
NCLM: 514/575.000  
NCLS: 562/621.000  
IC [6]  
ICM: A61K031-19  
ICS: C07C239-00  
EXF 562/800; 562/621; 514/575; 514/419; 548/490  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 156 OF 239 USPTFULL  
AN 97:27192 USPTFULL  
TI Peptide derivatives of collagenase inhibitor  
IN Gray, Robert D., Louisville, KY, United States  
Spatola, Arno F., Louisville, KY, United States  
Darlak, Krzysztof, Louisville, KY, United States  
Research Corporation Tech., Inc., Tucson, AZ, United States (U.S. corporation)  
PI US 5616605 19970401  
US 1994-287320 19940808 (8)  
Division of Ser. No. US 1992-981149, filed on 24 Nov 1992, now patented,  
Pat. No. US 5387610 which is a continuation of Ser. No. US 1991-715948,  
filed on 14 Jun 1991, now abandoned  
DT Utility  
FS Granted  
LN CNT 1905  
INCL INCLM: 514/415.000  
NCLM: 548/415.000; 546/139.000; 546/149.000; 546/175.000; 546/330.000;  
546/332.000  
NCLM: 514/415.000  
NCLS: 546/139.000; 546/149.000; 546/175.000; 546/330.000; 546/332.000;  
548/415.000  
IC [6]  
ICM: C07D209-12  
ICS: C07D209-14; A61K031-405  
EXF 514/307; 514/311; 514/415; 546/139; 546/149; 546/175; 548/507  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 157 OF 239 USPTFULL  
AN 97:27061 USPTFULL  
TI Effects of growth factors on hair follicle cell proliferation and  
release of collagenolytic factors  
IN Yuspa, Stuart H., Bethesda, MD, United States  
The United States of America as represented by the Department of Health  
and Human Services, Washington, DC, United States (U.S. government)  
PI US 5616471 19970401  
US 1991-650572 19910204 (7)  
Continuation-in-part of Ser. No. US 1987-48537, filed on 6 May 1987

DT Utility  
FS Granted  
LN CNT 958  
INCL INCLM: 435/029.000  
NCLM: 435/243.000; 435/244.000; 514/021.000; 514/880.000; 530/356.000;  
623/015.000  
NCLM: 435/029.000  
NCLS: 435/243.000; 435/244.000; 514/021.000; 514/880.000; 530/356.000;  
623/015.110  
IC [6]  
ICM: A01N001-02  
ICS: C12N005-00; A61K038-00; C07K001-00  
EXF 435/29; 435/240.23; 435/240.21; 435/240.243; 435/260; 435/243; 435/244;  
514/880; 514/21; 530/356; 623/15  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 158 OF 239 USPTFULL  
AN 97:16085 USPTFULL  
TI Compositions and methods for treating and preventing  
pathologies including cancer  
IN Samd, Dvorit, Rockville, MD, United States  
The United States of America as represented by the Department of Health  
and Human Services, Washington, DC, United States (U.S. government)  
PI US 5605930 19970225  
US 1994-207521 19940307 (8)  
Continuation-in-part of Ser. No. US 1993-135661, filed on 12 Oct 1993,  
which is a continuation-in-part of Ser. No. US 1991-779744, filed on 21  
Oct 1991  
RLI  
DT Utility  
FS Granted  
LN CNT 7722  
INCL INCLM: 514/510.000  
NCLM: 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;  
514/567.000  
NCLM: 514/510.000  
NCLS: 514/513.000; 514/515.000; 514/529.000; 514/538.000; 514/563.000;  
514/567.000  
IC [6]  
ICM: A61K031-21  
ICS: A01N037-00; A01N047-40; A01N047-46  
EXF 514/538; 514/563; 514/567; 514/510; 514/513; 514/515; 514/529  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
L9 ANSWER 159 OF 239 USPTFULL  
AN 96:118515 USPTFULL  
TI DNA encoding a hyaluronan receptor expressed in human umbilical vein  
endothelial cells  
IN Hawkins, Phillip R., Mountain View, CA, United States  
Wilde, Craig G., Sunnyvale, CA, United States  
Seilhamer, Jeffrey J., Los Altos Hills, CA, United States  
Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)  
PI US 5587301 19961224  
US 1995-402217 19950310 (8)  
RLI  
DT Utility  
FS Granted  
LN CNT 1142  
INCL INCLM: 435/069.100  
NCLM: 435/252.300; 435/320.100; 536/023.500  
NCLM: 435/069.100  
NCLS: 435/252.300; 435/320.100; 536/023.500  
IC [6]  
ICM: C12N005-10  
ICS: C12N015-12

EXF 435/69.1: 435/252.3; 435/320.1; 536/23.5  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 160 OF 239 USPATFOLL

AN 96:116379 USPATFOLL  
TI Tricyclic cefem sulphones  
IN Alpegiani, Marco, Milan, Italy  
Bispolino, Pierluigi, San Giorgio di Lomellina, Italy  
Pierone, Ettore, Boffalora Ticino, Italy  
Rizzo, Vincenzo, Arese, Italy  
Pharmacia S.p.A., Milan, Italy (non-U.S. corporation)

PI US 5585312 19941208  
WO: 9428003 19941208  
US: 1995-367319 19950120  
WO: 1994-EP1643 19950120

AI 19950120 (8)  
PCT 371 date  
19950120 PCT 102(e) date

PRAI GB 1993-10428 19930520

DT Utility

FS Granted

LN.CNT 1301

INCL INCLM: 514/200.000

INCL INCLM: 514/202.000; 514/208.000; 540/216.000

NCL NCIM: 514/200.000

NCL NCIS: 514/202.000; 514/208.000; 540/216.000

IC [6]

ICM: C07D501-62

ICS: A61K031-545

EXF 540/221; 540/222; 540/216; 514/202; 514/200; 514/204

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 161 OF 239 USPATFOLL

AN 96:113902 USPATFOLL

TI Agents affecting thrombosis and hemostasis

IN Wolf, David L., Palo Alto, CA, United States

IN Sinha, Uma, San Francisco, CA, United States

PA COR Therapeutics, Inc., South San Francisco, CA, United States (U.S. corporation)

PI US 5583107 19961210

AI US 1994-268003 19940629 (8)

RI Continuation-in-part of Ser. No. US 1994-249777, filed on 26 May 1994

RI which is a continuation of Ser. No. US 1991-808329, filed on 16 Dec

RI 1991, now abandoned which is a continuation-in-part of Ser. No. US

RI 1990-578646, filed on 4 Sep 1990, now patented, Pat. No. US 5278144

DT Utility

FS Granted

LN.CNT 1935

INCL INCLM: 514/012.000

INCL INCLM: 514/021.000; 424/094.640; 435/069.600; 530/381.000; 530/384.000;

NCL NCIM: 514/012.000

NCL NCIS: 424/094.640; 435/069.600; 514/021.000; 530/381.000; 530/384.000;

IC [6]

ICM: A61K038-36

ICS: A61K035-16; C07K014-435; C07K014-475

EXF 514/12; 514/21; 514/834; 514/8; 530/381; 530/384; 530/350; 530/829;

EXF 530/830; 530/380; 530/381; 530/395; 930/100; 435/69.1; 435/69.2;

EXF 435/69.6; 435/212; 424/94.64

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 162 OF 239 USPATFOLL

AN 96:111551 USPATFOLL

TI Single-chain hepatocyte growth factor variants

IN Godowski, Paul J., Pacifica, CA, United States

IN Lokker, Natalie A., San Francisco, CA, United States

IN Mark, Melanie R., San Jose, CA, United States

PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

PI US 5580963 19961203

AI US 1994-194088 19940209 (8)

RI Division of Ser. No. US 1992-884811, filed on 18 May 1992, now patented.

RI Pat. No. US 5316921

DT Utility

FS Granted

LN.CNT 1985

INCL INCLM: 530/339.000

INCL NCLM: 530/339.000

IC [6]

ICM: C07K014-475

ICS: A61K038-18

EXF 530/339; 530/351; 435/69.4; 435/69.5; 435/106; 435/69.1; 574/2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 163 OF 239 USPATFOLL

AN 96:97138 USPATFOLL

TI Peptides derived from trifluoromethylketones

IN de Nanteuil, Guillaume, Suresnes, France

IN Portevin, Bernard, Elancourt, France

PA Canet, Emmanuel, Paris, France

PA Adir et Compagnie, Courbevoie, France (non-U.S. corporation)

PI US 5567804 19961022

AI US 1995-437433 19950505 (8)

PRAI FR 1994-5494 19940505

DT Utility

FS Granted

LN.CNT 522

INCL INCLM: 530/331.000

INCL INCLM: 530/345.000; 530/350.000; 514/018.000

NCL NCIM: 530/331.000

NCL NCIS: 530/345.000; 530/350.000

IC [6]

ICM: A61K038-06

EXF 514/18; 530/331; 530/350; 530/323; 530/345

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 164 OF 239 USPATFOLL

AN 96:94559 USPATFOLL

TI Peptides derived from trifluoromethylketones

IN Vincent, Michel, Bagneux, France

IN de Nanteuil, Guillaume, Suresnes, France

IN Remond, Georges, Versailles, France

IN Portevin, Bernard, Elancourt, France

IN Herve, Yolande, Puteaux, France

PA Canet, Emmanuel, Paris, France

PA lonchamp, Michel, Rungis, France (non-U.S. corporation)

PI US 5565429 19961015

AI US 1995-439233 19950511 (8)

RI Continuation of Ser. No. US 1993-99915, filed on 30 Jul 1993, now

RI abandoned

PRAI FR 1992-9254 19920728

DT Utility

FS Granted

LN.CNT 1271

INCL INCLM: 514/018.000

INCL INCLM: 530/331.000

NCL NCIM: 514/018.000



IC NCLTS: 530/331.000  
[6]  
ICM: A61K038-00  
ICS: C07K005-00; C07K007-00; C07K017-00  
EXF 514/18; 530/331  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 165 OF 239 USPTAFULL  
96:592094 USPTAFULL  
TI Iliudin analogs useful as antitumor agents  
IN Keiner, Michael J., La Jolla, CA, United States  
McMorris, Trevor C., La Jolla, CA, United States  
Taëlle, Raymond, Tucson, AZ, United States  
The Regents of the University of California, Oakland, CA, United States  
PA (U.S. corporation)  
PI US 5563176 19961008  
AI US 1994-276169 19940715 (8)  
RLI Continuation-in-part of Ser. No. US 1993-15179, filed on 9 Feb 1993, now patented, Pat. No. US 5439936 which is a continuation-in-part of Ser. No. US 1990-606511, filed on 31 Oct 1990, now patented, Pat. No. US 5439942 which is a continuation-in-part of Ser. No. US 1989-416395, filed on 3 Oct 1989, now abandoned

DT Utility  
FS Granted  
LN.CNT 1120  
INCL INCLM: 514/691.000  
NCL INCLTS: 560/162.000; 560/255.000; 560/256.000; 568/374.000  
NCLM: 514/691.000  
NCLTS: 560/162.000; 560/255.000; 560/256.000; 568/374.000  
IC [6]  
ICM: A61K031-12  
ICS: C07C049-403  
EXF 514/691; 568/374; 560/162; 560/255; 560/256  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 166 OF 239 USPTAFULL  
96:80286 USPTAFULL  
TI Arylsulfonamido-substituted hydroxamic acids  
IN MacPherson, Lawrence J., Hampton, NJ, United States  
Parker, David T., Livingston, NJ, United States  
Ciba-Geigy Corporation, Tarrytown, NY, United States (U.S. corporation)  
PI US 5552419 19960903  
AI US 1994-333676 19941103 (8)  
RLI Continuation-in-part of Ser. No. US 1994-265296, filed on 24 Jun 1994 which is a continuation-in-part of Ser. No. US 1993-1136, filed on 6 Jan 1993, now patented, Pat. No. US 5455258  
PRAI NZ 1993-250517 19931220  
DT Utility  
FS Granted  
LN.CNT 3589  
INCL INCLM: 514/357.000  
NCL INCLTS: 544/058.100; 544/168.000; 544/130.000; 544/131.000; 544/133.000; 540/524.000; 540/531.000; 514/604.000; 546/175.000; 546/194.000; 546/247.000; 546/209.000; 546/283.400; 546/283.400; 546/282.100; 546/333.000; 546/337.000; 546/280.400; 546/284.400; 546/281.700; 546/275.100; 548/205.000; 548/335.100; 548/338.100; 549/013.000; 549/065.000; 549/426.000; 564/084.000; 564/090.000; 564/092.000; 564/094.000; 514/237.800; 514/311.000; 514/331.000; 514/332.000; 514/341.000; 514/365.000; 514/396.000; 514/406.000; 514/432.000; 514/445.000; 514/451.000; 514/602.000  
NCLM: 514/357.000  
NCLTS: 514/237.800; 514/311.000; 514/331.000; 514/332.000; 540/524.000; 540/531.000; 544/058.100; 544/130.000; 544/131.000; 544/133.000; 544/168.000; 546/175.000; 546/194.000; 546/209.000; 546/247.000;

IC 546/265.000; 546/275.100; 546/280.400; 546/281.700; 546/282.100; 546/283.400; 546/284.100; 546/284.400; 546/333.000; 546/337.000; 548/205.000; 548/335.100; 548/338.100; 549/013.000; 549/065.000; 549/426.000; 564/084.000; 564/090.000; 564/092.000; 564/094.000  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 167 OF 239 USPTAFULL  
96:77966 USPTAFULL  
TI Transgenic animal model system for human cutaneous melanoma  
IN Mintz, Beatrice, Elkins Park, PA, United States  
Fox Chase Cancer Center, Philadelphia, PA, United States (U.S. corporation)  
PI US 5550316 19960827  
AI US 1993-11060 19930129 (8)  
RLI Continuation-in-part of Ser. No. US 1991-636798, filed on 2 Jan 1991, now abandoned

DT Utility  
FS Granted  
LN.CNT 1436  
INCL INCLM: 800/002.000  
NCL INCLTS: 800/DIG.001; 435/172.300; 536/023.100; 536/023.720; 536/024.100; 424/009.200  
NCLM: 800/010.000  
NCLTS: 424/009.200; 424/093.210; 424/573.000; 536/023.100; 536/023.720; 536/024.100; 800/018.000  
IC [6]  
ICM: C12N015-00  
ICS: A01K067-00  
EXF 800/2; 800/DIG.1; 435/172.3; 536/23.1; 536/23.72; 536/24.1; 424/9  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 168 OF 239 USPTAFULL  
96:75302 USPTAFULL  
TI Hepatocyte growth factor variants  
IN Godowski, Paul J., Burlingame, CA, United States  
Lokker, Natalie A., San Francisco, CA, United States  
Mark, Melanie R., Burlingame, CA, United States  
Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)  
PI US 5547856 19960820  
AI US 1993-87783 19930713 (8)  
RLI Continuation-in-part of Ser. No. US 1992-884811, filed on 18 May 1992, now patented, Pat. No. US 5316921 which is a continuation-in-part of Ser. No. US 1992-885971, filed on 18 May 1992, now patented, Pat. No. US 5328837  
DT Utility  
FS Granted  
LN.CNT 2175  
INCL INCLM: 435/694.000  
NCL INCLTS: 435/240.100; 435/320.100; 536/023.510; 530/399.000  
NCLM: 435/069.400  
NCLTS: 435/320.100; 435/325.000; 530/399.000; 536/023.510  
IC [6]  
ICM: C12P021-06  
ICS: C12N015-18; C07H017-00; C07K014-475  
EXF 530/399; 530/351; 536/23.51; 435/69.4; 435/106; 435/240.1; 435/320.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 169 OF 239 USPTAFULL  
 LN 96:70435 USPTAFULL  
 TI Proline phosphonate derivatives  
 IN Poweys, James C., Atlanta, GA, United States  
 Boduszek, Bogdan, Wroclaw, Poland  
 Oleksyszyn, Jozef, Arlington, MA, United States  
 Georgia Tech Research Corp., Atlanta, GA, United States (U.S. corporation)  
 PI US 5543396  
 AI US 1994-234181  
 DT Utility  
 FS Granted  
 IN.CNT 1747  
 INCL INCLM: 514/019.000  
 INCLS: 514/087.000; 514/089.000; 514/094.000; 548/412.000; 548/111.000; 546/021.000; 540/542.000; 540/450.000; 544/053.000; 544/057.000; 544/088.000; 544/106.000; 558/170.000  
 NCL NCIM: 514/019.000  
 NCLS: 514/087.000; 514/089.000; 514/094.000; 540/450.000; 540/542.000; 544/053.000; 544/057.000; 544/088.000; 544/106.000; 546/021.000; 548/111.000; 548/412.000; 558/170.000  
 IC [6]  
 ICM: A61K031-67; A01N057-00; C07F005-02  
 EXF 514/87; 514/89; 514/94; 514/101; 548/412; 548/111; 546/21; 546/450;  
 540/542; 544/53; 544/57; 544/88; 544/106; 558/170  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 170 OF 239 USPTAFULL  
 AN 96:65461 USPTAFULL  
 TI Prostate-specific membrane antigen  
 IN Israel, Ron S., Forest Hills, NY, United States  
 Heston, Warren D. W., New York, NY, United States  
 Fair, William R., New York, NY, United States  
 Sloan-Kettering Institute for Cancer Research, New York, NY, United States (U.S. corporation)  
 PI US 5538866  
 AI US 1994-325553  
 RLI 19941018 (8)  
 Continuation of Ser. No. US 1992-973337, filed on 5 Nov 1992, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 1966  
 INCL INCLM: 435/069.300  
 INCLS: 435/252.300; 435/320.500; 435/240.200; 435/254.200; 935/012.000; 935/023.000; 935/022.000; 935/066.000; 536/023.500  
 NCL NCIM: 435/069.300  
 NCLS: 435/252.300; 435/254.200; 435/320.100; 435/325.000; 435/348.000; 536/023.500  
 IC [6]  
 ICM: C12N015-12  
 EXF 435/69; 435/320.1; 435/252.3; 435/254.2; 435/240.2; 935/8; 935/12;  
 935/23; 935/24; 935/27; 935/66; 935/70; 935/72; 536/23.5  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 171 OF 239 USPTAFULL  
 AN 96:63201 USPTAFULL  
 TI Integrin-binding peptides  
 IN Ruoslahti, Erkki, Rancho Sante Fe, CA, United States  
 Koivunen, Erkki, San Diego, CA, United States  
 La Jolla Cancer Research Foundation, United States (U.S. corporation)  
 PI US 5536814  
 19960716

AI US 1994-212186 19940311 (8)  
 RLI Continuation-in-part of Ser. No. US 1993-127422, filed on 27 Sep 1993, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 847  
 INCL INCLM: 530/329.000  
 INCLS: 530/317.000; 530/328.000  
 NCL NCIM: 530/329.000  
 NCLS: 530/317.000; 530/328.000  
 IC [6]  
 ICM: C07K007-06  
 EXF 530/300; 530/317; 530/321; 530/326; 530/327; 530/328; 530/329; 530/330  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 172 OF 239 USPTAFULL  
 AN 96:58109 USPTAFULL  
 TI Method for regulating formation of a complex of plasminogen activator, its receptor and inhibitor  
 IN Wang, Ning, Wuhan, China  
 Barlovatz-Meimon, Georgia, Paris, France  
 Fredberg, Jeffrey J., Sharon, MA, United States  
 President and Fellows of Harvard University, Cambridge, MA, United States (U.S. corporation)  
 PI US 5532132  
 AI US 1993-127977 19930928 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 984  
 INCL INCLM: 435/007.210  
 INCLS: 435/007.230; 435/007.900; 436/501.000; 436/503.000  
 NCL NCIM: 435/007.210  
 NCLS: 435/007.230; 435/007.900; 436/501.000; 436/503.000  
 IC [6]  
 ICM: G01N033-567  
 EXF 435/7.21; 435/7.23; 435/7.9; 435/13; 435/24; 436/503; 436/501  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 173 OF 239 USPTAFULL  
 AN 96:55915 USPTAFULL  
 TI Hydroxamic acid based collagenase inhibitors  
 IN Campion, Colin, Oxon, England  
 Davidson, Alan H., Oxon, England  
 Dickens, Jonathan P., Buckinghamshire, England  
 Crimmin, Michael J., Ascot, England  
 British Bio-technology Limited, Oxford, England (non-U.S. corporation)  
 PI US 5530161 19940625  
 AI US 1994-195818 19940214 (8)  
 RLI Division of Ser. No. US 1993-48413, filed on 14 Apr 1993, now patented, Pat. No. US 5310763 which is a continuation of Ser. No. US 1991-689848, filed on 8 Jul 1991, now patented, Pat. No. US 5240958  
 DT Utility  
 FS Granted  
 LN.CNT 1525  
 INCL INCLM: 562/623.000  
 NCL NCIM: 562/623.000  
 IC [6]  
 ICM: C07C259-04  
 EXF 514/575; 562/623; 562/621  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 174 OF 239 USPATFULL  
 AN 96:48574 USPATFULL  
 TI Iludin analogs  
 IN Kainer, Michael J., La Jolla, CA, United States  
 McMorris, Trevor C., La Jolla, CA, United States  
 Teale, Raymond, Tucson, AZ, United States  
 The Regents of the University of California, Oakland, CA, United States  
 (U.S. corporation)  
 PI US 5523490 19860604  
 AI US 1994-332940 19941101 (8)  
 RLI Continuation of Ser. No. US 1993-15179, filed on 9 Feb 1993, now patented, Pat. No. US 5439936 which is a continuation-in-part of Ser. No. US 1990-606511, filed on 31 Oct 1990, now patented, Pat. No. US 5439942 which is a continuation-in-part of Ser. No. US 1989-416395, filed on 3 Oct 1989, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 919  
 INCL INCLM: 568/374.000  
 NCL NCLM: 568/374.000  
 IC [6]  
 ICM: C07C211-00  
 EXF 514/546; 514/691; 568/374  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 175 OF 239 USPATFULL  
 AN 96:43770 USPATFULL  
 TI Urokinase-type plasminogen activator receptor antibodies  
 IN Dano, Keld, Charlottenlund, Denmark  
 Ronne, Ebbe, Copenhagen, Denmark  
 Behrendt, Niels, Bagsvaerd, Denmark  
 Ellis, Vincent, Copenhagen, Denmark  
 Hoyer-Hansen, Gunilla, Gentofte, Denmark  
 Pyke, Charles, Soborg, Denmark  
 Bruener, Nils, Virum, Denmark  
 Cancerforskningsfondet af 1989, Copenhagen, Denmark (non-U.S. corporation)  
 PI US 5519120 19960521  
 AI US 1993-88122 19930617 (8)  
 RLI Continuation-in-part of Ser. No. US 1991-824189, filed on 6 Dec 1991, now abandoned which is a continuation-in-part of Ser. No. US 1989-374854, filed on 3 Jul 1989, now abandoned which is a continuation-in-part of Ser. No. US 1989-334613, filed on 7 Apr 1989, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 5458  
 INCL INCLM: 530/388.220  
 INCLS: 530/388.100; 530/388.800; 530/388.260; 530/391.100; 530/391.300; 435/240.270  
 NCL NCLM: 530/388.220  
 NCLS: 530/388.100; 530/388.260; 530/388.800; 530/391.100; 530/391.300  
 IC [6]  
 ICM: C07K016-40  
 ICS: C07K016-18; C07K016-00; C12N005-12  
 EXF 530/391.1; 530/391.3; 530/388.22; 530/388.26; 530/388.1; 530/388.8; 435/240.27  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 176 OF 239 USPATFULL  
 AN 96:38938 USPATFULL  
 TI Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof  
 IN Gowravaram, Madhusudan R., West Chester, PA, United States

Johnson, Jeffrey, Phoenixville, PA, United States  
 Cook, Ewell R., Royersford, PA, United States  
 Wahl, Robert C., Collegeville, PA, United States  
 Mathewetz, Allen M., Schwenksville, PA, United States  
 Tomazuk, Bruce E., Collegeville, PA, United States  
 Saha, Ashis K., Harleysville, PA, United States  
 Stealing Winthrop, Inc., Malvern, PA, United States (U.S. corporation)  
 PI US 5514716 19960507  
 AI US 1994-201837 19940225 (8)  
 RLI Utility  
 DT Utility  
 FS Granted  
 LN.CNT 1648  
 INCL INCLM: 514/563.000  
 INCLS: 560/034.000; 560/035.000; 560/037.000; 560/038.000; 560/039.000; 560/040.000; 560/041.000; 560/042.000; 560/168.000; 560/169.000; 562/437.000; 562/439.000; 562/442.000; 562/445.000; 562/448.000; 562/450.000; 564/448.000; 564/450.000; 564/165.000; 564/166.000; 564/168.000; 564/169.000; 564/170.000; 564/193.000; 564/199.000; 564/201.000  
 NCL NCLM: 514/563.000  
 NCLS: 560/034.000; 560/035.000; 560/037.000; 560/038.000; 560/039.000; 560/040.000; 560/041.000; 560/042.000; 560/168.000; 560/169.000; 562/437.000; 562/439.000; 562/442.000; 562/445.000; 562/448.000; 562/450.000; 564/164.000; 564/165.000; 564/166.000; 564/168.000; 564/170.000; 564/193.000; 564/199.000; 564/201.000  
 IC [6]  
 ICM: A61K031-195  
 EXF 514/825; 514/563; 514/534; 514/567; 514/538; 514/540; 514/542; 514/613; 514/616; 514/617; 514/618; 514/619; 514/626; 514/627; 560/34; 560/35; 560/37; 560/38; 560/40; 560/41; 560/42; 560/168; 560/169; 562/437; 562/439; 562/442; 562/445; 562/448; 562/450; 564/164; 564/165; 564/166; 564/168; 564/169; 564/170; 564/193; 564/199; 564/201  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 177 OF 239 USPATFULL  
 AN 96:21100 USPATFULL  
 TI Signal transduction inhibitor 1,2,3-triazolo compounds  
 IN Kohn, Elise C., Olney, MD, United States  
 Liotta, Lance A., Potomac, MD, United States  
 Felder, Christian C., Bethesda, MD, United States  
 The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)  
 PI US 5498620 19960312  
 AI US 1995-455761 19950531 (8)  
 RLI Continuation-in-part of Ser. No. US 1992-894891, filed on 8 Jun 1992, now abandoned and a continuation of Ser. No. US 1994-270181, filed on 1 Jul 1994 which is a division of Ser. No. US 1992-965402, filed on 4 Dec 1992, now patented, Pat. No. US 5359078 which is a continuation-in-part of Ser. No. US 1989-355744, filed on 19 May 1989, now patented, Pat. No. US 5132315 And a continuation-in-part of Ser. No. US 1992-944009, filed on 11 Sep 1992, now abandoned which is a continuation of Ser. No. US 1991-637145, filed on 3 Jan 1991, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 1396  
 INCL INCLM: 514/359.000  
 INCLS: 548/255.000; 548/264.800; 548/326.500  
 NCL NCLM: 514/359.000  
 NCLS: 548/255.000; 548/264.800; 548/326.500  
 IC [6]  
 ICM: A61K031-41  
 ICS: C07D249-06  
 EXF 548/255; 548/264.8; 548/326.5; 514/359  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 178 OF 239 USPATFULL  
 AN 96:5730 USPATFULL  
 TI Antibodies specific for human streptolysin-3 and a method for  
 IN detection of streptolysin-3  
 PA Bassel, Paul, Strasbourg, France  
 Belloq, Jean-Pierre, Strasbourg, France  
 Chamion, Pierre, Blesheim, France  
 Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S.  
 corporation)  
 PA Institut National de la Sante et de la Recherche Medicale, Paris Cedex,  
 France (non-U.S. government)  
 Centre National de la Recherche Scientifique, Paris Cedex, France  
 (non-U.S. government)  
 Universite Louis Pasteur, Strasbourg Cedex, France (non-U.S.  
 corporation)  
 PI US 5484726 19960116  
 AI US 1993-1711 19930107 (8)  
 RLI Continuation-in-part of Ser. No. US 1991-794393, filed on 21 Nov 1991,  
 now patented, Pat. No. US 5236844  
 PRAI GB 1990-25326 19901121  
 DT Utility  
 FS Granted  
 LN.CNT 2805  
 INCL INCLM: 435/007.400  
 INCLM: 530/387.100; 530/388.100; 530/387.700; 530/388.260; 530/388.800  
 NCLM: 435/007.400  
 NCLM: 530/387.100; 530/387.700; 530/388.100; 530/388.260; 530/388.800  
 IC [6]  
 ICM: C120001-25  
 ICS: C07K016-40; C07K016-30  
 435/7.23; 435/7.1; 435/7.4; 530/387.1; 530/388.1; 530/387.7; 530/388.26;  
 530/388.8  
 EXF 530/388.8  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 179 OF 239 USPATFULL  
 TI Signal transduction inhibitor triazole and diazole compounds  
 AN Kohn, Elise C., Olney, MD, United States  
 IN Liotta, Lance A., Potomac, MD, United States  
 Felder, Christian C., Bethesda, MD, United States  
 PA The United States of America as represented by the Department of Health  
 and Human Services, Washington, DC, United States (U.S. government)  
 PI US 5482954 19960109  
 AI US 1994-270181 19940701 (8)  
 RLI Division of Ser. No. US 1992-985402, filed on 4 Dec 1992, now patented,  
 Pat. No. US 5359078 which is a continuation-in-part of Ser. No. US  
 1989-355744, filed on 19 May 1989, now patented, Pat. No. US 5132315 And  
 Ser. No. US 1992-944009, filed on 11 Sep 1992, now abandoned which is a  
 continuation of Ser. No. US 1991-637145, filed on 3 Jan 1991, now  
 abandoned And a continuation-in-part of Ser. No. US 1992-894891, filed  
 on 8 Jun 1992, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 1451  
 INCL INCLM: 514/359.000  
 INCLM: 548/255.000; 548/264.800; 548/265.400; 548/265.600; 548/326.500;  
 548/335.100; 548/374.100; 514/383.000; 514/398.000; 514/407.000  
 NCLM: 514/359.000  
 NCLM: 514/383.000; 514/398.000; 514/407.000; 548/255.000; 548/264.800;  
 548/265.400; 548/265.600; 548/326.500; 548/335.100; 548/374.100  
 IC [6]  
 ICM: A61K031-41  
 ICS: A61K031-415; C07D249-06

EXF 514/255; 514/256; 514/258; 514/261; 514/283; 514/359; 514/398; 514/407;  
 548/255; 548/264.8; 548/265.4; 548/265.6; 548/326.5; 548/335.1;  
 548/374.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 180 OF 239 USPATFULL  
 AN 95:105959 USPATFULL  
 TI Maspin, a serpin with tumor suppressing activity  
 IN Sager, Ruth, Brookline, MA, United States  
 Anisowicz, Anthony, West Newton, MA, United States  
 Zou, Zhifang, Gaithersburg, MD, United States  
 Dana-Farber Cancer Institute, Inc., Boston, MA, United States (U.S.  
 corporation)  
 PI US 5470970 19951128  
 AI US 1993-121714 19930901 (8)  
 RLI Continuation-in-part of Ser. No. US 1992-938823, filed on 1 Sep 1992,  
 now abandoned which is a continuation-in-part of Ser. No. US  
 1992-844296, filed on 28 Feb 1992, now abandoned which is a  
 continuation-in-part of Ser. No. US 1991-662216, filed on 28 Feb 1991,  
 now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 1403  
 INCL INCLM: 536/023.500  
 INCLM: 536/024.310; 435/320.100; 435/252.300; 435/240.100; 530/350.000;  
 INCLM: 530/828.000; 930/250.000; 930/010.000; 935/009.000  
 NCLM: 536/023.500  
 NCLM: 435/252.300; 435/320.100; 435/354.000; 530/350.000; 530/828.000;  
 536/024.310; 930/010.000; 930/250.000  
 IC [6]  
 ICM: C12N001-21  
 ICS: C12N005-10; C12N015-15; C07K014-47  
 435/6; 435/69.1; 435/69.2; 435/320.1; 536/23.1; 536/23.2; 530/350;  
 530/828; 930/250  
 EXF 435/6; 435/69.1; 435/69.2; 435/320.1; 536/23.1; 536/23.2; 530/350;  
 530/828; 930/250  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 181 OF 239 USPATFULL  
 AN 95:105868 USPATFULL  
 TI Cell signaling inhibitors  
 IN Michnick, John, Seattle, WA, United States  
 Underiner, Gail E., Brier, WA, United States  
 Klein, J. Peter, Vashon Island, WA, United States  
 Rice, Glenn C., Seattle, WA, United States  
 PA Cell Therapeutics, Inc., Seattle, WA, United States (U.S. corporation)  
 PI US 5470878 19951128  
 AI US 1993-164081 19931208 (8)  
 RLI Continuation-in-part of Ser. No. US 1993-40820, filed on 31 Mar 1993,  
 now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 2665  
 INCL INCLM: 514/558.000  
 INCLM: 514/258.000; 514/262.000; 514/274.000; 514/299.000; 514/315.000;  
 514/418.000; 514/425.000; 514/529.000; 514/552.000; 514/561.000;  
 514/613.000; 514/617.000; 514/626.000; 514/629.000; 514/659.000;  
 544/254.000; 544/285.000; 544/301.000; 546/183.000; 546/243.000;  
 548/486.000; 548/586.000; 554/055.000; 554/061.000; 554/108.000;  
 554/213.000; 560/130.000; 560/145.000; 562/553.000; 562/567.000;  
 564/183.000; 564/197.000; 564/198.000; 564/201.000; 564/506.000  
 NCLM: 514/558.000  
 NCLM: 514/274.000; 514/299.000; 514/315.000; 514/418.000; 514/425.000;  
 514/529.000; 514/552.000; 514/561.000; 514/613.000; 514/617.000;  
 514/626.000; 514/629.000; 514/659.000; 544/254.000; 544/285.000;  
 544/301.000; 546/183.000; 546/243.000; 548/486.000; 548/556.000

IC [6]  
 ICM: A61K031-20  
 ICS: C07C233-00  
 554/51; 554/61; 554/55; 554/108; 554/213; 564/224; 564/506; 564/198;  
 564/415; 564/201; 564/197; 514/623; 514/629; 514/613; 514/588; 514/552;  
 514/589; 514/561; 514/526; 514/669; 560/130; 560/145; 562/553; 562/567  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 182 OF 239 USPTAFULL  
 AN 95:105824 USPTAFULL  
 TI Sulfonamide and sulfoximine matrix metalloproteinase inhibitors  
 IN Schwartz, Martin A., Tallahassee, FL, United States  
 PA Van Wart, Harold, Los Altos, CA, United States  
 PI Florida State University, Tallahassee, FL, United States (U.S. corporation)  
 PI US 5470834 19951128  
 AI US 1993-132411 19931006 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 4014  
 INCL INCLM: 514/019.000  
 INCLS: 260/998.000; 514/397.000; 514/400.000; 514/414.000; 514/415.000;  
 514/562.000; 514/607.000; 514/824.000; 514/825.000; 514/843.000;  
 514/912.000; 530/331.000; 548/312.100; 548/313.100; 548/313.700;  
 548/336.100; 548/455.000; 548/503.000  
 NCL NCLM: 514/019.000  
 NCLS: 260/998.000; 514/397.000; 514/400.000; 514/414.000; 514/415.000;  
 514/562.000; 514/607.000; 514/824.000; 514/825.000; 514/843.000;  
 514/912.000; 530/331.000; 548/312.100; 548/313.100; 548/313.700;  
 548/336.100; 548/455.000; 548/503.000

IC [6]  
 ICM: A61K038-05  
 ICS: A61K038-06; C07K005-062; C07K005-065  
 514/19; 514/607; 514/824; 514/825; 514/843; 514/912; 514/397; 514/400;  
 514/414; 514/415; 514/562; 530/331; 564/101; 260/998.2; 548/312.1;  
 548/313.1; 548/313.7; 548/336.1; 548/455; 548/503; 562/426; 562/427;  
 562/556  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 183 OF 239 USPTAFULL  
 AN 95:88477 USPTAFULL  
 TI Mercaptosulfide metalloproteinase inhibitors  
 IN Schwartz, Martin A., Tallahassee, FL, United States  
 PA Van Wart, Harold, Los Altos, CA, United States  
 PI Florida State University, Tallahassee, FL, United States (U.S. corporation)  
 PI US 5435262 19951003  
 AI US 1993-132414 19931006 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 4063  
 INCL INCLM: 514/418.000  
 INCLS: 514/399.000; 514/419.000; 514/601.000; 514/602.000; 514/604.000;  
 514/616.000; 514/618.000; 548/340.100; 548/485.000; 548/494.000;  
 548/495.000; 564/080.000; 564/081.000; 564/085.000; 564/153.000;  
 564/154.000  
 NCL NCLM: 514/418.000  
 NCLS: 514/399.000; 514/419.000; 514/601.000; 514/602.000; 514/604.000;  
 514/616.000; 514/618.000; 548/340.100; 548/485.000; 548/494.000;  
 548/495.000; 564/080.000; 564/081.000; 564/085.000; 564/153.000;  
 564/154.000

IC [6]  
 ICM: A61K031-40  
 ICS: A61K031-165; C07D209-32; C07C233-05

EXF 564/154; 564/153; 564/80; 564/81; 564/85; 564/154; 514/618; 514/19;  
 514/20; 514/601; 514/602; 514/604; 514/616; 514/418; 514/419; 514/399;  
 548/485; 548/494; 548/495; 548/340.1  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 184 OF 239 USPTAFULL  
 AN 95:86442 USPTAFULL  
 TI Hydroxamic acid based collagenase inhibitors  
 IN Campion, Colin, Oxon, England  
 PA Davidson, Alan H., Oxon, England  
 PI Dickens, Jonathan P., Buckinghamshire, England  
 PI Critten, Michael J., Ascot, England  
 PI British Biotech Pharmaceuticals Limited, Oxford, England (non-U.S. corporation)  
 PI US 5453438 19950926  
 AI WO 9102716 19910307  
 US 1992-820664 19920116 (7)  
 WO 1990-GB1117 19920116 PCT 371 date  
 19920116 PCT 102(e) date  
 PRAI GB 1989-19251 19890824  
 DT Utility  
 FS Granted  
 LN.CNT 1170  
 INCL INCLM: 514/424.000  
 INCLS: 514/343.000; 514/422.000; 514/269.000; 548/543.000; 548/527.000;  
 546/281.000; 544/333.000  
 NCL NCLM: 514/424.000  
 NCLS: 514/269.000; 514/343.000; 514/422.000; 544/333.000; 546/278.400;  
 548/527.000; 548/543.000

IC [6]  
 ICM: C07D207-27  
 ICS: C07D401-12; C07D409-12; C07D405-12; A61K031-505  
 548/543; 514/424; 514/423; 514/269; 546/281; 544/333  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 185 OF 239 USPTAFULL  
 AN 95:71366 USPTAFULL  
 TI Method of treating certain tumors using illudin analogs  
 IN Kerner, Michael J., La Jolla, CA, United States  
 IN McMorris, Trevor C., La Jolla, CA, United States  
 PA Taetle, Raymond, Tucson, AZ, United States  
 PI The Regents of the University of California, Oakland, CA, United States (U.S. corporation)  
 PI US 5439936 19950808  
 AI US 1993-15179 19930209 (8)  
 RLI Continuation-in-part of Ser. No. US 1990-606511, filed on 31 Oct 1990  
 which is a continuation-in-part of Ser. No. US 1989-416395, filed on 3 Oct 1989, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 984  
 INCL INCLM: 514/546.000  
 INCLS: 514/678.000; 514/681.000; 514/691.000  
 NCL NCLM: 514/546.000  
 NCLS: 514/678.000; 514/681.000; 514/691.000

IC [6]  
 ICM: A61K031-22  
 ICS: A61K031-12  
 514/681; 514/546; 514/678; 514/691  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 186 OF 239 USPTAFULL  
 AN 95:38854 USPTAFULL

TI P2'-modified hydroxamic acid collagenase inhibitors  
 IN Crimmin, M. J., Marlow Bottom, England  
 Davidson, A. H., Witney, England  
 Beckert, R. P., Aston, England  
 British Bio-Technology Limited, Oxford, England (non-U.S. corporation)  
 PI US 541245  
 US 1993-172440  
 Division of Ser. No. US 1991-760741, filed on 16 Sep 1991, now patented,  
 Pat. No. US 5300674, issued on 5 Apr 1994  
 PRAI GB 1991-7635 19910207  
 Utility  
 FS Granted  
 LN.CNT 1227  
 INCL INCLM: 558/414.000  
 INCLM: 560/039.000; 562/444.000  
 NCLM: 558/414.000  
 NCLM: 560/039.000; 562/444.000  
 IC [6]  
 ICM: C07C255-50  
 ICS: C07C259-06  
 EXF 558/414; 560/39; 562/444  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 187 OF 239 USPTAFULL  
 AN 95:38689 USPTAFULL  
 TI Benzisothiazolinone-1-dioxide derivatives as elastase inhibitors  
 IN Ladstias, Robert, Sauteny, France  
 Moczar, Elmer, Gif Sur Yvette, France  
 Hornebeck, William Georges, Versailles, France  
 Kerneux, Christiane M., Vitry Sur Seine, France  
 PRAI Cheebrough-Pond's USA Co., Division of Conopco, Inc., Greenwich, CT,  
 United States (U.S. corporation)  
 PI US 5411978 19950502  
 US 1994-230048 19950419 (8)  
 Division of Ser. No. US 1991-666093, filed on 7 Mar 1991, now patented,  
 Pat. No. US 5338747 19900308  
 PRAI FR 1990-2951  
 Utility  
 FS Granted  
 LN.CNT 833  
 INCL INCLM: 514/373.000  
 NCLM: 514/373.000  
 IC [6]  
 ICM: C07D275-06  
 ICS: A61K031-41  
 EXF 514/373  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 188 OF 239 USPTAFULL  
 AN 95:29749 USPTAFULL  
 TI Substituted cyclic derivatives as novel antidiabetic agents  
 IN Hagmann, William, Westfield, NJ, United States  
 Caldwell, Charles G., Scotch Plains, NJ, United States  
 Gooley, Paul R., Westfield, NJ, United States  
 PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
 PI US 5403952 19950404  
 US 1993-133493 19931008 (8)  
 Utility  
 FS Granted  
 LN.CNT 1679  
 INCL INCLM: 510/085.000  
 INCLM: 560/010.000; 560/015.000; 560/018.000; 560/024.000; 560/025.000;  
 560/026.000; 560/034.000; 560/051.000; 560/053.000; 560/054.000;  
 560/055.000; 560/056.000; 560/060.000; 560/076.000; 560/080.000;

560/100.000; 562/433.000; 562/439.000; 562/459.000; 562/461.000;  
 562/470.000; 562/473.000; 562/488.000; 562/490.000  
 NCLM: 560/085.000  
 NCLM: 560/010.000; 560/015.000; 560/018.000; 560/024.000; 560/025.000;  
 560/026.000; 560/034.000; 560/051.000; 560/053.000; 560/054.000;  
 560/055.000; 560/056.000; 560/060.000; 560/076.000; 560/080.000;  
 560/100.000; 562/433.000; 562/439.000; 562/459.000; 562/461.000;  
 562/470.000; 562/473.000; 562/488.000; 562/490.000  
 IC [6]  
 ICM: C07K007-100  
 EXF 560/85; 560/10; 560/15; 560/18; 560/24; 560/25; 560/26; 560/34; 560/51;  
 560/53; 560/54; 560/55; 560/56; 560/60; 560/76; 560/80; 560/100;  
 560/122; 562/433; 562/439; 562/459; 562/461; 562/470; 562/473; 562/488;  
 562/490; 514/530; 514/562; 514/564; 514/565  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 189 OF 239 USPTAFULL  
 AN 95:16247 USPTAFULL  
 TI Method for inhibition of cell motility by sphingosine-1-phosphate, its derivatives and mimetics and method of synthesizing sphingosine-1-phosphate and its derivatives  
 IN Igarashi, Yasuyuki, Seattle, WA, United States  
 Ruan, Fuguang, Seattle, WA, United States  
 Sadahira, Yoshito, Seattle, WA, United States  
 Kawa, Shigeyuki, Seattle, WA, United States  
 Hakomori, Sen-Itiro, Seattle, WA, United States  
 The Biomedical Research Institute, Seattle, WA, United States (U.S. corporation)  
 PI US 5391800 19950221  
 US 1993-104504 19930809 (8)  
 Division of Ser. No. US 1992-863179, filed on 3 Apr 1992, now patented,  
 Pat. No. US 5260288  
 PRAI  
 Utility  
 FS Granted  
 LN.CNT 970  
 INCL INCLM: 558/145.000  
 INCLM: 558/169.000; 558/170.000  
 NCLM: 558/145.000  
 NCLM: 558/169.000; 558/170.000  
 IC [6]  
 ICM: C07F009-113  
 EXF 558/101; 558/145; 558/169  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 L9 ANSWER 190 OF 239 USPTAFULL  
 AN 95:11626 USPTAFULL  
 TI Peptide derivatives of collagenase inhibitor  
 IN Gray, Robert D., Louisville, KY, United States  
 Spatola, Arno F., Louisville, KY, United States  
 Darlak, Krzysztof, Louisville, KY, United States  
 Research Corporation Technologies, Inc., Tucson, AZ, United States (U.S. corporation)  
 PI US 5387610 19950207  
 US 1992-981149 19921124 (7)  
 Continuation of Ser. No. US 1991-715948, filed on 14 Jun 1991, now  
 abandoned  
 PRAI  
 Utility  
 FS Granted  
 LN.CNT 1949  
 INCL INCLM: 514/575.000  
 INCLM: 514/018.000; 514/507.000; 530/323.000; 530/330.000; 530/331.000;  
 562/623.000  
 NCLM: 514/575.000  
 NCLM: 514/018.000; 514/507.000; 530/323.000; 530/330.000; 530/331.000;  
 562/623.000

IC (6)  
 ICM: A61K037-02  
 EXF 530/323; 530/330; 530/331; 562/623; 514/575; 514/507; 514/18  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 192 OF 239 USPTAFULL  
 AN 95:7873 USPTAFULL  
 TI Composition and method for enhancing wound healing  
 IN Henkin, R. I., 6601 Broxburn Dr., Bethesda, MD, United States 20817  
 PI US 5384308 19950124  
 AI US 1993:76058 19930614 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 656  
 INCL INCLM: 514/007.000; 514/969.000; 424/550.000; 530/843.000  
 NCLM: 514/008.000  
 NCL: 514/008.000  
 NCLM: 514/008.000  
 NCL: 424/550.000; 514/007.000; 514/969.000; 530/843.000  
 IC (6)  
 ICM: A61K037-16  
 ICS: A61K033-37  
 EXF 514/2; 514/338; 514/969; 514/7; 514/8; 424/85.8; 424/550; 530/843  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 192 OF 239 USPTAFULL  
 AN 94:102323 USPTAFULL  
 TI Structure, production and use of heregulin  
 IN Vandlen, Richard L., Hillsborough, CA, United States  
 PI US 5367060 19941122  
 AI US 1992-867743 19920306 (7)  
 RLI Continuation-in-part of Ser. No. US 1991-790801, filed on 8 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-765212, filed on 25 Sep 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-705256, filed on 24 May 1991, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 3698  
 INCL INCLM: 530/339.000  
 INCLM: 530/350.000  
 NCLM: 530/339.000  
 NCL: 530/350.000  
 IC (5)  
 ICM: C07K013-00  
 ICS: A61K037-36  
 EXF 435/69.1; 530/350; 530/339; 530/389.2  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 193 OF 239 USPTAFULL  
 AN 94:102319 USPTAFULL  
 TI Endothelial cell-leukocyte adhesion molecules (ELAMs) and molecules involved in leukocyte adhesion (MLAs)  
 IN Hession, Catherine A., South Weymouth, MA, United States  
 PI US 5367056 19941122  
 AI US 1993-35674 19930323 (8)

RLI Division of Ser. No. US 1989-452675, filed on 18 Dec 1989, now patented, Pat. No. US 5272263 which is a continuation-in-part of Ser. No. US 1989-359516, filed on 1 Jun 1989, now abandoned which is a continuation-in-part of Ser. No. US 1989-345151, filed on 28 Apr 1989, now patented, Pat. No. US 5217870  
 DT Utility  
 FS Granted  
 LN.CNT 2368  
 INCL INCLM: 530/380.000  
 INCLM: 530/350.000  
 NCLM: 530/380.000  
 NCL: 530/350.000  
 IC (5)  
 ICM: C07K013-00  
 EXF 530/380; 530/350  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 194 OF 239 USPTAFULL  
 AN 94:93457 USPTAFULL  
 TI Signal transduction inhibitor compounds  
 IN Kohn, Elise C., Olney, MD, United States  
 PI US 5359078 19941025  
 AI US 1992-985402 19921204 (7)  
 RLI Continuation-in-part of Ser. No. US 1989-355744, filed on 19 May 1989, now patented, Pat. No. US 5132315 And a continuation-in-part of Ser. No. US 1992-944009, filed on 11 Sep 1992, now abandoned which is a continuation of Ser. No. US 1991-637145, filed on 3 Jan 1991, now abandoned which is a continuation-in-part of Ser. No. US 1992-894891, filed on 8 Jun 1992, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 1287  
 INCL INCLM: 544/255.000  
 INCLM: 544/242.000; 544/254.000; 544/264.000; 544/335.000; 548/262.200; 548/262.800; 548/264.800; 548/265.400; 548/265.600; 548/265.800; 548/266.800; 548/267.600  
 NCLM: 548/255.000  
 NCL: 544/238.000; 544/242.000; 544/254.000; 544/264.000; 544/335.000; 548/262.200; 548/262.800; 548/264.800; 548/265.400; 548/265.600; 548/265.800; 548/266.800; 548/267.600  
 IC (5)  
 ICM: C07D249-06  
 EXF 544/254; 544/264; 544/335; 544/336; 544/238; 544/242; 548/255; 548/263.2; 548/265.4; 548/265.8; 548/267.5; 548/267.8; 548/269.4; 548/337; 548/346; 548/262.8; 548/264.8; 548/266.8; 548/262.2; 548/265.6; 548/267.6  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 195 OF 239 USPTAFULL  
 AN 94:71030 USPTAFULL  
 TI Benzothiazolone-1-dioxide derivatives as elastase inhibitors  
 IN Robert, Ladislav, Senteay, France  
 PI US 5338747 19940816  
 AI US 1991-666093 19910307 (7)  
 PRAI FR 1990-2951 19900308

DT Utility  
FS Granted  
LN.CNT 797  
INCL INCLM: 514/373.000  
NCL INCLM: 548/210.000  
NCLM: 514/373.000  
NCLM: 548/210.000  
IC [5]  
ICM: C07D275-06  
EXF 548/210: 514/373  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 196 OF 239 USPATFULT  
AN 94:60089 USPATFULT  
TI Hepatocyte growth factor protease domain variants  
IN Godowski, Paul J., Pacifica, CA, United States  
Lokker, Natalie A., San Francisco, CA, United States  
Mark, Melanie R., San Jose, CA, United States  
Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)  
PI US 5328837 19940712  
AI US 1992-885971 19920518 (7)  
DT Utility  
FS Granted  
LN.CNT 1881  
INCL INCLM: 435/069.400  
NCL INCLM: 530/399.000; 536/023.510  
NCLM: 435/069.400  
NCLM: 530/399.000; 536/023.510  
IC [5]  
ICM: C12P021-06  
ICM: A61K037-36  
EXF 530/399: 536/27; 435/23.51; 435/69.1; 435/69.4  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 197 OF 239 USPATFULT  
AN 94:47042 USPATFULT  
TI Cysteine proteinase inhibitors and inhibitor precursors  
IN Bartlett, Paul A., Kensington, CA, United States  
Mader, Mary M., El Cerrito, CA, United States  
The Regents of the University of California, Oakland, CA, United States (U.S. corporation)  
PI US 5317086 19940531  
AI US 1992-848377 19920309 (7)  
DT Utility  
FS Granted  
LN.CNT 555  
INCL INCLM: 530/327.000  
NCL INCLM: 530/331.000; 530/330.000; 530/329.000; 530/328.000  
NCLM: 530/327.000  
NCLM: 530/328.000; 530/329.000; 530/330.000; 530/331.000  
IC [5]  
ICM: C07K005-00  
ICM: C07K007-00; A61K037-00  
EXF 514/19; 514/18; 514/17; 514/16; 514/15; 514/14; 530/331; 530/330;  
530/329; 530/328; 530/327  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 198 OF 239 USPATFULT  
AN 94:46878 USPATFULT  
TI Single-chain hepatocyte growth factor variants  
IN Godowski, Paul J., Pacifica, CA, United States  
Lokker, Natalie A., San Francisco, CA, United States  
Mark, Melanie R., San Jose, CA, United States

PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)  
PI US-5316921 19940531  
AI US-1992-884811 19920518 (7)  
DT Utility  
FS Granted  
LN.CNT 1870  
INCL INCLM: 435/069.400  
NCL INCLM: 530/399.000; 536/023.510  
NCLM: 435/069.400  
NCLM: 530/399.000; 536/023.510  
IC [5]  
ICM: C12P021-06  
ICM: A61K037-36  
EXF 530/399: 536/27; 536/23.51; 435/69.1; 435/69.4  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 199 OF 239 USPATFULT  
AN 94:44735 USPATFULT  
TI Inhibitor of tissue-type and urokinase-type plasminogen activators  
IN Loskutoff, David J., Solana Beach, CA, United States  
Ny, Tor, Umea, Sweden  
Sawdey, Michael, La Jolla, CA, United States  
Scripps Clinic and Research Foundation, La Jolla, CA, United States (U.S. corporation)  
PI US 531994 19940524  
AI US 1992-877271 19920429 (7)  
R1 Abandoned which is a division of Ser. No. US 1990-573485, filed on 27 Aug 1990, now abandoned which is a division of Ser. No. US 1986-897990, filed on 19 Aug 1986, now patented, Pat. No. US 4952512 which is a continuation-in-part of Ser. No. US 1984-623357, filed on 22 Jun 1984, now patented, Pat. No. US 4791068  
DT Utility  
FS Granted  
LN.CNT 2544  
INCL INCLM: 530/350.000  
NCL INCLM: 530/395.000  
NCLM: 530/350.000  
NCLM: 530/395.000  
IC [5]  
ICM: C07K013-00  
EXF 435/69.2; 530/350; 530/395; 930/250  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 200 OF 239 USPATFULT  
AN 94:40082 USPATFULT  
TI Hydroxamino acid based collagenase inhibitors  
IN Campion, Colin, Oxon, England  
Davidson, Alan H., Oxon, England  
Dickens, Jonathan P., Buckinghamshire, England  
Crimmin, Michael J., Ascot, England  
British Bio-technology Limited, Oxford, England (non-U.S. corporation)  
PI US 5310763 19940510  
AI US 1993-48413 19930414 (8)  
R1 Continuation of Ser. No. US 1991-689848, filed on 8 Jul 1991, now patented, Pat. No. US 5240958  
PRAI GR 1988-27305 19881123  
DT Utility  
FS Granted  
LN.CNT 1437  
INCL INCLM: 514/575.000  
NCL INCLM: 514/616.000; 558/230.000; 562/621.000; 562/623.000  
NCLM: 514/575.000  
NCLM: 514/616.000; 558/230.000; 562/621.000; 562/623.000



IC [5]  
 ICM: A61K031-19  
 ICS: A61K031-16; C07C327-04  
 EXF 514/575; 514/615; 558/230; 562/621; 562/623  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 201 OF 239 USPTFULL  
 AN 93:107133 USPTFULL  
 TI DNA sequences encoding vascular cell adhesion molecules (VCAMs)  
 IN Hession, Catherine A., South Weymouth, MA, United States  
 Lobb, Roy R., Westwood, MA, United States  
 Goelz, Susan E., Winchester, MA, United States  
 Osborn, Laurelee, Brighton, MA, United States  
 Benjamin, Christopher D., Beverly, MA, United States  
 Rosa, Margaret D., Winchester, MA, United States  
 Biogen, Inc., Cambridge, MA, United States (U.S. corporation)  
 PI US 5272263 19931221  
 AI US 1989-452675 19891218 (7)  
 RLI Continuation-in-part of Ser. No. US 1989-359516, filed on 1 Jun 1989,  
 now abandoned which is a continuation-in-part of Ser. No. US  
 1989-345151, filed on 28 Apr 1989

DT Utility  
 FS Granted  
 LN.CNT 2440  
 INCL INCLM: 536/023.500  
 INCLS: 530/380.000; 435/069.600; 435/320.100  
 NCLM: 536/023.500  
 NCLS: 435/069.600; 435/320.100; 530/380.000  
 IC [5]  
 ICM: C07K013-00  
 ICS: C12N015-00; C12P021-06  
 EXF 435/69.1; 435/69.9; 435/320.1; 530/380; 536/27  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 202 OF 239 USPTFULL  
 AN 93:96120 USPTFULL  
 TI Glycosaminoglycan derivatives and their use as inhibitors of tumor  
 IN invasiveness of metastatic proflusion-II  
 Nicolson, Garth L., Kingwood, TX, United States  
 Iimura, Tatsuro, Tokyo, Japan  
 Nakajima, Motowo, Kamagaya, Japan  
 Board of Regents, The University of Texas System, Austin, TX, United  
 States (U.S. corporation)  
 PI US 5262403 19931116  
 AI US 1990-550827 19900710 (7)  
 RLI Continuation-in-part of Ser. No. US 1989-342627, filed on 8 Apr 1989,  
 now abandoned which is a continuation of Ser. No. US 1986-899511, filed  
 on 21 Aug 1986, now abandoned And a continuation-in-part of Ser. No. US  
 1986-839890, filed on 7 Mar 1986, now abandoned

DT Utility  
 FS Granted  
 LN.CNT 1188  
 INCL INCLM: 514/056.000  
 INCLS: 514/054.000; 536/021.000  
 NCLM: 514/056.000  
 NCLS: 514/054.000; 536/021.000  
 IC [5]  
 ICM: A61K031-725  
 ICS: C08B037-10  
 EXF 514/45; 514/56; 536/21  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 203 OF 239 USPTFULL  
 AN 93:93778 USPTFULL

TI Method for inhibition of cell motility by sphingosine-1-  
 phosphate and derivatives  
 IN Igarashi, Yasuyuki, Seattle, WA, United States  
 Ruan, Eugenio, Seattle, WA, United States  
 Sadahira, Yoshito, Seattle, WA, United States  
 Kawa, Shigeyuki, Seattle, WA, United States  
 Hakomori, Sen-Itiro, Seattle, WA, United States  
 The Biomedicine Institute, Seattle, WA, United States (U.S. corporation)  
 PI US 5260288 19931109  
 AI US 1992-863179 19920403 (7)  
 DT Utility  
 FS Granted  
 LN.CNT 889  
 INCL INCLM: 514/114.000  
 INCLS: 514/119.000  
 NCLM: 514/114.000  
 NCLS: 514/119.000  
 IC [5]  
 ICM: A61K031-66  
 EXF 514/114; 514/119  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 204 OF 239 USPTFULL  
 AN 93:67545 USPTFULL  
 TI Analytical markers for malignant breast cancer  
 IN Bassett, Paul, Strasbourg, France  
 Bellocq, Jean-Pierre, Strasbourg, France  
 Chambon, Pierre, Blaesheim, France  
 Institut National de la Sante et de la Recherche Medicale, France  
 (non-U.S. government)  
 Centre National de Recherche Scientifique, France (non-U.S. government)  
 Universite Louis Pasteur Strasbourg, France (non-U.S. corporation)  
 PI US 5236844 19930817  
 AI US 1991-794393 19911121 (7)  
 PRAI GB 1990-25326 19901121  
 DT Utility  
 FS Granted  
 LN.CNT 1495  
 INCL INCLM: 435/320.100  
 INCLS: 536/023.500  
 NCLM: 435/320.100  
 NCLS: 536/023.500  
 IC [5]  
 ICM: C12N015-70  
 ICS: C07H021-04  
 EXF 435/6; 435/320.1; 536/27; 536/23.5; 530/350  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 205 OF 239 USPTFULL  
 AN 93:18572 USPTFULL  
 TI Method of ophthalmic testing  
 IN Salonen, Eeva-Marjatta, Espoo, Finland  
 Labystems Oy, Helsinki, Finland (non-U.S. corporation)  
 PI US 5192665 19930309  
 AI US 1989-336249 19890411 (7)  
 RLI Division of Ser. No. US 1986-838339, filed on 11 Mar 1986, now patented,  
 Pat. No. US 4849406

DT Utility  
 FS Granted  
 LN.CNT 663  
 INCL INCLM: 435/018.000  
 INCLS: 424/009.000; 435/023.000  
 NCLM: 435/018.000  
 NCLS: 435/023.000

IC [5]  
 ICM: C120001-34  
 EXF 435/18; 435/23; 424/9  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 206 OF 239 USPATFULT  
 AN 93:5469 USPATFULT  
 TI Adhesion receptor for laminin and its use  
 IN Rengvahl, Erkki I., Rancho Santa Fe, CA, United States  
 +Engvall, Eva, Rancho Santa Fe, CA, United States  
 +Genslen, Kurt R., San Diego, CA, United States  
 PA La Jolla Cancer Research Foundation, La Jolla, CA, United States (U.S. corporation)  
 PI US 5180809 19930119  
 AI US 1989-357354 19890525 (7)  
 RLI Continuation-in-part of Ser. No. US 1988-196986, filed on 20 May 1988, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 849  
 INCL INCLM: 530/350.000  
 INCLS: 530/395.000; 530/413.000; 530/810.000; 530/388.220; 530/389.100; 424/450.000  
 NCL NCIM: 530/350.000  
 NCIS: 424/450.000; 530/388.220; 530/389.100; 530/395.000; 530/413.000; 530/810.000

IC [5]  
 ICM: C07K015-06  
 EXF ICS: C07K015-14; C07K003-20; C07K017-02  
 436/501; 436/503; 436/518; 436/534; 436/547; 436/548; 436/829; 435/7.21; 435/7.23; 424/420; 424/450; 530/350; 530/381; 530/395; 530/413; 530/810; 514/2  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 207 OF 239 USPATFULT  
 AN 92:76614 USPATFULT  
 TI Inhibition of tumor growth by blockade of the protein C system  
 IN Esmon, Charles T., Oklahoma City, OK, United States  
 Comp, Philip C., Oklahoma City, OK, United States  
 PA Oklahoma Medical Research Foundation, Oklahoma City, OK, United States (U.S. corporation)  
 PI US 5147638 19920915  
 AI US 1989-389617 19890804 (7)  
 RLI Continuation-in-part of Ser. No. US 1988-292447, filed on 30 Dec 1988, now abandoned  
 DT Utility  
 FS Granted  
 LN.CNT 1023  
 INCL INCLM: 424/085.800  
 INCLS: 424/085.100; 424/085.200; 424/085.400; 424/085.500; 435/212.000; 514/002.000; 514/008.000; 514/012.000; 530/351.000; 530/381.000; 530/388.250; 530/389.300  
 NCL NCIM: 424/085.100  
 NCIS: 424/085.200; 424/085.400; 424/085.500; 424/152.100; 424/172.100; 424/282.100; 435/212.000; 514/002.000; 514/008.000; 514/012.000; 530/351.000; 530/381.000; 530/388.250; 530/389.300

IC [5]  
 ICM: A61K037-00  
 ICS: A61K037-66; A61K039-00  
 EXF 424/85.1; 424/85.2; 424/85.5; 424/85.8; 514/2; 514/12; 530/387  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 208 OF 239 USPATFULT  
 AN 92:66111 USPATFULT

TI Cyclopeptide derivatives usable as selective inhibitors with respect to  
 IN proteases with active serine  
 Maksielmann, Michel, Paris, France  
 Mazaleyrat, Jean-Paul, Choisy-Le-Roi, France  
 Reboud-Ravaux, Michele, Paris, France  
 PA Centre National de la Recherche Scientifique, Paris, France (non-U.S. corporation)  
 PI US 5138035 19920811  
 AI US 1990-477820r 19900601 (7)  
 PRAI FR 1988-11528 19880902  
 DT Utility  
 FS Granted  
 LN.CNT 1074  
 INCL INCLM: 530/317.000  
 NCL NCIM: 530/317.000  
 IC [5]  
 ICM: C07K005-12  
 ICS: A61K037-00  
 EXF 530/317; 514/9  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 209 OF 239 USPATFULT  
 AN 92:59884 USPATFULT  
 TI Therapeutic application of an anti-invasive compound  
 IN Kohn, Elise C., Olney, MD, United States  
 Liotta, Lance A., Potomac, MD, United States  
 PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)  
 PI US 5132315 19920721  
 AI US 1989-355744 19890519 (7)  
 DT Utility  
 FS Granted  
 LN.CNT 460  
 INCL INCLM: 514/359.000  
 INCLS: 514/650.000; 514/648.000; 548/257.000  
 NCL NCIM: 514/359.000  
 NCIS: 514/648.000; 514/650.000; 548/257.000

IC [5]  
 ICM: A61K031-41  
 EXF 514/263; 514/663; 514/648; 514/359; 514/650; 548/257  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 210 OF 239 USPATFULT  
 AN 92:59483 USPATFULT  
 TI Method of treating a synthetic naturally occurring surface  
 IN growth, and the surface itself  
 Williams, Stuart K., Wilmington, DE, United States  
 Jarrell, Bruce E., Philadelphia, PA, United States  
 PA Thomas Jefferson University, Philadelphia, PA, United States (U.S. corporation)  
 PI US 5131907 19920721  
 AI US 1991-666475 19910306 (7)  
 RLI Continuation of Ser. No. US 1986-848453, filed on 4 Apr 1986, now abandoned which is a continuation-in-part of Ser. No. US 1985-742086, filed on 6 Jun 1985, now patented, Pat. No. US 4820626  
 DT Utility  
 FS Granted  
 LN.CNT 1848  
 INCL INCLM: 600/036.000  
 INCLS: 623/001.000; 427/040.000; 427/041.000; 424/093.000; 435/001.000; 435/240.700; 435/240.241  
 NCL NCIM: 600/036.000  
 NCIS: 424/093.700; 427/534.000; 427/538.000; 435/001.100; 435/375.000;

IC 435/399.000; 623/921.000

[5]  
 ICM: A61F002-04  
 ICS: A61F002-02; B05D003-06; C12N005-06  
 EXF 435/240.241; 623/1; 424/93; 427/40; 427/41; 600/36  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 211 OF 239 USPATFOLL  
 AN 92:38510 USPATFOLL  
 TI Method of stabilizing plasminogen activator inhibitor by  
 treatment with vitronectin  
 IN Wun, Tze-Chen, St. Louis, MO, United States  
 PA Monsanto Company, St. Louis, MO, United States (U.S. corporation)  
 PI US 5112955 19920512  
 AI US 1991-681304 19910408 (7)  
 RLI Division of Ser. No. US 1990-532410, filed on 4 Jun 1990, now patented,  
 Pat. No. US 5073626 which is a continuation-in-part of Ser. No. US  
 1988-268916, filed on 9 Nov 1988, now abandoned

DT Utility  
 FS Granted

LN.CNT 714  
 INCL INCLM: 530/409.000  
 INCLM: 530/350.000; 530/402.000; 530/395.000  
 NCLM: 530/409.000  
 NCL NCLM: 530/350.000; 530/395.000; 530/402.000  
 IC [5]  
 ICM: A61K037-64  
 ICS: C07K003-04  
 EXF 530/402; 530/409; 530/350; 530/395; 514/2; 514/13; 514/21  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 212 OF 239 USPATFOLL  
 AN 92:38361 USPATFOLL  
 TI Pharmaceutical preparation for promoting epithelial healing and  
 prevention of epithelial destruction  
 IN Salonen, Eeva-Marjatta, Espoo, Finland  
 PA LabSystems, Oy, Helsinki, Finland (non-U.S. corporation)  
 PI US 5112805 19920512  
 AI US 1989-336231 19890411 (7)  
 RLI Continuation of Ser. No. US 1986-838339, filed on 11 Mar 1986, now  
 patented, Pat. No. US 4849406

DT Utility  
 FS Granted

LN.CNT 655  
 INCL INCLM: 514/008.000  
 INCLM: 514/012.000; 514/802.000  
 NCLM: 514/008.000  
 NCL NCLM: 514/012.000; 514/802.000  
 IC [5]  
 ICM: A61K037-02  
 ICS: A61K037-64  
 EXF 424/101; 424/530; 514/802; 514/12; 514/8; 514/912  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 213 OF 239 USPATFOLL  
 AN 91:102292 USPATFOLL  
 TI Affinity purification of plasminogen activator inhibitor I using a  
 modified urokinase  
 IN Wun, Tze-Chen, St. Louis, MO, United States  
 PA Monsanto Company, St. Louis, MO, United States (U.S. corporation)  
 PI US 5073626 19911217  
 AI US 1990-532410 19900604 (7)  
 RLI Continuation-in-part of Ser. No. US 1988-268916, filed on 9 Nov 1988,  
 now abandoned

DT Utility  
 FS Granted

LN.CNT 748  
 INCL INCLM: 530/350.000  
 INCLM: 530/413.000; 435/069.200; 435/212.000; 435/215.000  
 NCLM: 530/350.000  
 NCL NCLM: 435/069.200; 435/212.000; 435/215.000; 530/413.000  
 IC [5]  
 ICM: C07K003-18  
 ICS: C07K005-06  
 EXF 530/413; 530/350; 435/69.2; 435/212; 435/215  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 214 OF 239 USPATFOLL  
 AN 91:102238 USPATFOLL  
 TI Bioactive metabolites from cribrochalina vasculum  
 IN Gunasekera, Sarah P., Vero Beach, FL, United States  
 FAircloth, Glynn T., Ft. Pierce, FL, United States  
 Wright, Amy E., Ft. Pierce, FL, United States  
 Thompson, Winnie C., Vero Beach, FL, United States  
 Burres, Neal, Highland Park, IL, United States  
 PA Harbor Branch Oceanographic Institution, Inc., Fort Pierce, FL, United  
 States (U.S. corporation)  
 PI US 5073572 19911217  
 AI US 1990-481475 19900216 (7)  
 RLI Utility  
 FS Granted

LN.CNT 501  
 INCL INCLM: 514/739.000  
 INCLM: 514/544.000; 514/546.000; 514/552.000; 560/113.000; 560/261.000;  
 568/873.000  
 NCLM: 514/739.000  
 NCL NCLM: 514/544.000; 514/546.000; 514/552.000; 560/113.000; 560/261.000;  
 568/873.000  
 IC [5]  
 ICM: C07C033-02  
 ICS: C07C033-03; A61K031-045; A61K031-22  
 EXF 568/873; 560/113; 560/261; 514/739; 514/544; 514/546; 514/552  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 215 OF 239 USPATFOLL  
 AN 91:102160 USPATFOLL  
 TI Synergistic composition for endothelial cell growth  
 IN Chen, Chung-Ho, Phoenix, MD, United States  
 PA The Johns Hopkins University, Baltimore, MD, United States (U.S.  
 corporation)  
 PI US 5073492 19911217  
 AI US 1987-1844 19870109 (7)  
 RLI Utility  
 FS Granted

LN.CNT 624  
 INCL INCLM: 435/240.200  
 INCLM: 435/240.300; 435/240.310; 435/240.230  
 NCLM: 435/384.000  
 NCL NCLM: 435/392.000; 435/405.000  
 IC [5]  
 ICM: C12N005-00  
 EXF 435/240.1; 435/240.2; 435/240.3; 435/240.21; 435/240.23; 435/240.31;  
 530/449; 424/95; 424/531; 424/571; 514/2; 514/21; 514/42; 514/43  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 216 OF 239 USPATFOLL  
 AN 91:73352 USPATFOLL

TI Tripeptide compounds having a nitrogenous polycyclic structure  
IN Vincent, Michel, Bagnaux, France  
Remond, Georges, Versailles, France  
Portevin, Bernard, Elancourt, France  
Cuemeneq, Claude, La Celle St-Cloud, France  
PA Adir et Cie, Neuilly-sur-Seine, France (non-U.S. corporation)  
PI US 50479400 19910910  
AI US 1988-207710 19880616 (7)  
PRAI FR 1987-8350 19870616  
DT Utility  
FS Granted  
LN.CNT 773  
INCL INCLM: 514/018.000  
INCLS: 546/112.000; 546/146.000; 546/147.000; 546/164.000; 546/165.000;  
546/169.000; 546/175.000; 548/472.000; 548/515.000  
NCLM: 514/018.000  
NCLS: 546/112.000; 546/146.000; 546/147.000; 546/164.000; 546/165.000;  
546/169.000; 546/175.000; 548/472.000; 548/515.000  
IC [5]  
ICM: A61K031-40  
EXF ICS: C07D221-02; C07D217-00; C07D209-46  
546/146; 546/147; 546/112; 546/164; 546/165; 546/169; 546/175; 548/472;  
548/515; 514/18  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 217 OF 239 USPTFULL  
AN 91:13045 USPTFULL  
TI cDNA encoding 92-KDA type IV collagenase  
IN Eisen, Arthur Z., St. Louis, MO, United States  
PA Washington University, St. Louis, MO, United States (U.S. corporation)  
PI US 4992537 19910212  
AI US 1989-352078 19890515 (7)  
DT Utility  
FS Granted  
LN.CNT 562  
INCL INCLM: 536/027.000  
INCLS: 435/069.100; 435/172.300; 530/219.000; 530/226.000  
NCLM: 536/023.200  
NCLS: 435/069.100; 530/219.000; 530/226.000  
IC [5]  
ICM: C12N015-00  
EXF 536/27; 435/69.1; 435/172.3; 530/219; 530/226  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 218 OF 239 USPTFULL  
AN 90:81777 USPTFULL  
TI Peptide compounds having a nitrogenous polycyclic structure  
IN Vincent, Michel, Bagnaux, France  
Remond, Georges, Versailles, France  
Cuemeneq, Claude, La Celle St-Cloud, France  
PA Adir ET Cie, Neuilly-sur-Seine, France (non-U.S. corporation)  
PI US 4965250 19901023  
AI US 1988-148027 19880125 (7)  
PRAI FR 1987-1810 19870213  
DT Utility  
FS Granted  
LN.CNT 692  
INCL INCLM: 514/018.000  
INCLS: 514/885.000; 530/330.000  
NCLM: 514/018.000  
NCLS: 514/885.000; 530/330.000  
IC [5]  
ICM: A61K037-02

ICS: C07K005-10  
EXF 530/330; 514/18; 514/885  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 219 OF 239 USPTFULL  
AN 90:79963 USPTFULL  
TI Boron analogs of amino acid/peptide protease inhibitors  
IN Kinder, David H., Rochester, MN, United States  
PA Ames, Matthew M., Rochester, MN, United States  
Mayo Foundation for Medical Education and Research, Rochester, MN, United States (U.S. corporation)  
PI US 4963655 19901016  
AI US 1988-199891 19880527 (7)  
DT Utility  
FS Granted  
LN.CNT 376  
INCL INCLM: 530/331.000  
INCLS: 548/110.000; 549/213.000; 560/029.000; 564/008.000  
NCLM: 530/331.000  
NCLS: 548/110.000; 549/213.000; 560/029.000; 564/008.000  
IC [5]  
ICM: C07K005-08  
EXF 514/64; 514/18; 514/19; 530/331; 548/110; 549/213; 560/29; 564/8  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 220 OF 239 USPTFULL  
AN 90:67565 USPTFULL  
TI Gene encoding an inhibitor of tissue-type and urokinase-type plasminogen  
IN Loskutoff, David J., 426 Glencrest Dr., Solana Beach, CA, United States  
92075  
NY, Tor, Lodjursvagen 11, Umea, Sweden  
Sawdey, Michael, 9232 (C) Regents Rd., La Jolla, CA, United States  
92037  
PI US 4952512 19900828  
AI US 1986-897990 19860819 (6)  
RLI Continuation-in-part of Ser. No. US 1984-623357, filed on 22 Jun 1984,  
now patented, Pat. No. US 4791068  
DT Utility  
FS Granted  
LN.CNT 2547  
INCL INCLM: 435/320.000  
INCLS: 435/091.100; 435/172.300; 435/069.200; 435/212.000; 435/219.000;  
536/027.000; 935/009.000; 935/060.000  
NCLM: 435/320.100  
NCLS: 435/069.200; 435/212.000; 435/219.000; 536/023.200; 536/023.500;  
536/024.310  
IC [5]  
ICM: C12N015-12  
EXF ICS: C12N015-58  
435/91; 435/172.3; 435/68; 435/253; 435/240.2; 435/320; 435/219;  
435/212; 435/11; 935/29; 935/73; 935/9; 935/60; 536/27  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 221 OF 239 USPTFULL  
AN 90:54619 USPTFULL  
TI Use of bis-(5-amidino-2-benzimidazolyl) methane (BABIM) to treat  
arthritis  
IN Tidwell, Richard R., Chapel Hill, NC, United States  
Geratz, Joachim D., Chapel Hill, NC, United States  
Schwab, John H., Chapel Hill, NC, United States  
Pryzwansky, Katherine B., Chapel Hill, NC, United States  
Anderle, Sonia K., Chapel Hill, NC, United States  
PA University of North Carolina, Chapel Hill, Chapel Hill, NC, United

States (U.S. corporation)  
 PI US 4940723 19900710  
 AI US 1988-260056 19881020 (7)  
 DT Utility  
 FS Granted  
 IN.CNT 489  
 INCL INCLM: 514/396.000  
 NCL INCLM: 514/401.000  
 NCIM: 514/396.000  
 NCIS: 514/401.000  
 IC [5]  
 ICM: A61K031-415  
 EXE 514/401; 514/396  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 222 OF 239 USPATFULL  
 L9 90:48878 USPATFULL  
 TI Protease inhibitors  
 IN Bachovchin, William W., Melrose, MA, United States  
 Plat, Andrew G., Lexington, MA, United States  
 Kettner, Charles A., Wilmington, DE, United States  
 E. I. Du Pont de Nemours and Company, Wilmington, DE, United States  
 PA (U.S. corporation)  
 New England Medical Center Hospitals, Inc., Boston, MA, United States  
 (U.S. corporation)  
 Tuts University, Medford, MA, United States (U.S. corporation)  
 PI US 4935493 19900619  
 AI US 1987-105768 19871006 (7)  
 DT Utility  
 FS Granted  
 IN.CNT 524  
 INCL INCLM: 530/331.000  
 NCL INCLM: 530/330.000  
 NCIM: 530/331.000  
 NCIS: 530/330.000  
 IC [5]  
 ICM: A61K037-02  
 EXE 514/2; 514/18; 514/19; 530/330; 530/331  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 223 OF 239 USPATFULL  
 L9 90:48835 USPATFULL  
 TI Cancer therapy system for effecting oncolysis of malignant neoplasms  
 IN Cone, Jr., Clarence D., Yorktown, VA, United States  
 PA Therapeutic Systems Corporation, Yorktown, VA, United States (U.S. corporation)  
 PI US 4935450 19900619  
 AI US 1988-234036 19880822 (7)  
 RLI Continuation-in-part of Ser. No. US 1987-130563, filed on 8 Dec 1987, now abandoned And Ser. No. US 1987-130290, filed on 8 Dec 1987, now abandoned which is a continuation of Ser. No. US 1985-792257, filed on 28 Oct 1985, now patented, Pat. No. US 4728234, issued on 9 Feb 1988 which is a continuation of Ser. No. US 1982-419324, filed on 17 Sep 1982, now abandoned, said Ser. No. 130563 which is a continuation of Ser. No. US 1984-634267, filed on 25 Jun 1984, now patented, Pat. No. US 4724230, issued on 9 Feb 1988 which is a continuation-in-part of Ser. No. 419324  
 DT Utility  
 FS Granted  
 IN.CNT 4266  
 INCL INCLM: 514/728.000  
 NCIM: 514/558.000; 514/561.000  
 NCIS: 514/728.000

NCIS: 514/558.000; 514/561.000  
 IC [5]  
 ICM: A61K031-045  
 ICS: A61K031-20; A61K031-195  
 EXE 514/728; 514/558; 514/561  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 224 OF 239 USPATFULL  
 L9 90:7722 USPATFULL  
 TI Immobilized fluorogenic substrates for enzymes; and processes for their preparation  
 IN Brynes, Paul J., Libertyville, IL, United States  
 Andrade-Gordon, Patricia, Port Jefferson, NY, United States  
 PA The Research Foundation of the State University of New York, Albany, NY, United States (U.S. corporation)  
 PI US 4897444 19900130  
 AI US 1985-740706 19850603 (6)  
 RLI Continuation-in-part of Ser. No. US 1985-739746, filed on 31 May 1985, now abandoned  
 DT Utility  
 FS Granted  
 IN.CNT 1569  
 INCL INCLM: 525/054.100  
 NCL INCLM: 435/023.000; 435/024.000; 530/330.000; 530/331.000; 530/300.000  
 NCIM: 525/054.100  
 NCIS: 435/023.000; 435/024.000; 530/300.000; 530/330.000; 530/331.000  
 IC [4]  
 ICM: C08L089-00  
 EXE 530/380; 530/330; 530/331; 525/54.1; 435/23; 435/24  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 225 OF 239 USPATFULL  
 L9 89:92234 USPATFULL  
 TI Device and method for separating leucocytes from platelet concentrate  
 IN Pali, David B., Roslyn Estates, NY, United States  
 Gsell, Thomas C., Glen Cove, NY, United States  
 PA Pall Corporation, Glen Cove, NY, United States (U.S. corporation)  
 PI US 4880548 19891114  
 AI US 1988-185993 19880425 (7)  
 RLI Continuation-in-part of Ser. No. US 1988-156894, filed on 17 Feb 1988, now abandoned  
 DT Utility  
 FS Granted  
 IN.CNT 2857  
 INCL INCLM: 210/767.000  
 NCL INCLM: 210/435.000; 210/504.000; 210/508.000  
 NCIM: 210/767.000  
 NCIS: 210/435.000; 210/504.000; 210/508.000  
 IC [4]  
 ICM: B01D039-04  
 EXE 210/651; 210/767; 210/435; 210/446; 210/506; 210/507; 210/508; 210/503; 210/504; 210/505; 210/648

L9 ANSWER 226 OF 239 USPATFULL  
 L9 89:90794 USPATFULL  
 TI Method of isolating tumor-secreted products using a novel protein-free medium  
 IN Alderman, Edward M., Dedham, MA, United States  
 Fect, James W., Waltham, MA, United States  
 PA Vallee, Bert L., Brookline, MA, United States  
 President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)  
 PI US 4879222 19891107

AI US 1986-901101 19860828 (6)  
 DT Utility  
 FS Granted  
 TI  
 LN CNT 619  
 INCL INCLM: 435/068.000  
 INCL: 435/240.230; 435/240.310  
 NCL NCIM: 435/068.100  
 IC [4]  
 ICM: C12P021-00  
 ICS: C12N005-00  
 EXF 435/240.83; 435/66; 435/240.31  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 227 OF 239 USPATFULT  
 AN 89:69709 USPATFULT  
 TI Affinity column and process for detection of low molecular weight toxic substances  
 IN Groopman, John D., Lynnfield, MA, United States  
 Wogan, Gerald N., Belmont, MA, United States  
 Barfoot, Frederick G., Wellesley, MA, United States  
 Ferarri, Christopher, Marlborough, MA, United States  
 PA Massachusetts Institute of Technology, Cambridge, MA, United States  
 (U.S. corporation)  
 PI Boston University, Boston, MA, United States (U.S. corporation)  
 AI US 4859611 19890822 (6)  
 RI US 1986-820388 19860121 (6)  
 Continuation-in-part of Ser. No. US 1985-706984, filed on 28 Feb 1985  
 And a continuation-in-part of Ser. No. US 1985-706983, filed on 28 Feb 1985  
 DT Utility  
 FS Granted  
 LN CNT 795  
 INCL INCLM: 436/518.000  
 INCL: 436/513.000; 436/548.000; 436/815.000; 436/824.000; 436/825.000  
 NCL NCIM: 436/518.000  
 NCL: 436/513.000; 436/548.000; 436/815.000; 436/824.000; 436/825.000  
 IC [4]  
 ICM: G01N033-543  
 ICS: G01N033-577  
 EXF 422/69; 422/70; 436/513; 436/518; 436/529; 436/807; 436/815; 436/824;  
 436/825; 436/112; 436/548; 530/413  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 228 OF 239 USPATFULT  
 AN 89:58716 USPATFULT  
 TI Method for promoting epithelial healing and prevention of epithelial destruction  
 IN Salonen, Eeva-Marjatta, Espoo, Finland  
 PA Labystems Oy, Helsinki, Finland (non-U.S. corporation)  
 PI US 4849406 19890718  
 AI US 1986-838339 19860311 (6)  
 PRI FI 1985-4634 19851122  
 DT Utility  
 FS Granted  
 LN CNT 661  
 INCL INCLM: 514/008.000  
 INCL: 514/012.000; 514/802.000; 424/101.000  
 NCL NCIM: 514/008.000  
 NCL: 514/012.000; 514/802.000  
 IC [4]  
 ICM: A61K037-02  
 EXF 424/101; 514/802; 514/12; 514/8  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 229 OF 239 USPATFULT  
 AN 89:25776 USPATFULT  
 TI Affinity column and process for detection of low molecular weight toxic substances  
 IN Groopman, John D., Essex County, MA, United States  
 Wogan, Gerald N., Middlesex County, MA, United States  
 PA Massachusetts Institute of Technology, Cambridge, MA, United States  
 (U.S. corporation)  
 PI Boston University, Boston, MA, United States (U.S. corporation)  
 AI US 4818687 19890404  
 RI US 1985-667069 19850228 (2)  
 DT Utility  
 FS Granted  
 LN CNT 633  
 INCL INCLM: 436/518.000  
 INCL: 436/529.000; 436/548.000; 436/815.000; 436/822.000; 436/824.000;  
 436/825.000  
 NCL NCIM: 436/518.000  
 NCL: 436/529.000; 436/548.000; 436/815.000; 436/822.000; 436/824.000;  
 436/825.000  
 IC [4]  
 ICM: G01N033-543  
 ICS: G01N033-577  
 EXF 436/518; 436/529; 436/815; 436/824; 436/825; 436/548; 436/822; 530/413

L9 ANSWER 230 OF 239 USPATFULT  
 AN 88:47337 USPATFULT  
 TI Serine protease inhibitors and methods for isolation of same  
 IN Thompson, Robert C., Boulder, CO, United States  
 PA Synergen Biologics, Inc., Boulder, CO, United States (U.S. corporation)  
 PI US 4760130 19880726  
 RI US 1985-803423 19851202 (6)  
 Continuation-in-part of Ser. No. US 1984-678823, filed on 6 Dec 1984,  
 now abandoned  
 DT Utility  
 FS Granted  
 LN CNT 805  
 INCL INCLM: 530/350.000  
 INCL: 530/350.000  
 NCL NCIM: 530/350.000  
 NCL: 930/010.000; 930/250.000; 930/DIG.821  
 IC [4]  
 ICM: C07K013-00  
 EXF 530/324; 530/350  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 231 OF 239 USPATFULT  
 AN 88:29409 USPATFULT  
 TI Hydroxamic acid based collagenase inhibitors  
 IN Dickens, Jonathan P., High Wycombe, England  
 PA Donald, David K., High Wycombe, England  
 Kneen, Geoffrey, West Wycombe, England  
 PI Mckay, William R., High Wycombe, England  
 G. D. Searle & Co., Chicago, IL, United States (U.S. corporation)  
 PI US 4743587 19880510  
 AI US 1986-880130 19860707 (6)  
 RLI Continuation-in-part of Ser. No. US 1985-774491, filed on 10 Sep 1985,  
 now patented, Pat. No. US 4599361  
 DT Utility  
 FS Granted  
 LN CNT 1007  
 INCL INCLM: 514/575.000  
 INCL: 260/500.500H

NCL NCLM: 514/575.000  
NCLS: 562/623.000  
[4]  
IC ICM: C07C083-10  
ICS: A61K031-085; A61K031-165; A61K031-185  
EXF 260/500.5H; 514/575  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 232 OF 239 USPTAFULL  
88:4279 USPTAFULL  
TI Method of inhibiting vertebrate collagenase activity using  
peptide hydroxamic acid derivatives  
IN Spilburg, Curtis A., Chesterfield, MO, United States  
Moore, William M., St. Charles, MO, United States  
PA Monsanto Company, St. Louis, MO, United States (U.S. corporation)  
PI US 4720486 19880119  
AI US 1987-1265 19870107 (7)  
RLI Division of Ser. No. US 1985-789271, filed on 18 Oct 1985, now patented,  
Pat. No. US 4687841  
DT Utility  
FS Granted  
LN.CNT 565  
INCL INCLM: 514/018.000  
INCLS: 525/054.100  
NCL NCLM: 514/018.000  
NCLS: 525/054.100  
IC [4]  
ICM: A61K037-02  
ICS: C08E283-00  
EXF 514/18; 525/54.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 233 OF 239 USPTAFULL  
87:58655 USPTAFULL  
TI Peptide hydroxamic acid derivatives  
IN Spilburg, Curtis A., Chesterfield, MO, United States  
Moore, William M., St. Charles, MO, United States  
PA Monsanto Company, St. Louis, MO, United States (U.S. corporation)  
PI US 4687841 19870818  
AI US 1985-789271 19851018 (6)  
DT Utility  
FS Granted  
LN.CNT 542  
INCL INCLM: 530/331.000  
INCLS: 530/810.000; 530/813.000  
NCL NCLM: 530/331.000  
NCLS: 530/810.000; 530/813.000  
IC [4]  
ICM: C07C103-52  
EXF 530/331; 530/810; 530/813  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 234 OF 239 USPTAFULL  
87:34104 USPTAFULL  
TI Peptide derivatives, the preparation and their use as elastase  
inhibitors  
IN Robert, Ladislav, Santeny, France  
Hornebeck, William, Saint Cyr l'Ecole, France  
Moczar, Elemer, Gif-sur-Yvette, France  
PA Centre National de la Recherche Scientifique, Paris, France (non-U.S.  
government)  
PI US 4665053 19870512  
AI US 1984-610111 19840514 (6)  
PRAI FR 1983-8052 19830516

DT Utility  
FS Granted  
LN.CNT 631  
INCL INCLM: 514/018.000  
INCLS: 514/844.000; 530/330.000; 530/331.000  
NCL NCLM: 514/018.000  
NCLS: 514/844.000; 530/330.000; 530/331.000; 930/250.000; 930/DIG.785  
IC [4]  
ICM: A61K037-02  
ICS: C07K005-08; C07K005-10  
EXF 424/177; 260/112.5R; 514/18; 514/844; 530/330; 530/331  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 235 OF 239 USPTAFULL  
86:76655 USPTAFULL  
TI Hydroxamic acid based collagenase inhibitors  
IN Dickens, Jonathan P., High Wycombe, England  
Donald, David K., High Wycombe, England  
Kneen, Geoffrey, West Wycombe, England  
McKay, William R., High Wycombe, England  
PA G. D. Searle & Co., Skokie, IL, United States (U.S. corporation)  
PI US 4599361 19860708  
AI US 1985-774491 19850910 (6)  
DT Utility  
FS Granted  
LN.CNT 714  
INCL INCLM: 514/575.000  
INCLS: 260/500.500H  
NCL NCLM: 514/575.000  
NCLS: 562/623.000  
IC [4]  
ICM: C07C083-10  
ICS: A61K031-085; A61K031-165; A61K031-185  
EXF 260/500.5H; 514/575  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 236 OF 239 USPTAFULL  
86:6621 USPTAFULL  
TI Carboxylalkyl peptide derivatives  
IN McCullagh, Keith G., Princes Risborough, United Kingdom  
Wadsworth, Harry J., High Wycombe, United Kingdom  
Hann, Michael M., Watlington, United Kingdom  
PA G. D. Searle & Co., Skokie, IL, United States (U.S. corporation)  
PI US 4568666 19860204  
AI US 1984-662129 19841018 (6)  
DT Utility  
FS Granted  
LN.CNT 3163  
INCL INCLM: 514/020.000  
INCLS: 260/112.500R  
NCL NCLM: 514/020.000  
NCLS: 260/001.000; 562/443.000; 930/250.000  
IC [4]  
ICM: A61K037-00  
ICS: C07C103-52  
EXF 514/20; 260/112.5R  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 237 OF 239 USPTAFULL  
84:64289 USPTAFULL  
TI Therapeutic hypothermia instrument  
IN Witeles, Eleonora M., Rancho Palos Verdes, CA, United States  
Atlantic Richfield Company, Los Angeles, CA, United States (U.S.  
corporation)

PI	US 4483341	19841120
AI	US 1982-448114	19821209 (6)
DT	Utility	
FS	Granted	
LN.CNT	805	
INCL	INCLM: 128/402.000	
NCL	INCLS: 128/303.100; 128/784.000; 062/003.000	
IC	ICM: 062/003.100; 062/003.200	
EXF	128/303.1; 128/399-403; 128/DIG.27; 128/784; 062/3; 062/335	
L9	ANSWER 238 OF 239 USPATFULL	
AN	77:51189 USPATFULL	
TI	Steroidal erythropoietic agents and therapeutic compositions and methods	
IN	Strade, Henry A., Montville, NJ, United States	
PA	Akzona Incorporated, Asheville, NC, United States (U.S. corporation)	
P1	US 4049805	19770920
A1	US 1976-693249	19760604 (5)
RI	Continuation-in-part of Ser. No. US 1975-618176, filed on 30 Sep 1975, now patented, Pat. No. US 4004005	
DT	Utility	
FS	Granted	
LN.CNT	235	
INCL	INCLM: 424/243.000	
NCL	NCLM: 514/178.000	
IC	ICM: A61K031-565	
EXF	424/243	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
L9	ANSWER 239 OF 239 USPATFULL	
AN	77:3777 USPATFULL	
TI	Steroidal erythropoietic agents and therapeutic compositions and methods	
IN	Strade, Henry A., Montville, NJ, United States	
PA	Akzona Incorporated, Asheville, NC, United States (U.S. corporation)	
P1	US 4004005	19770118
A1	US 1975-618176	19750930 (5)
DT	Utility	
FS	Granted	
LN.CNT	188	
INCL	INCLM: 424/243.000	
NCL	NCLM: 514/178.000	
IC	ICM: A61K031-56	
EXF	424/243	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		